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Abstract 
 
Asthma is a disease with increasing global prevalence and patients typically suffer from symptoms 
such as wheezing, breathlessness, chest tightness and cough. In allergic asthma, exposure to allergen 
can lead to episodes of bronchoconstriction known as the late asthmatic response (LAR).Despite this 
being a facet of asthma that patients find debilitating and the fact that this feature of asthma is often 
used in clinical research as an end point to study new therapeutic options, the mechanisms driving the 
LAR remain unclear. The aim of this thesis was to study the LAR. 
Initial studies utilised genetically modified (GM) mice missing key allergic effector cells. The data 
showed that CD4+ and CD8+T cells are central to the aetiology of the LAR. Further studies into the role 
of the B-cell – mast cell– IgE axis in the murine model indicated that an alternative model was required.  
In a rat model, it was found that a mast cell stabiliser Disodium Cromoglycate (DSCG), but not a mast 
cell degranulator, compound 48/80, suppressed the LAR. This suggested that DSCG may be inhibiting 
LAR independently of its activity on mast cells. 
As previous data has shown a role for airway sensory nerves and the TRPA1 ion channel in the LAR, 
the impact of DSCG on sensory nerve activity was investigated. The data indicated that DSCG can 
inhibit TRPA1 responses in airway sensory nerves and further investigations demonstrated that this 
was via its actions on the G-protein coupled receptor, GPR35. 
Overall, this body of work provides new insights into the driving mechanisms behind the LAR and may 
have uncovered the mystery of the mechanism of action of DSCG. From this, new therapeutic options 
for asthmatics may become available in the future. 
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1 Introduction 
1.1 Asthma 
Asthma is defined as a chronic inflammatory disease of the airways with symptoms such as wheezing, 
chest tightness, breathlessness and cough (Lemanske  Jr. & Busse, 2003; Levy et al., 2006; Bateman et 
al., 2008). It affects approximately 300 million people worldwide and the World Health Organisation 
estimates asthma to represent 1% of the total global disease burden. The prevalence of asthma is still 
on the rise and escalating healthcare costs are making it a global health concern (Masoli et al., 2004; 
Bateman et al., 2008; Akinbami, Moorman & Liu, 2011; Fahy, 2015). 
The phenotype of asthma is characterised by airway hyperresponsiveness (AHR), reversible 
bronchoconstriction, airway remodelling events and chronic inflammation. A wide range of 
environmental and endogenous stimuli have been shown to trigger asthma symptoms including; 
allergens, exercise and cold air (Holgate, 2008b, 2008a). Recent attempts at phenotyping asthma have 
adopted cluster based approaches whereby patients are grouped according to a multitude of possible 
features such as age of onset, atopic status, severity of airways obstruction and medication 
requirements. Atopic asthma is associated with allergy (elevated levels of allergen specific IgE) and 
atopic sensitisation has been implied as an important determinant in the development of asthma. The 
most common etiological allergens include House Dust Mite (HDM), fungal species, animal dander and 
plant pollen (Pearce, Pekkanen & Beasley, 1999; Wenzel, 2006). The focus of this thesis will be on 
atopic asthma whereby the asthmatic response is thought to occur in allergen sensitised patients upon 
which allergen challenge results in a response. 
1.2 Allergic Sensitisation in Asthma 
The pathogenesis of allergic asthma linking the initial triggers, the inflammatory process and the 
resulting asthma phenotype is complex and involves numerous cells and mediators. The immune 
response in atopic asthma involves two phases; the sensitisation phase following initial allergen 
exposure and the challenge or allergic response phase following re-exposure in sensitised patients. 
Allergens in the airways are detected by Antigen Presenting cells (APCs), primarily dendritic cells, 
which patrol the airway epithelium and submucosa in order to scan the lumen for invading pathogens. 
Upon contact, the APCs phagocytose the allergen. This action, along with the presence of cytokines 
such as Thymic Stromal Lymphopoietin (TSLP), triggers the maturation of the APCs during which they 
up-regulate their surface expression of major histocompatibility complex class II (MHC-II) molecules 
and migrate to the lymph nodes (Ito et al., 2005; Wang et al., 2006; Burgess et al., 2005). Following 
the internalisation of allergen, it is processed and loaded into MHC-II molecules at the cell surface. 
20 
 
The APC then presents the allergen to naive B-cells and T-cells in a process known as antigen 
presentation (Hintzen et al., 2006; Neefjes, 1996). 
During antigen presentation, when an APC encounters a naive CD4+ T-cell expressing a relevant T-cell 
Receptor (TCR) for the allergen, a complex is formed between the MHC-II/antigen complex and the T-
cell. For this to be a success, the T-cell must express the correct TCR for the allergen. However, it must 
be noted that it is thought that each TCR can recognise a vast number of antigenic peptides 
(Wooldridge et al., 2012). The coupling of the MHC-II/antigen and TCR (along with costimulatory 
molecules from the APC) activates the naive CD4+ T-cell to proliferate and differentiate into effector 
cells in a process known as clonal selection and expansion. The main effector phenotypes which the 
activated CD4+ T-cells differentiate into are predominantly T-helper type 1 (Th1) and T-helper type 2 
(Th2), and is dependent on the cytokine environment in which antigen presentation occurs (Buc et al., 
2009; Ito et al., 2005; Wang et al., 2006). Cytokines such as Interleukin-4 (IL-4) promote Th2 
polarisation whereas cytokines such as Interferon-γ (IFN-γ) promote Th1 polarisation. In asthma 
typically the Th2 endotype is a key hallmark in the pathogenesis of the disease and stimulated Th2 
cells are involved in directing a host of cellular immune responses via the release of various cytokines 
(Hammad & Lambrecht, 2008). 
B-cells also function as APCs. CD40 ligand (CD40L) is expressed on the surface of T-cells and will bind 
to CD40 Receptor (CD40R) expressed on the surface of B-cells, though only if the T-cell expresses the 
correct TCR for the allergen. This interaction, along with the release of the cytokines IL-4 and IL-13 
from the Th2 cell stimulates B-cell activation and triggers the release of allergen specific IgE via a 
process known as class switching (McKenzie et al., 1999; Grünig et al., 1998). IgE is known to bind to 
high affinity receptor FcR1 which is present on the surfaces of mast cells and basophils (Barnes, 2008). 
This action effectively primes the cells to respond to future allergen exposure (see figure 1.1). 
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Figure 1.1: Schematic representation of the inflammatory cascade in allergic asthma. (Adapted from 
Holgate 2008). 
 
1.3 Allergic Asthmatic Responses: The EAR and LAR 
Further exposure to an allergen following sensitisation results in an allergic response. The allergen 
activates sensitised mast cells by inducing the cross linking of the IgE-FcεRI complexes and results in 
the release of mediators such as histamine, 5-hydroxytryptamine (5-HT), prostaglandins and cysteinyl 
leukotrienes. This results in a reaction characterised by rapid bronchoconstriction, oedema (plasma 
extravasation) and mucus secretion which all contribute to airflow obstruction. This immediate 
bronchoconstriction is termed the Early Asthmatic Response (EAR) and typically occurs within 1hour 
of contact with aeroallergen. This reaction has been well characterised by researchers and occurs via 
the IgE-mast cell products axis as highlighted in this section (Barnes, 2008; Holgate, 2008a). 
The Late Asthmatic Response (LAR) refers to a more prolonged bronchoconstriction event taking place 
approximately 3-8 hours following contact with allergen. The response is characterised by an influx of 
inflammatory cells such as eosinophils, mast cells, neutrophils and T cells (Hogan et al., 1998). This 
particular feature of asthma is experienced by approximately 50% of asthma sufferers and the 
aetiology is less well understood in comparison to that of the EAR (Booij-Noord, Orie & De Vries, 1971; 
Booij-Noord et al., 1972). It is also noteworthy that the LAR could be considered to be a more relevant 
marker of asthma than the EAR as the bronchoconstriction is more pronounced and long-lived and 
the LAR is also often used as an endpoint in clinical studies exploring new therapeutic options with 
which to treat asthma (O’Byrne, Dolovich & Hargreave, 1987; Stevens & van Bever, 1989; Muller et 
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al., 1993).  Despite this, the specific mechanisms driving the LAR have yet to be elucidated. The focus 
of this thesis is to explore the driving mechanisms behind this response. 
 
Figure 1.2: The EAR and LAR. The EAR takes place within 1hr of allergen exposure and is known to 
involve IgE cross-linking of allergen on mast cells, degranulation and release of mediators acting 
directly on smooth muscle. The LAR takes place 3-8 hrs following exposure. Mechanisms are unclear 
but are thought to involve cellular allergic airway inflammation. 
 
1.4 Other features of Allergic Asthma 
1.4.1 Airway Remodelling 
The asthmatic airway is characterised by several pathological changes in comparison to that of the 
non-asthmatic airway, collectively described as airway remodelling. Structural changes within the 
epithelium include goblet cell metaplasia and hyperplasia which leads to increases in epithelial mucin 
stores. This along with changes in the submucosal gland cells leads to airway obstruction due to 
excessive mucus production (Fahy, 2015; Wadsworth, Sin & Dorscheid, 2011). Subepithelial fibrosis is 
also a common feature of the asthmatic airway. This term defines the thickening of the basement 
membrane due to the enhanced deposition of extracellular matrix factors such as Collagens and 
Fibronectins (Karjalainen et al., 2003; Beasley, Roche & Holgate, 1989; Brewster et al., 1990). Another 
characteristic of airway remodelling is enhanced airway smooth muscle (ASM) mass caused ASM 
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hypertrophy and hyperplasia (Woodruff et al., 2004; Bara et al., 2010). Increases in the number of 
blood vessels serving the asthmatic airway in comparison to non-asthmatics have also been noted 
(Siddiqui et al., 2007). 
It is widely believed that airway remodelling occurs as a result of the chronic inflammation associated 
with asthma. Numerous mediators released during the inflammatory process in the asthmatic airway 
have been implicated in this pathological feature. Cytokines such as IL-1β and IL-6 have been shown 
to have the capability to enhance ASM proliferation (De et al., 1995). IL-13 and Transforming Growth 
Factor β (TGFβ) has also been shown to induce fibrosis (Kenyon et al., 2003; Fichtner-Feigl et al., 2006). 
A role for mast cells has been implied as they have the ability to release matrix metallopeptidases 
(MMPs) which have been suggested as likely mediators of remodelling and repair (Dahlen, Shute & 
Howarth, 1999; Wenzel et al., 2003). Murine models have also highlighted a role for eosinophilia and 
IL-5 within remodelling events (Tanaka et al., 2001; Cho et al., 2004; Humbles et al., 2004). However, 
it is also of note that some believe inflammation not to be a cause of remodelling, but simply an 
observed factor occurring in parallel, as in some cases airway remodelling occurs in the absence of 
inflammation (Malmström et al., 2011; Wadsworth, Sin & Dorscheid, 2011). 
1.4.2 Airway Hyperresponsiveness 
AHR is a cardinal feature of the asthma phenotype. It is defined as an increased sensitivity to inhaled 
stimuli resulting in narrowing of the airways which would not usually occur in healthy individuals. This 
response manifests as excessive bronchoconstriction and airflow limitation, resulting in shortness of 
breath and chest tightness. Stimuli of AHR include pollution, allergens, cold air and spasmogens such 
as Methacholine (Spina & Page, 2002). 
AHR is largely thought to occur as a result of airway remodelling and inflammation. Indeed, 
researchers have described the pathological changes occurring in airway remodelling as predisposing 
asthmatics to exaggerated responses to inhaled stimulants by narrowing the baseline calibre and 
altering structural elements in such a manner which allows for this (Fahy, 2015). More specifically, 
hypertrophy and hyperplasia of ASM have been associated with AHR (Ebina et al., 1993; Lambert et 
al., 1993), as has airway wall oedema (Van de Graaf et al., 1991; Kimura et al., 1992; Chung et al., 
1999). Inflammation has been associated with AHR as steroids have been shown to attenuate this 
response in asthmatic patients (Djukanović et al., 1992, 1997; Laitinen, Laitinen & Haahtela, 1992; 
Chalmers et al., 2002; Clearie et al., 2012). Increases in cytokines (IL-4, IL-5 and IL-13) and eosinophilic 
inflammation have also been shown to correlate with asthma severity and AHR (Grünig et al., 1998; 
Walter et al., 2001; Taube et al., 2002; Bousquet et al., 1990). 
24 
 
1.5 Cells and Mediators in Allergic Asthma 
1.5.1 Dendritic Cells 
Dendritic cells are APCs and, as previously described, play a central role in allergic sensitisation in 
asthma. They are derived from bone marrow pre-cursor cells and originate in the blood. Immature 
forms of this cell type are principally found in tissues such as the skin, the lining of the nose, the 
airways and the gastrointestinal (GI) tract. In the airway, they patrol the lumen and submucosa 
scanning for invading pathogens. Dendritic cells recognise Pathogen Associated Molecular Patterns 
(PAMPs) present on invading pathogens via Pattern Recognition Receptors (PRRs) present on their cell 
surface. Following this recognition they internalise, process and present the antigen on MHC-II 
molecules at the cell surface and migrate to the lymph nodes where antigen presentation takes place 
(Hintzen et al., 2006; Wang et al., 2006; Buc et al., 2009; Salazar & Ghaemmaghami, 2013).  
During antigen presentation, the dendritic cells promote the polarisation of the naive CD4+ T-cells into 
Th1 and Th2 phenotypes, which is determined by the cytokine environment. The mechanism by which 
this takes place is not well understood though several have been proposed. The possibility that certain 
dendritic cell types are preconditioned to polarise to a specific response (either Th1 or Th2) has been 
raised by researchers. Lymphoid derived dendritic cells have been shown to stimulate IL-2 and IFN-γ 
production from T-cells which is associated with the Th1 phenotype. Myeloid derived dendritic cells 
have been shown to induce the production of IL-4 from T-cells which is allied with a Th2 response 
(Pulendran et al., 1999; Hammad et al., 2010). Others have suggested that ingestion of different 
pathogens can promote maturation of dendritic cells to differentially express various cytokine profiles. 
A role for feedback cytokine regulation from T-cells has also been linked with this theory (Pulendran, 
2004; d’Ostiani et al., 2000; Bozza et al., 2002; Edwards et al., 2002). Indeed, various cytokines 
originating in Th2 cells such as IL-4, IL-13 and IL-6 have been shown to promote the Th2 response. 
Whilst cytokines originating in Th1 cells such as IL-12 have been shown to promote Th1 differentiation 
(Eisenbarth, Piggott & Bottomly, 2003). Overall, dendritic cells are known to play a role in controlling 
T-cell polarisation. Whether this is due to a predetermined bias to specific endotypes, or via 
modulatory effects of microbes and mediators in the pulmonary environment, requires further 
elucidation. 
1.5.2 T-Cells 
1.5.2.1 CD4+ T-Cells 
CD4+ T-cells are a subset of lymphocyte termed T-helper cells which mature in the thymus. They are 
identified by the expression of a TCR on the cell surface and antigens are presented to them via APCs 
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on MHC-II molecules (Buc et al., 2009; Salazar & Ghaemmaghami, 2013). There are a number of CD4+ 
T-cell subtypes associated with asthma; Th1, Th2, Th17 and Treg cells which will be discussed in the 
following sections. 
1.5.2.1.1 Th1/Th2 Cell Paradigm 
Th1 cells are responsible for phagocyte dependent protective responses, and produce the cytokines 
IL-2 and IFN-γ. In contrast, Th2 cells produce cytokines such as IL-4, IL-5 and IL-13 and have been widely 
implicated in the promotion of the chronic inflammation associated with asthma (Romagnani, 1999). 
There is an increased presence of Th2 cells and associated cytokines in the airways of asthmatic 
patients which has lead to asthma being traditionally described as a Th2 cell driven disease (Robinson 
et al., 1992; Bentley et al., 1992).  
As previously explained, in the process of antigen presentation, the subtype the CD4+ cells 
differentiates into is dependent on the cytokine environment present. IFN-γ and IL-2 drive the 
differentiation of Th1 cells, while IL-4 drives the Th2 subtype (Hammad & Lambrecht, 2008; Buc et al., 
2009). The development of the Th1 and Th2 subtypes are described as being mutually inhibitory as 
the associated cytokines for each subtype inhibits the differentiation of the other (Varga et al., 2000; 
Romagnani, 1999). Th1 development is dependent on the transcription factor T-bet, which regulates 
the production of IFN-γ (Salazar & Ghaemmaghami, 2013). Th2 development is dependent on Trans-
acting T-cell-specific transcription factor 3 (GATA3) (Zheng & Flavell, 1997). T-bet has been shown to 
inhibit Th2 responses via preventing GATA3 binding to DNA, resulting in the dominance of a Th1 
response (Hwang et al., 2005; Usui et al., 2006). Indeed, T-bet expression in asthmatics is reduced 
compared with non-asthmatics leading to the speculation that lack of Th1 promoting signals in 
asthmatics may allow the Th2 subtype to predominate (Finotto et al., 2002). 
1.5.2.1.2 Th2 Cells 
Th2 cells have been widely implicated in asthma as playing a major role in promoting innate and 
adaptive responses. As previously described, they are important for promoting the production of IgE 
from B-cells and produce cytokines such as IL-4, IL-5 and IL-13. This cytokine milieu has been 
associated with various features of disease, with enhanced expression found in the airways of 
asthmatic patients (Robinson et al., 1992; Jaffar et al., 1999; Cohn, Elias & Chupp, 2004). IL-4 has 
mainly been associated with the allergic sensitization process alone and in combination with IL-13 
(Corry et al., 1996, 1998; McKenzie et al., 1999). In addition, IL-13 has been shown to be vital to 
orchestrating allergic responses such as AHR, inflammation and airway remodelling (Zhu et al., 1999; 
Mattes et al., 2001; Walter et al., 2001). IL-5 is a selective eosinophil chemoattractant and activator 
and is therefore important in eosinophil recruitment and survival. Indeed, allergen challenge in 
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asthmatic patients results in the influx of activated Th2 cells into the airway, accompanied by 
prominent eosinophil recruitment. Eosinophilic inflammation has been associated with many features 
of allergic asthma such as AHR and airway remodelling (Finkelman et al., 2010). 
1.5.2.1.3 Th17 Cells 
Th17 cells express IL-17 and have been widely implicated in asthma. CD4+IL17+ T-cells have been 
observed in the lungs of asthmatic patients (Pène et al., 2008). Levels of IL-17 have also been found 
to be elevated in the lungs of patients with asthma, with levels correlating with disease severity (Molet 
et al., 2001). IL-17 has been suggested to play a role in neutrophil recruitment, possibly via inducing 
the production of the neutrophil chemoattractant IL-8 (Bullens et al., 2006). Studies have shown that 
the transfer of Th17 cells promotes steroid resistant AHR and inflammation which is associated with 
neutrophilia (He et al., 2007; Wilson et al., 2009; McKinley et al., 2008). 
1.5.2.1.4 Treg Cells 
Unlike other CD4+ cell subsets, regulatory T-cells (Tregs) are important in the suppression of 
inflammatory responses. They have been shown to inhibit Th2 cytokine driven asthmatic responses 
such as AHR, airway inflammation and remodelling events. They are thought to exert these 
suppressive actions through the secretion of the anti-inflammatory cytokine IL-10 and expression of 
inhibitory molecules such as cytotoxic T lymphocyte antigen 4 (CTLA4) (Ostroukhova et al., 2004; 
Kearley et al., 2005; Kearley, Robinson & Lloyd, 2008). Due to this it has been suggested that a reduced 
function of this cell type within the asthmatic lung could be responsible for the enhanced immune 
response to allergens observed in asthma (Lloyd & Hessel, 2010). 
1.5.2.2 CD8+ T-Cells 
CD8+ T-cells are known as Cytotoxic T-cells. They also express a TCR on the cell surface and antigens 
are presented to them via MHC-I molecules. They have been identified in the lungs of asthmatic 
patients, with certain subtypes present in increased proportions (Hirosako et al., 2010). Animal models 
have shown that the actions of CD8+ cells can be either protective or injurious within the asthmatic 
lung. Studies examining the role of the CD8+γδ subtype showed that with suppression asthma 
symptoms worsened, and with adoptive transfer symptoms were improved, highlighting protective 
capabilities (Olivenstein et al., 1993b; Allakhverdi et al., 2000; Suzuki et al., 1999). Conversely, 
adoptive transfer studies of CD8+αβ cells demonstrated this subtype to exacerbate asthma symptoms 
(Isogai et al., 2004). 
1.5.3 Eosinophils 
Eosinophils are polymorphonuclear granulocytes which develop in the bone marrow from common 
myeloid progenitor cells. They are found in the sputum, bronchoalveolar lavage (BAL) fluid and 
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bronchial biopsies of allergic asthmatic patients and as such their presence in the lung is commonly 
used as a marker of allergic asthma (Vieira & Prolla, 1979; Gibson, Saltos & Borgas, 2000; Shahana et 
al., 2005). They have been shown to release a plethora of toxic proteins such as Major Basic Protein 
(MBP), Eosinophil Cationic Protein (ECP), Eosinophil Derived Neurotoxin (EDN) and Eosinophil 
Peroxidase (EPX) which have been implicated in the pathogenesis of asthma (Frigas et al., 1981; 
Motojima et al., 1989; De Monchy et al., 1985). They have also been shown to release other mediators 
such Cysteinyl Leukotrienes and Prostanoids which are potent bronchoconstricting agents, in addition 
to Th2 promoting cytokines such as IL-4 and IL-13 (Weller et al., 1983; Nonaka et al., 1995; Woerly et 
al., 2002). 
The differentiation, survival and migration of eosinophils to the lungs has been shown to be mediated 
by a number of chemokines and cytokines. Eotaxin is a chemokine produced by a number of cell types 
such as mast cells, macrophages and epithelial cells present within the allergic lung (Liu, Yang & Huang, 
2006; Zeibecoglou et al., 1999). It signals via the CC Chemokine receptor-3 (CCR3) receptor which is 
expressed on eosinophils and has been shown to mediate the recruitment of this cell type to the lungs 
(Sehmi et al., 1997; Griffiths-Johnson et al., 1993). IL-5 is a Th2 cytokine produced by a range of cell 
types as previously described and is important for eosinophil differentiation, migration and survival 
(Yamaguchi et al., 1988, 1991). Numerous clinical and animal studies have presented evidence linking 
Eotaxin, IL-5 and eosinophilia with key hallmarks of asthma. The inhalation of IL-5 by asthmatic 
patients was shown to result in enhanced eosinophilia and AHR (Shi et al., 1998). In a murine allergic 
asthma model, IL-5 deficient mice exhibited a lack of eosinophilia, inflammation, AHR and airway 
remodelling compared with controls. Eosinophil transfer into these knockout mice restored levels of 
Th2 cytokines and AHR (Shen et al., 2003). Other studies utilising various genetically modified (GM) 
mice in allergic asthma models have also concluded eosinophils, Eotaxin and IL-5 to be key in the 
presentation of AHR, airway remodelling events and airway inflammation (Mattes et al., 2002; Justice 
et al., 2003; Lee et al., 2004). 
The hypothesis that eosinophilic inflammation plays a key role in the presentation of asthma 
symptoms is supported by the fact that certain subsets of asthma patients respond well to inhaled 
corticosteroids (ICS) resulting in diminished symptoms and airway inflammation (Djukanović et al., 
1992). However, it has also been suggested that eosinophils may not be as important as once thought 
within allergic asthma. Certain subsets of asthmatics present little evidence of eosinophilia and some 
investigations have shown that AHR does not correlate with inflammation in BAL fluid, sputum and 
bronchial biopsies (Crimi et al., 1998; Wenzel et al., 1999; Wenzel, 2005). Animal studies have also 
shown that AHR is not dependent on lung and airway eosinophilia (Hessel et al., 1997; Wilder et al., 
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1999; Humbles et al., 2004). Nevertheless, therapeutics for asthma targeting eosinophilia are 
currently in development. Mepolizumab, Benralizumab and Reslizumab are antibody therapeutics 
which target IL-5 and have reached at least Phase II in clinical trial and their efficacy assessed. Initial 
trials of Mepolizumab concluded that it had no significant effect on asthma exacerbation rates (Flood-
Page et al., 2007). However, these initial trials did not specifically target the subgroup of patients 
expected to benefit the most such as those with persistent eosinophilia. More recent studies of 
Mepolizumab targeted this subgroup and concluded that the treatment significantly decreased 
asthma exacerbations and was corticosteroid sparing (Nair et al., 2009; Haldar et al., 2009; Pavord et 
al., 2012; Bel et al., 2014; Ortega et al., 2014). Data from Phase II clinical trials of Benralizumab and 
Reslizumab also showed that they were effective in reducing exacerbations and improving asthma 
control but only in patients with persistent eosinophilia (Castro et al., 2011, 2014). 
Overall, eosinophilia is considered to be a feature of allergic asthma in certain subsets of patients 
although their specific role remains controversial. 
1.5.4 Macrophages 
Macrophages are derived from monocytes generated in bone marrow and develop into macrophages 
in tissues such as that of the lung. They are phagocytic in nature, protecting the body from infection 
and cleaning up dead and dying cells. Despite being major players in the innate immune system, they 
have also been linked with adaptive immunity associated with asthma immunology (Murray & Wynn, 
2011).  
They have been shown to be one of the predominate cell types in sputum samples taken from 
asthmatic patients and release mediators associated with features of asthma such as prostaglandins 
and cysteinyl leukotrienes (Woodruff et al., 2001; Holgate et al., 2003). They also release cytokines 
such as IL-1β, Tumour Necrosis Factor-α (TNF-α) and IL-6 which may be associated with the promotion 
of ongoing inflammation in asthmatic patients (Rincon & Irvin, 2012). Macrophages are capable of 
functioning as APCs, ingesting allergens and presenting them to T-cells (Unanue, 1984). They express 
Fc receptors on their cell surface and may provide proinflammatory signals in response to allergen 
exposure (Melewicz et al., 1982; Borish, Mascali & Rosenwasser, 1991). Alveolar macrophages have 
been shown to release leukotrienes in response to IgE or IgE allergen immune complexes which 
further highlights this point (Rankin et al., 1982, 1984). 
1.5.5 Neutrophils 
Neutrophils are polymorphonuclear granulocytes and function as phagocytes within the innate 
immune system. They are the immediate defence mechanism against invading pathogens and migrate 
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to the site of infection via multiple chemokine gradients such as that of Leukotriene B4 (LTB4) and IL-
8. They are known to release phagosomes containing high levels of Reactive Oxygen Species (ROS) 
which enhance their ability to fight pathogens (Galli, Borregaard & Wynn, 2011; Kolaczkowska & 
Kubes, 2013). Their role in asthma is not yet fully understood, although their presence in the asthmatic 
lung has been noted (Woodruff et al., 2001). Clinical and Pre-clinical models have also elucidated that 
they are recruited to the airways following allergen exposure (Koh et al., 1993; Nocker et al., 1999; 
Underwood et al., 2002). They secrete proinflammatory mediators such as IL-6, IL-8 and TNF-α which 
have been deemed as important in promoting the chronic inflammation associated with asthma (Cicco 
et al., 1990; Dubravec et al., 1990; Strieter et al., 1992). Neutrophils have also been implicated in 
steroid resistant asthma exacerbations (Ito et al., 2008). 
1.5.6 B-Cells 
B-cells undergo development in the bone marrow and then migrate to the lymph nodes. Their major 
role is to produce antibodies to fight invading pathogens. They are capable of functioning as APCs and 
recognise antigen via B-cell receptors. This recognition results in internalisation, processing and 
presentation on MHC-II molecules at the cell surface. T-helper cells (such as Th2 cells in asthma) 
expressing the correct TCR for the allergen interact with this complex. CD40L on the T-cell also binds 
with CD40R on the B-cell surface. Together these interactions are known as the formation of an 
immunological synapse. This, along with cytokines such as IL-4 and IL-13 released from the Th2 cell 
results in the promotion of the B-cell to undergo the production of IgE in a process known as class 
switching (Grünig et al., 1998; McKenzie et al., 1999). IgE will then bind to high affinity FcεRI receptor 
on mast cells and basophils to effectively prime them for future allergen exposure. In addition to IgE 
release, the B-cells also undergo clonal selection and expansion to result in the formation of plasma 
B-cells and memory B-cells (Mitchison, 2004). 
1.5.7 Mast Cells 
Mast cells develop from pluripotent hematopoietic stem cells in the bone marrow. They circulate as 
CD34+ precursors until they migrate into tissues where they mature into granulocytes (Kirshenbaum 
et al., 1992). They are found in various tissue types but are especially numerous at barriers such as the 
skin, respiratory tract and GI tract (Sayed et al., 2008). There are two subtypes of mast cell which are 
determined based upon their protease content. The first contains only tryptase and is termed MCT. 
The second contains tryptase, chymases and carboxypeptidase A and is denoted MCTC. MCT are the 
predominate subtype found in the human lung and bronchus. However, similar numbers of both 
subtypes are found in the pulmonary vasculature (Irani et al., 1986; Andersson et al., 2009). 
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Mast cells are largely associated with allergic asthma. As previously explained, following the 
sensitisation process, allergen binds to allergen specific IgE on high affinity FcεRI receptor at the mast 
cell surface. This results in cross linking of the complexes and subsequent mast cell degranulation to 
release mediators such as histamine, cysteinyl leukotrienes and prostaglandins. These mediators act 
to cause the EAR characterised by rapid bronchoconstriction, oedema and mucus secretion (Barnes, 
2008; Holgate, 2008a).  
Following this immediate release of mediators, mast cells have also been shown to synthesise and 
release a host of cytokines, chemokines and growth factors implicated in the chronic inflammation 
associated with asthma. Indeed, activated mast cells have been shown to synthesise and release 
cytokines associated with Th2 pathology such as IL-4 and IL-13 (Galli & Tsai, 2012; Bradding, Walls & 
Holgate, 2006). Mast cells have also been implicated in airway remodelling events. The number of 
mast cells present in ASM bundles is increased in asthmatics compared to healthy controls and they 
have been shown to promote the release of TGFβ (important in ASM fibrosis) from ASM (Brightling et 
al., 2002; Woodman et al., 2008). 
Mast cells are often found in close proximity to nerve terminals and as such are thought to interact 
with sensory and parasympathetic neurons (Nilsson et al., 1990; Marshall, 2004). Mast cell mediators 
such as histamine and 5-HT have been shown to cause depolarisation of parasympathetic neurons and 
antigen mediated bronchoconstriction has been shown to be dependent on mast cell mediator release 
(Myers, Undem & Weinreich, 1991; Undem et al., 1995). Overall this implies that mast cell derived 
spasmogens may contribute to antigen induced bronchoconstriction via the activation of airway 
nerves. 
1.5.8 Basophils 
Basophils are granulocytes which develop in the bone marrow and then circulate in the peripheral 
blood. They are understood to play a similar role to mast cells in allergic disease but their specific 
function is less well understood (Voehringer, 2013). They express high affinity FcεRI on their cell 
surface and have been shown to respond to IgE stimulation to release mediators such as histamine. 
As such they have been implicated in immediate bronchoconstriction events such as the EAR 
(Schroeder et al., 1994; Seder et al., 1991; Thompson, Metcalfe & Kinet, 1990; Nabe et al., 2013). They 
have also been shown to release Th2 cytokines such as IL-4 and IL-13 amongst other inflammatory 
mediators and are thought to orchestrate allergic inflammation (Min et al., 2004; Voehringer, Shinkai 
& Locksley, 2004; Kondo et al., 2008). There is also evidence to suggest that basophils function as 
APCs. They have been observed to migrate to the lymph nodes upon allergen stimulation and have 
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been found to be important in the differentiation of Th2 cells via IL-4 release (Perrigoue et al., 2009; 
Sokol et al., 2009). 
1.5.9 Immunoglobulins 
Immunoglobulins are antibodies produced by B-cells. There are five main isotypes which have been 
identified: IgA, IgD, IgE, IgG and IgM. The main isotype implicated in allergic asthma aetiology is IgE 
(Schroeder & Cavacini, 2010). As previously explained, antigen presentation along with Th2 cytokines 
induces B-cells to produce IgE in a process known as class switching. Allergen specific IgE then 
sensitises mast cells and basophils to future allergen exposure by binding to high affinity FcεRI on the 
cell surface. Upon re-exposure, the allergen is recognised by and binds to the antigen binding site on 
IgE resulting in activation of the mast cells and basophils (McKenzie et al., 1999; Grünig et al., 1998; 
Barnes, 2008). High affinity FcεRI and low affinity FcεRII are both capable of binding IgE and these 
receptors are present on, and expression can be induced on, a range of other allergic cells such as 
eosinophils, B-cells, T-cells and macrophages. As such, IgE could play a role in the chronic inflammation 
associated with asthma (Dullaers et al., 2012). Due to the strong association of IgE and asthma, IgE is 
now a target for new therapeutics. Omalizumab is an anti-IgE antibody which targets IgE to prevent it 
from binding to high affinity FcεRI. In the clinic this has been shown to inhibit allergen induced 
responses such as the EAR and LAR. Reduced frequency of asthma exacerbations and decreased use 
ICS were also reported with treatment. A review of the clinical trial data concluded that although 
reductions to symptoms were modest, overall treatment improved exacerbations (Normansell et al., 
2014). 
IgG is an immunoglobulin with 4 main subtypes (IgG1-4) mainly found in the blood. Its main role has 
been identified as protecting the body from pathogen invasion, although roles within allergy and 
asthma have been suggested. Increased levels of IgG1 have been reported in the BAL fluid of asthmatic 
patients (Out et al., 1991; Kitz, Ahrens & Zielen, 2000). Exposure to allergens such as HDM has been 
associated with IgG1 and IgG4 production (Platts-Mills et al., 2001). More specifically, development of 
the LAR has been associated with increased serum levels of IgG and IgE, with some studies suggesting 
that levels IgG1 rather than IgE is predictive of the LAR following allergen challenge (Pelikan & Pelikan-
Filipek, 1986; Ito et al., 1986). IgG is known to interact with FC gamma receptors (FcγRs) which are 
expressed on many effector cell types such as macrophages, eosinophils, neutrophils, basophils, B-
cells and mast cells. Due to this, there is an association of IgG with allergic inflammation (Williams, 
Tjota & Sperling, 2012). Studies have demonstrated this by showing that inhalation of anti-allergen-
IgG immune complexes can induce Th2 type airway inflammation and eosinophilia (Hartwig et al., 
2010). 
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1.5.10 Epithelial Cells 
Epithelial cells line the airways and are capable of releasing a plethora of cytokines in response to cell 
damage induced by environmental and endogenous stimuli. These cytokines are thought of as 
mediators between innate and adaptive immunity as they have been shown to direct adaptive and 
innate cellular responses (Islam & Luster, 2012; Jovanovic, Siebeck & Gropp, 2014). The main 
epithelium derived innate cytokines identified in the context of allergic asthma are TSLP, IL-25 and IL-
33 and will be discussed below. 
1.5.10.1 TSLP 
TSLP is released by epithelial cells and has been associated with the promotion of Th2 responses. This 
is understood to occur via promoting dendritic cell maturation. TSLP treatment of dendritic cells has 
been shown to promote the proliferation of CD4+ T-cells and production of IL-4, IL-5 and IL-13 
(Soumelis et al., 2002). Elevated levels of TSLP have been found in the BAL fluid of asthmatic patients 
compared with healthy controls which also correlates with Th2 cytokine production (Ying et al., 2005; 
Shikotra et al., 2012). Increased TSLP expression has been shown in animal models of allergic asthma 
which also correlates with allergic inflammation, AHR and airway remodelling events (Zhou et al., 
2005; Shi et al., 2008; Chen et al., 2013). TSLP has also been shown to activate mast cells to produce 
Th2 cytokines such as IL-13, thus, enhancing mast cell driven responses in the lungs (Jovanovic, Siebeck 
& Gropp, 2014). Other observed roles of TSLP in allergic asthma include the suppression of IL-10 
production from Tregs and so the reduction of their repressive abilities in terms of allergic inflammation 
(Nguyen, Vanichsarn & Nadeau, 2010). TSLP has also been observed to activate sensory nerves which 
are increasingly being implicated in allergic asthma (Wilson et al., 2013) (Later discussed in section 
1.6). 
1.5.10.2 IL-25 
IL-25 has also been linked with the promotion of Th2 responses in allergic inflammation.  Animal 
models have demonstrated that IL-25 induces features of asthma such as AHR, eosinophilia and 
remodelling events (Fort et al., 2001; Sharkhuu et al., 2006; Angkasekwinai et al., 2007; Gregory et al., 
2013). IL-25 released by epithelial cells in response to cell damage has been shown to activate 
receptors in innate lymphoid type 2 (ILC2) cells (discussed in later section) which respond by secreting 
Th2 cytokines. It has also been shown to promote the development of multipotent progenitor cells to 
give rise to mast cells, basophils and macrophages (Jovanovic, Siebeck & Gropp, 2014; Saenz et al., 
2010). 
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1.5.10.3 IL-33 
IL-33 is also released in response to epithelial cell damage. This cytokine binds to the ST2 receptor (an 
IL-1 family receptor) which is found on cell types including Th2 cells, mast cells, basophils, ILC2s and 
eosinophils. This induces the release of a plethora of cytokines including IL-4, IL-5 and IL-13 from these 
cell types (Imai et al., 2013; Jovanovic, Siebeck & Gropp, 2014). Animal models have shown IL-33 to 
exacerbate allergic responses such as inflammation, AHR and airway remodelling (Kurowska-Stolarska 
et al., 2008; Oboki et al., 2010; Stolarski et al., 2010; Kouzaki et al., 2011). 
1.5.11 Innate Lymphoid Cells 
ILCs are a family of effector cells which are increasingly being implicated in inflammatory diseases such 
as allergic asthma. They are described as innate as they do not express a TCR and react independently 
of specific antigens (Jovanovic, Siebeck & Gropp, 2014). The specific characteristics of these cell types 
have not yet been fully elucidated but a classification scheme based on functional criteria such as the 
cytokine milieu they produce has been described (Bernink, Mjösberg & Spits, 2013). The subtypes 
within this effector cell family are ILC1, ILC2 and ILC3 cells. The subtype most widely implicated in 
allergic airways disease are ILC2s which will be discussed in more detail below. 
ILC2s were previously known as natural helper cells or nuocytes and require the transcription factors 
RAR-related orphan receptor α (RORα) and GATA-3 for effective development (Spits & Cupedo, 2012; 
Halim et al., 2012b; Wong et al., 2012; Hoyler et al., 2012). They are responsive to IL-25 and IL-33 and 
upon stimulation produce characteristic Th2 cytokines such as IL-5 and IL-13. Due to this they are 
associated with a Th2 like immune response and have been linked with hallmarks of allergic asthma 
such as enhanced serum IgE levels and eosinophilia (Yu et al., 2014). 
In the lung, upon allergen exposure, epithelial cell damage is thought to occur resulting in the release 
of IL-33. This cytokine has been shown to activate ILC2s via the ST2 receptor (IL-33 receptor) expressed 
on the cell surface, which in turn results in the release of Th2 cytokines and associated asthma 
pathology (Yu et al., 2014; Dekruyff et al., 2014). Animal studies have demonstrated that protease 
containing allergens damaged epithelial cells causing the release of IL-33 which activated ILC2s, 
resulting in enhanced Th2 cytokine levels, eosinophilia and remodelling events. Depletion of the ILC2 
population in these investigations resulted in decreased allergic asthma symptoms. Studies have also 
shown that ILC2s generally appear to be increased in the lungs of mouse models of allergic airways 
disease (Halim et al., 2012a; Wilhelm et al., 2011; Kearley et al., 2009; Barlow et al., 2012). 
ILC2s have also been shown to interact with other inflammatory cells in the allergic lung. Indeed, they 
are thought to be important in the control of lung eosinophilia due to their production of IL-5 
(Nussbaum et al., 2013). Their interaction with mast cells has also been observed. The IL-13 produced 
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by ILC2s has been shown to interact with mast cells, leading to their release of IL-33. Therefore, it 
could be suggested that the recognition of allergens by IgE on mast cells could lead to increased IL-33 
secretion and activation of ILC2s which then secrete IL-5 to enhance eosinophilia (Hsu, Neilsen & 
Bryce, 2010). On the other hand, Th2 cells have also been shown to express ST2 and so this pathway 
could also drive their expansion (Dekruyff et al., 2014). It should be noted that these interactions were 
observed in mast cells in the skin, but it is thought likely that it could also occur within the allergic lung 
(Roediger et al., 2013). 
Translational studies in human subjects involving this cell type are in their infancy. However, it has 
been reported that a non-B, non-T cell type producing IL-13 and IL-5 is present in the sputum of 
asthmatics but not healthy subjects. This cell type has also been shown to express receptors for and 
respond to IL-33 by producing IL-5 and Il-13 and has also been shown to increase in number after 
allergen inhalation challenge (Allakhverdi et al., 2009). Genome Wide Association Studies (GWAS) 
have identified genes for IL-33, ST2 and RORα as susceptibility genes for human asthma (Moffatt et 
al., 2010). As products of these genes are associated with ILC2 cell function, these GWAS studies imply 
a role for ILC2s in human disease. 
1.6 Innervation of the Lung 
The airways are innervated by a number of nerve fibre types. Interactions between nerves and the 
inflammation associated with asthma have been postulated by a number of studies and so 
understanding airway innervation is advantageous when conducting investigations into the 
mechanisms behind allergic asthmatic responses (Zhang et al., 2008; Weigand et al., 2009; Cyphert et 
al., 2009).  
The vagus nerve supplies all parasympathetic and most sensory nerve fibres to the airways, although 
some sensory nerves originate in the dorsal root ganglia (see figure 1.3). The cell bodies of vagal 
sensory fibres are found in the jugular and nodose ganglia with peripheral projections to the airways 
and central projections to the medulla (Belvisi, 2002). Symptoms of allergic disease such as 
bronchoconstriction and mucus hypersecretion have been shown to manifest following inappropriate 
activation of these nerve types (Barnes, 1992, 1996). 
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Figure 1.3:  Schematic representation of innervation of the airways. The vagus nerve supplies all 
parasympathetic and most of the sensory nerve fibres to the airways. Some sensory innervation 
originates from the dorsal root ganglia and these sensory fibres run with spinal sympathetic nerves. 
(Adapted from Belvisi 2002). 
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Motor control of the airways is predominantly exerted by efferent cholinergic parasympathetic 
nerves. These nerves originate in the vagal nuclei of the medulla and travel to the airways via the 
vagus nerve where they relay in the parasympathetic ganglia located within the airway wall. The main 
neurotransmitter involved in parasympathetic transmission is Acetylcholine (ACh) which binds to 
muscarinic receptors (Belvisi, 2002). Subtypes of muscarinic receptor thought to play important roles 
in the control of airway tone are M1, M2 and M3 receptors. M1 receptors are located within 
parasympathetic ganglia and activation results in the facilitation of cholinergic neurotransmission. M2 
receptors are thought to protect against bronchoconstriction by acting as feedback autoreceptors and 
inhibiting ACh release. M3 receptors are located on ASM and mucus glands and activation results in 
bronchoconstriction and mucus secretion (Barnes, 1992; Patel et al., 1995a; Barnes, 1995, 1996). 
Afferent airway sensory nerves are also important in the control of airway tone. The main purpose of 
airway sensory nerves is to relay sensory information from the airways to the Central Nervous System 
(CNS) in order to initiate appropriate motor outputs elicited via parasympathetic pathways (Coleridge 
& Coleridge, 1994). Airway sensory nerve receptors have been classified into categories of nerve fibre 
types based on their functional properties namely; slowly adapting stretch receptors (SARs), rapidly 
adapting stretch receptors (RARs), and C-fibre receptors. SARs are primarily involved in the control of 
breathing pattern. RARs respond to mechanical stimuli such as lung hyper- and hypo-inflation of the 
lung. C-fibre receptors respond to chemical stimuli such as mediators released in lung inflammation 
and as such are considered to be of most relevance with respect to asthma (McAlexander, Myers & 
Undem, 1999; Fox et al., 1993a; Adcock, 2002; Belvisi, 2002).  
C-fibres originate in the nodose and jugular ganglia. They are activated by chemical stimuli but not by 
mechanical stimuli such as changes in pulmonary volume. As such, activation of these fibres by 
chemical stimulation is thought to occur directly rather than indirectly as a result of 
bronchoconstriction. Mediators which activate these fibres include inhaled irritants (such as cigarette 
smoke and air pollution), aromatic compounds in food and perfume (such as mustard oil, wasabi and 
cinnamon) and endogenous inflammatory mediators (such as PGE2) (Coleridge & Coleridge, 1984; 
Mohammed, Higenbottam & Adcock, 1993; Riccio & Proud, 1996; Lee & Pisarri, 2001; Undem et al., 
2004). In addition to relaying sensory nerve information to the CNS, the activation of c-fibres has also 
been shown to result in local axonal reflexes and the release of neuropeptides such as calcitonin gene 
related peptide (CGRP), Substance P (SP) and Neurokinin A (NKA) (Barnes, 1986, 1995). Studies have 
shown that the peripheral release of neuropeptides can contribute to inflammatory processes in the 
lung resulting in bronchoconstriction, mucus production and oedema (Nasra & Belvisi, 2009). As such, 
local effects of stimulation in addition to central reflex events leading to parasympathetic cholinergic 
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effector responses must be considered when studying c-fibres and their role in innervation of the 
allergic asthmatic lung. 
1.7 Transient Receptor Potential Receptors and Asthma 
The transient receptor potential (TRP) superfamily of ion channels are cation-selective 
transmembrane proteins consisting of six subfamilies (TRPC, TRPV, TRPM, TRPA, TRPP and TRPML) 
based on sequence homology (Clapham, 2003). These receptors are increasingly being identified in a 
range of cell types associated with respiratory diseases such as asthma (Banner, Igney & Poll, 2011a; 
Prasad et al., 2008). This section will summarise the key roles of four members of the TRP family in 
asthma: TRPA1, TRPV1, TRPV4 and TRPM8. 
1.7.1 TRPA1 
TRPA1 is thought to be mainly expressed in neurons such as airway sensory nerves (Bautista et al., 
2006b; Story et al., 2003; Bandell et al., 2004; Jang et al., 2012; Nassenstein et al., 2008). It has also 
been reported to be expressed in non-neuronal tissues such as human and mouse lung; and in asthma 
relevant cell types such as CD4+ T-cells, CD8+ T-cells, B-cells and mast cells (Banner, Igney & Poll, 
2011a; Prasad et al., 2008). Links between the symptoms of asthma and TRPA1 activation are also 
beginning to emerge. For example, studies have shown that environmental irritants usually causing 
asthma-like symptoms also activate TRPA1 in the airways (Deering-Rice et al., 2011; Shapiro et al., 
2013). 
Roles for TRPA1 in allergic airway inflammation and AHR have been explored by researchers. These 
studies have mainly utilised murine models whereby GM strains could be applied. Hox et al (2013) 
showed TRPA1 to be involved in non-allergic AHR. In this investigation the authors modelled the 
increased incidents of AHR in swimmers in mice via exposure to hyperchlorite. When TRPA1 deficient 
mice were applied, the AHR was abolished. Similarly, it has been reported that TRPA1 deficient mice 
have reduced inflammation and AHR when applied to ovalbumin (OVA) driven murine models of 
allergic asthma (Caceres et al., 2009). Although conversely, a study by Spiess et al (2013) showed that 
exposure to acrolein (a known TRPA1 agonist) resulted in a decreased inflammatory response in their 
murine allergic asthma model. It should be noted that although acrolein is defined as a TRPA1 agonist, 
it is not considered a clean compound. Due to this it could be expected to elicit a number of different 
effects in vivo. Animal models utilising more clinically relevant allergens (e.g. HDM) are emerging and 
may help to further elucidate the role of TRPA1 in key features of allergic asthma such as inflammation 
and AHR. 
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Studies have also indicated a direct role for TRPA1 in the control of airway tone. Andre et al (2008) 
reported that activation of TRPA1 channels on isolated guinea-pig bronchus resulted in contraction 
which was found to be secondary to the release of neuropeptides via local axons. Within the 
Respiratory Pharmacology group, TRPA1 was found to be associated with the characteristic 
bronchoconstriction of the LAR (Raemdonck et al., 2012). This will be discussed in more detail in 
section 1.8. 
1.7.2 TRPV1 
Similarly to TRPA1, TRPV1 has been reported to be mainly expressed in airway sensory nerves but is 
also expressed in lung tissue (Banner, Igney & Poll, 2011a; Jang et al., 2012; Kunert-Keil et al., 2006). 
It is thought to play a role in the control of airway tone as agonists of TRPV1 have been shown to 
contract isolated guinea-pig ASM. This constriction has been demonstrated to involve the release of 
sensory neuropeptides from finite stores in nerve endings which consequently act upon neurokinin 
receptors on ASM (Belvisi et al., 1992). It is currently unclear whether TRPV1 is involved in 
bronchospasm in humans and if its action is altered in diseases such as asthma. 
TRPV1 is increasingly been shown to be involved in inflammatory processes such as those in allergic 
asthma. Animal models have so far been useful in exploring this but results produced are often 
conflicting. Rehman et al (2013) reported that TRPV1 modulation inhibited inflammation, AHR and 
airway remodelling in an IL-13 driven allergic asthma model. However, other studies have indicated a 
protective role for TRPV1 in allergic inflammation (Mori et al., 2011) and some have reported that no 
part at all is played by TRPV1 in features of allergic asthma (Raemdonck et al., 2012; Caceres et al., 
2009). 
1.7.3 TRPV4 
TRPV4 expression has been reported in a number of tissues in the lung including ASM, lung vessel and 
alveolar wall (Grant, Amadesi & Bunnett, 2007; Jia et al., 2004; Alvarez et al., 2006; Dietrich et al., 
2006; Yang et al., 2006). It has been shown to have roles in thermosensitisation, 
mechanosensitisation, and osmotic stress (Watanabe et al., 2003; Strotmann et al., 2000; Suzuki et 
al., 2003; Liedtke & Friedman, 2003a). The bronchial fluid of asthmatics has been reported to be 
hypotonic due to airway remodelling and this implies a role for TRPV4 in asthma (Liedtke & Simon, 
2004). TRPV4 in isolated human and guinea-pig trachea has also been shown to be activated by 
hypotonic solution and results in contraction (Jia et al., 2004). 
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1.7.4 TRPM8 
Little TRPM8 expression data has been published but it has been reported to be present in airway 
sensory nerves and human bronchial epithelial cells (Peier et al., 2002; Li et al., 2011b). It is a 
thermosensor of temperatures approximately 15-28 °C and, consequently, TRPM8 activators include 
compounds which elicit a cooling sensation such as menthol and eucalyptol (McKemy, Neuhausser & 
Julius, 2002; Zhou et al., 2011). 
The role of TRPM8 in airway diseases such as asthma remains fairly unexplored; however, certain links 
have been made. Inhalation of cold air has been shown to trigger symptoms of asthma such as 
bronchoconstriction, cough, plasma extravasation and mucosal secretion (Carlsen & Carlsen, 2002). 
TRPM8, being a thermosensor, has been linked to this (Li et al., 2011b; Fisher, 2011). It has also been 
reported to be involved in cold triggered mast cell activation and so further study could implicate it in 
inflammatory processes in diseases such as asthma (Cho et al., 2010b). 
1.8 Aetiology behind the Late Asthmatic Response 
The LAR is experienced by approximately 50% of asthma suffers and is often used as an endpoint in 
clinical studies exploring new therapeutic options (Booij-Noord, Orie & De Vries, 1971; Booij-Noord et 
al., 1972). A number of hallmarks have been associated with the LAR although a clear picture of the 
mechanistic driving factors behind this response has yet to be uncovered. Studies so far exploring this 
particular feature of asthma have concluded that it is likely that the LAR is at least in part driven by 
inflammation. This is largely based on the fact that the response is accompanied by cellular 
inflammatory influx into the lung and that steroid treatment impacts on the response (Bousquet et 
al., 2000; Barnes, 2008). Studies have explored the roles of specific inflammatory cell types in this 
response. Others have suggested other driving mechanisms behind the LAR such as possible roles for 
airway sensory nerves (Raemdonck et al., 2012). 
Clinical studies have demonstrated specific roles for T-cells within the LAR. Increased numbers of 
activated T-cells have been observed in the bronchial mucosa and BAL fluid of patients with atopic 
asthma (Walker et al., 1991; Gerblich, Salik & Schuyler, 1991; Azzawi et al., 1990; Bentley et al., 1993). 
Allergen challenge in atopic asthmatics has also been associated with increased numbers of BAL fluid 
T-cells at 6 hours post challenge, the LAR time-point (Gratziou et al., 1996). Studies utilising 
Cyclosporin A (a T-helper cell inhibitor) to investigate asthma specific endpoints concluded a role for 
T-cells within the LAR (Khan et al., 2000). Other studies involving the inhalation of T-cell peptides 
derived from feline allergen Fel d 1 demonstrated the induction of an isolated LAR in atopic asthmatics 
(Ali et al., 2004b). More specifically, CD4+ T-cells have been identified in increased numbers in 
bronchial biopsies from asthmatics and allergen challenge has been shown to be associated with less 
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circulating CD4+ T-cells in isolated early responders compared with dual responders (those displaying 
an EAR and LAR) (Muratov et al., 2005). 
Animal models have also implicated T-cell subsets in the driving mechanisms behind the LAR. CD4+ 
and CD8+ T-cells were found to be increased in BAL fluid 4 hours post allergen challenge in the lungs 
of dogs with ragweed allergy (Out et al., 2002). Mouse asthma models have demonstrated an increase 
in the accumulation of CD4+ T-cells and associated cytokine profile (IL-4, IL-5, IL-13) in the airway 
correlated to a LAR (Nabe et al., 2005). The application of  anti-CD4 monoclonal antibodies to these 
mouse LAR models has also demonstrated a central role for CD4+ cells in this response (Meyts et al., 
2008; Nabe et al., 2011a). Studies have also shown that transferring OVA reactive Th-cell clones into 
naïve mice have resulted in an LAR upon OVA challenge (Ohtomo et al., 2009). Rats have also been 
traditionally used to model the LAR. Watanabe et al (1995) demonstrated the importance of CD4+ T-
lymphocytes in Brown Norway rats using an adoptive transfer model of the LAR. In this study, naïve 
Brown Norway rats received OVA-primed CD4+ T-cells and upon exposure to aerosolised OVA 
exhibited a sustained bronchoconstriction (Watanabe et al., 1995). 
CD8+ cells have also been explored with respect to the LAR in animal models. Increased numbers of 
CD8+ T-cells have been found in the airway submucosa of sensitised Brown Norway Rats exposed to 
OVA (Haczku et al., 1995b; Watanabe et al., 1995). It has been shown that depletion of CD8+ cells using 
a monoclonal antibody in the Sprague Dawley Rat enhances the LAR (Olivenstein et al., 1993a; 
Allakhverdi et al., 2000). Suzuki et al (1999) demonstrated that adoptive transfer of CD8+ T-cells from 
sensitised donors into sensitised recipients resulted in a suppression of the LAR upon allergen 
exposure(Suzuki et al., 1999). The LAR suppression was associated with a decrease in IL-4 mRNA 
positive cells and an increase in IFN-γ positive cells in BAL fluid obtained at the time point of LAR. It 
has been shown that administration of exogenous IFN-γ can reduce the LAR (Isogai et al., 2000). It has 
also been well documented that IFN-γ can suppress the proliferation of Th2 type CD4+ T-cells 
(Gajewski, Goldwasser & Fitch, 1988; Gajewski, Joyce & Fitch, 1989; Young & Hardy, 1995; Nakamura 
et al., 1997) and it has been shown to inhibit the infiltration of CD4+ cells into the airways in a mouse 
allergic asthma model (Iwamoto et al., 1993). CD8+ T-cells are known producers of IFN-γ (Kemeny et 
al., 1994; Li et al., 1995) and so could elicit a protective effect in the allergic airway via this cytokine.  
Isogai et al (2003) investigated this further by isolating the highly expressing IFN-γ cells, CD8+γδ T-cells, 
from sensitised and unsensitised Brown Norway rats and adoptively transferring them to sensitised 
recipients. Upon OVA challenge, the recipient rats displayed a significantly decreased LAR. The levels 
of BAL Th2 type cytokines (IL-4, IL-5 and IL-13) were significantly decreased and levels of IFN-γ were 
significantly increased in recipients compared to controls, providing further evidence for a suppressive 
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effect of CD8+ cells on CD4+ cells and the LAR via the cytokine IFN-γ (Isogai et al., 2003).  In a later 
study, the authors again utilised their adoptive transfer model and showed that pre-treatment of 
CD8+γδ T-cells with an antisense oligonucleotide to inhibit IFN-γ before transfer into sensitised 
recipients resulted in complete recovery of the LAR compared with recipients receiving untreated 
CD8+γδ T-cells (Isogai et al., 2007).  
Isogai and colleagues combined the studies demonstrating the central role of CD4+ cells in driving the 
LAR and those exhibiting the suppressive effects of CD8+ cells in this response. In this investigation 
they demonstrated induction of an LAR response by adoptively transferring CD4+ cells into recipient 
rats. They then showed that by depleting CD8+ cells using a monoclonal antibody an enhanced LAR 
was exhibited (Isogai et al., 2005). 
Overall, these studies demonstrate that the balance between CD4+ and CD8+ cells in the allergic airway 
could be a likely determinant of the LAR. Levels of these cell types have been explored clinically in the 
asthmatic lung. Human subjects experiencing an isolated EAR after undergoing allergen challenge 
have been shown to have relative increases in CD8+ cells in the BAL fluid compared to patients 
experiencing a dual response who have increased levels of CD4+ cells in their BAL fluid (Gonzalez et 
al., 1987). It has also been postulated that T-cell dysfunction is involved in the mechanisms behind 
allergic respiratory tract disease (Rola-Pleszczynski & Blanchard, 1981). Studies assessing the effects 
of intradermal challenge in humans showed that a higher proportion of CD4+ T-lymphocytes and a 
lower proportion of CD8+ T-lymphocytes were accumulated in skin chamber fluids during the late 
phase response (Werfel et al., 1995). Although it should also be noted that studies investigating the 
patient characteristics indicating an LAR have showed that correlation exists between peripheral T-
lymphocytes and LAR, but not the late phase cutaneous response and LAR(van der Veen et al., 1999). 
So far it seems likely that there could be interactions between the CD4+ and CD8+ T-cell populations in 
the driving mechanisms of the LAR. CD4+ T-cell – CD8+ T-cell interactions have been demonstrated by 
researchers. It has been shown that when a naïve CD8+ T-cell encounters antigen binding to MHC-I 
molecules on the surface of an APC which is also bound to a CD4+ T-cell, the expression of 
costimulatory molecules can activate the CD8+ T-cell (Azuma et al., 1992). Researchers have also 
speculated that cytokines liberated from CD4+ T-cells such as IL-2 and IL-4 may activate the CD8+ T-
cells (Isogai et al., 2005). Direct effects of CD8+ cells on CD4+ cells have been shown through interaction  
of Fas ligand-Fas receptor where they have been shown to induce CD4+ T-cell apoptosis (Noble, 
Pestano & Cantor, 1998). Further investigations into these interactions and mechanisms further 
downstream of them with respect to responses such as the LAR could lead to the discovery of 
promising new drug targets. 
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There are a plethora of subsets of CD4+ and CD8+ T-cell which exist. Investigations into more specific 
cell types, their associated cytokines and their effects on the LAR have begun. Th2 cells and their 
cytokines have been linked to features of asthma extensively. In a study by Molet et al (1999) the 
inhibition of IL-4 in CD4+ cells blocked the adoptive transfer of the LAR into naïve animals, highlighting 
IL-4 to be essential in this response (Molet et al., 1999).Murine models of asthma have also elucidated 
IL-13 to be essential in the LAR (Taube et al., 2002). However, clinical trials targeting Th2 cytokines 
individually have yielded disappointing results (Holt & Sly, 2007) implying that targeting individual 
cytokines alone are insufficient in inhibiting the LAR (O’Byrne, Inman & Adelroth, 2004). Wenzel and 
colleagues have since demonstrated that Pitrakinra, a competitive inhibitor of the IL-4Rα complex, 
interferes simultaneously with the actions of IL-4 and IL-13 and significantly attenuates the LAR 
(Wenzel et al., 2007). 
The inhibitory role of CD8+ T-cells in the LAR has so far been shown to be due to actions of the CD8+γδ 
T-cell and the cytokine IFN-γ (Isogai et al., 2000, 2003, 2007). Allergen inhalation challenge in atopic 
asthmatic subjects is associated with decreased IFN-γ positive CD8+ T-lymphocytes in peripheral blood 
and sputum (Matsumoto et al., 2002; Yoshida et al., 2005) and so a deficiency in this cell type could 
account, at least partially, for the LAR in asthmatics. The mechanism by which IFN-γ exerts its 
protective effect has been speculated upon by researchers. For example, the phagocytic actions of 
alveolar macrophages have been shown to be stimulated by IFN-γ (Nacy et al., 1991; Careau & 
Bissonnette, 2004). It has also been postulated that CD8+γδ TCRs are capable of recognising antigen 
directly in the absence of antigen processing (Schild & Chien, 1994). 
IL-10, a typical anti-inflammatory cytokine, has been shown to be increased in the airway at the time 
point of LAR in a murine model and is produced by CD4+ regulatory T-cells (Nabe et al., 2005; 
Hawrylowicz & O’Garra, 2005).Afshar et al (2013) demonstrated an increase in T-regulatory cells in 
BAL fluid in a murine asthma model following allergen challenge (Afshar et al., 2013). In a clinical study, 
Kinoshita et al (2014) showed dual responders to exhibit a diminished percentage of airway T-
regulatory cells after allergen challenge compared with isolated early responders. The authors also 
showed fewer T-regulatory cells compared with CD4+ T-cells in the dual responders and the 
percentages of T-regulatory cells were correlated to the magnitude of LAR (Kinoshita et al., 2014). It 
could therefore be stipulated that an imbalance in the numbers of inhibitory T-regulatory cells is an 
important determinant of the LAR in atopic asthmatics. 
T-helper 17 cells have been shown to be activated by antigen stimulation in vivo (McKinley et al., 2008; 
Wilson et al., 2009). A monoclonal antibody targeting IL-17 in a murine model was found to suppress 
the LAR. The authors of this paper also demonstrated an increase in the numbers of CD4+IL17+ cells 
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(T-helper 17 cells) correlated with the LAR and concluded this cell type to be the origin of the LAR 
driving cytokine IL-17 (Mizutani et al., 2012). In clinic, it has recently been shown that the Th17/Treg 
ratio is significantly enhanced in dual responders compared to isolated early responders post allergen 
challenge. It has, therefore, been proposed that this imbalance post allergen challenge is an important 
contributor to the development of the LAR (Singh et al., 2014). 
The LAR has also been linked to the B-cell – Mast cell – IgE products axis. Some clinical studies have 
indicated a prominent role for these cell types and mediators in the LAR. Increased numbers of mast 
cells and increased levels of IgE in BAL fluid has been associated with the magnitude of the LAR 
(Peebles et al., 2001; Crimi et al., 1991). Patients being treated with corticosteroids (which inhibit the 
LAR) have been shown to have decreased numbers of mast cells in the smooth muscle and epithelium 
(James et al., 2012). Disodium Cromoglycate, a known mast cell stabiliser, has been shown to inhibit 
the LAR in asthmatic patients (Cockcroft & Murdock, 1987; Pepys et al., 1968, 1974; Booij-Noord, Orie 
& De Vries, 1971; Cieslewicz et al., 1999b). Anti-IgE monoclonal antibodies have also been shown to 
suppress allergen induced late phase bronchoconstriction (Busse et al., 2001; Holgate et al., 2004, 
2005; Fahy et al., 1997). 
In contrast, other clinical studies have alluded to mechanisms independent of B-cells, Mast cells and 
IgE to be important in driving the LAR. In asthmatic patients, Durham et al(1984) failed to see an 
association between total or allergen specific IgE and the LAR. Total IgE has been shown to be a poor 
indicator of the LAR (Tschopp et al., 1998). In the African population, serum levels of IgE have even 
been reported to be higher in non-asthmatics compared to asthmatics (Scrivener & Britton, 2000). 
Studies involving the inhalation of T-cell peptides derived from the feline allergen Fel d 1 
demonstrated the induction of an isolated LAR without an accompanying EAR, implying the LAR to be 
T-cell dependent and IgE independent (Ali et al., 2004a). Khan et al (2000) demonstrated that while 
Cyclosporin A decreased the LAR in patients, no effects were seen on the EAR indicating that the LAR 
occurs independently of the B-cell-Mast cell- IgE products axis. 
Animal models of the LAR have also resulted in conflicting conclusions being drawn on the role of B-
cells, Mast cells and IgE in the LAR. Mizutani et al (2012) demonstrated that mice sensitised with OVA-
specific IgE displayed an LAR upon OVA challenge. Inhibitors of mast cell products such as Cysteinyl 
Leukotrienes have been shown to inhibit the LAR at least partially (Nabe et al., 2002; Roquet et al., 
1997). Nabe et al (2005) demonstrated a correlation between the presence of mast cells and the ability 
to display an LAR in a mouse asthma model. However, the authors in this investigation also exhibited 
that the LAR was not associated with IgE as Dexamethasone was shown to suppress the LAR but not 
plasma levels of IgE(Nabe et al., 2005).The same authors also more recently showed that applying an 
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antibody targeting mast cells did not attenuate the LAR (Nabe et al., 2013). As previously described, 
authors adoptively transferring CD4+ and CD8+ cells into rat models of the LAR noted that there were 
no changes in the EAR and serum IgE levels where there were effects upon the LAR (Watanabe et al., 
1995; Isogai et al., 2003). Interestingly, McMenamin et al. (1995) showed that CD8+γδ T-cells suppress 
plasma IgE levels, although the authors did not demonstrate a functional link to the LAR. 
Eosinophilia and the LAR have been traditionally associated. This is mainly due to the fact that steroid 
treatment has been shown to suppress both eosinophilia and the LAR (Kidney et al., 1997; Cieslewicz 
et al., 1999b; Inman et al., 2001). Conversely, targeting eosinophilia via the application of monoclonal 
antibodies has been shown to have minimal impact on the LAR in pre-clinical models and in clinic 
(Flood-Page et al., 2007). Although it must be noted that, as previously described in section 1.5.3, the 
interpretation of clinical studies utilising antibodies targeting eosinophils is currently under review. 
The aetiology of the LAR has also been associated with sensory nerve interactions. Raemdonck et al 
(2012) showed that the LAR but not the EAR was lost under general anaesthesia in pre-clinical asthma 
models. The application of ruthenium red (a non-selective cation channel blocker) also resulted in 
inhibition of the LAR, confirming a role for sensory nerves. Tiotropium, a long acting muscarinic 
receptor antagonist (LAMA) also attenuated the LAR, suggesting a role for cholinergic constrictor 
responses in the driving mechanisms behind the response. This overall led to the conclusion that 
airway sensory nerves, a central reflex component and cholinergic constrictor responses are involved 
in the driving mechanisms behind the LAR. These studies also concluded that the specific TRP channel 
TRPA1 was also associated with the LAR via the application of specific TRP channel blockers. It was 
suggested as a possibility that TRPA1 channels present upon airway sensory nerves could be triggered 
directly by allergen challenge, leading to the bronchoconstriction that is the LAR (Raemdonck et al., 
2012). Indeed, the functional relevance of TRPA1 on airway sensory nerves has been well 
characterised, although the role of TRPA1 present on inflammatory cell types remains to be elucidated 
and so could also plausibly play a role in the LAR (Grace et al., 2012a). 
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1.9 Current Asthma Treatments 
The current gold standard in asthma therapy involves the application of inhaled glucocorticoids in 
combination with short acting and long acting β2-adrenoceptor agonists. Inhaled glucocorticoids treat 
the chronic inflammation associated with asthma, whereas the β2-adrenoceptor agonists provide 
symptomatic relief against reversible bronchoconstriction (Mullane, 2011). This combination has been 
shown to provide effective asthma control in asthmatics in clinic and has been shown to be beneficial 
compared with glucocorticoid treatment alone (Aubier et al., 1999; Zetterström et al., 2001; Lalloo et 
al., 2003). 
β2-adrenoceptor agonists induce the relaxation of ASM in order to promote airway conductance. They 
bind to β2-adrenoceptors on ASM which induces intracellular signalling cascades. This ultimately 
results in the relaxation of ASM. A number of secondary mechanisms of action have also been 
described for  β2-adrenoceptor agonists including anti-inflammatory and anti-proliferative effects 
(Barnes, 1999; Yan et al., 2011; Shore & Moore, 2003; Kotlikoff & Kamm, 1996). 
Glucocorticoids are anti-inflammatory and are thought to exert their effects via a number of 
mechanisms. They are known to bind to Glucocorticoid Receptors (GR) in the cytoplasm of various cell 
types. This results in the GR dimerizing and migrating to the nucleus of the cell where it binds to a 
Glucocorticoid Response Element (GRE) (a location in the promoter region of steroid responsive 
genes). This results in the up regulation of anti-inflammatory gene transcription or the down 
regulation of pro-inflammatory gene transcription (Barnes, 1998; Barnes, Pedersen & Busse, 1998). 
During inflammatory states, the activation of proinflammatory transcription factors results in the 
increased expression of inflammatory cytokines, chemokines and adhesion molecules. Transcription 
factors are thought to act via two main mechanisms. They bind to promoter regions of DNA and recruit 
co-activator molecules to the DNA transcription factor complex whilst aiding in the binding of RNA 
polymerase to catalyse gene transcription. They may also act via modulating the chromatin structure. 
DNA is usually wound around core histones (a structure known as chromatin). In basal condition this 
is a closed structure and results in minimal gene expression. The binding of transcription factors 
induces Histone acetylation by Histone Acetyltransferase (HAT) and results in the opening of the 
structure. This enables increased binding of the DNA transcription factor complex to result in 
increased transcription. Glucocorticoids are thought to inhibit inflammation through recruitment of 
Histone Deacetyltransferases (HDACs). HDACs counteract the activity of HATs and reduce DNA 
transcription by increasing DNA winding and hence reducing the binding of transcription factors 
(Barnes, 1998; Barnes, Pedersen & Busse, 1998). Steroids have also been shown to interact directly 
with proinflammatory transcription factors such as NF-κB. In basal states, NF-κB is sequestered in the 
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cytoplasm. HDACs have been shown to induce GR deacetylation causing it to bind to the NF-κB 
complex to prevent it from translocating to the nucleus where it would usually promote the 
transcription of pro-inflammatory genes (Ito, Barnes & Adcock, 2000; Ito et al., 2006; Kagoshima et 
al., 2001). 
In the clinic the treatment of asthma is approached in a stepwise manner. Patients who present with 
mild intermittent symptoms are treated with inhaled short acting β2-adrenoceptor agonists (SABA) 
such as salbutamol. More severe cases are treated with a combination of low dose ICS (e.g. 
Budesonide or Beclamethasone) and Long Acting β2-adrenoceptor agonists (LABA) such as Salmeterol 
or Formoterol. Even more severe cases gain a higher dose of ICS or oral corticosteroid such as 
Prednisolone. If symptoms are still poorly controlled, add on therapies are incorporated into 
treatment regimes such as leukotriene antagonists, Phosphodiesterase inhibitors or Anticholinergics. 
(Barnes, 2010; Bateman et al., 2008) (See Figure 1.4). 
Despite the available effective therapies, approximately 5-10% of asthma patients have uncontrolled 
symptoms. These patients account for a huge amount of healthcare spending, highlighting an urgent 
need for new therapeutics. 
 
 
Figure 1.4: Step-wise approach to asthma treatment. (Adapted from Barnes 2010). 
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1.10 In vivo models of allergic asthma 
Pre-clinical models closely mimicking the cardinal features of asthma are useful in understanding 
the mechanisms driving the disease and in identifying novel therapeutic targets. They are also 
invaluable in further investigating existing therapeutics in terms of their efficacy and side effect 
profile where in clinic this would limit development. Asthma is a complex disease comprised of 
many symptoms and influencing factors and so not surprisingly animal models of asthma do not 
exhibit all features of the disease.  Experimentally induced animal models of asthma tend to mimic 
certain aspects of the disease with a focus on specific asthma endpoints. The purpose of this thesis 
is to investigate the mechanisms driving the LAR and as such this will be the endpoint of interest 
focused upon in this body of work. 
1.10.1 Ovalbumin Model 
Laboratory animal do not naturally develop allergic asthma. Classical models of allergic asthma utilise 
OVA to induce asthma like symptoms. The protocols used to induce allergic reactions involve two 
distinct phases: sensitisation and challenge. In the first phase, animals are sensitised to OVA by a 
systemic intraperitoneal injection of OVA plus an adjuvant such as AlumTM (later described in section 
1.10.2). The challenge phase is typically a topical dose (i.e. intranasal, aerosol or intratracheal) of OVA 
only. Different research groups employing these models may vary in their approach to these protocols 
in terms of doses, sensitisation times and challenge times but the general principle of a sensitisation 
phase followed by a challenge phase remains consistent. 
Systemic sensitisation in OVA-driven models of asthma results in a robust increase in total and OVA-
specific IgE (Beck & Spiegelberg, 1989). Following this phase, OVA challenge has been shown to induce 
multiple asthma-like symptoms such as EAR, LAR, non-specific AHR, allergic airway inflammation and 
airway remodelling events (Stevenson & Belvisi, 2008). As such, OVA-driven models of asthma are 
considered extremely robust and have been used extensively as a platform to profile novel 
therapeutics and delineate disease mechanisms.  
There are also disadvantages associated with this model. OVA models require systemic sensitisation 
and atopy in asthma is associated with the lungs. Due to this, systemic sensitisation is believed to be 
less clinically relevant than other topical routes (Gregory et al., 2009). However, some groups have 
shown that while topical sensitisation may initially produce increases in IgE, this response has been 
reported to decrease with time and is not considered to be robust (Holt, Batty & Turner, 1981).  
Tolerance to OVA as an inducer of allergic responses has also been widely reported as a practical 
disadvantage to the model (Van Hove et al., 2007; Swirski et al., 2002). Acute challenge protocols  (e.g. 
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2 weeks) have been shown to result in allergic asthmatic responses, however, these responses have 
been shown to dissipate following chronic OVA challenge (e.g. 6-8 weeks) (Yiamouyiannis et al., 1999).  
Few people tend to develop an allergy to OVA and so the use of this as an allergen has been 
questioned. Models utilising more disease relevant allergens such as HDM are currently under 
development. So far success has been achieved in modelling features of asthma such as AHR, airway 
inflammation and remodelling events using this allergen (Verheijden et al., 2015; Sivapalan et al., 
2014; Mariñas-Pardo et al., 2014). However, none of these recently developed HDM-driven models 
display an EAR and LAR. As such, the use of a HDM driven model in this thesis was unfortunately not 
a possibility. 
The need for an adjuvant in the OVA-driven model has also been noted as a disadvantage in terms of 
clinical relevance. Although it should be noted that adjuvant free models have also been described 
(Renz et al., 1992; Hessel et al., 1995; Blyth et al., 1996; De Bie et al., 1996; Besnard et al., 2011). 
Adjuvants will be discussed in more detail in the next section. 
1.10.2 Adjuvants 
Adjuvants are widely used in vaccinations to aid in the development of immunity and have been 
adapted for use in preclinical models of allergic disease to aid the sensitisation process. One of the 
most widely used adjuvants is AlumTM which is comprised of aluminium hydroxide and magnesium 
hydroxide. Despite being widely used in animal models of allergic disease and in human vaccinations, 
the mechanism of action of AlumTM and other adjuvants remains poorly understood. Nevertheless, 
research into these mechanisms has resulted in the suggestion of some theories which will be 
discussed below. 
The first theory proposed on the mechanism of action of adjuvants is the depot theory. It has been 
suggested that adjuvants form a depot to allow the slow uptake and presentation of allergens by APCs. 
Indeed, dendritic cells and allergen specific T-cells have been found around AlumTM precipitates. It has 
also been shown that the effects of adjuvants can be transferred between animals via the 
transplantation of these precipitates (Kool, Fierens & Lambrecht, 2012). However, others have also 
suggested that depot formation and the slow uptake of allergens may not be important in the 
mechanisms surrounding the effects of adjuvants. Researchers have shown that antigen presentation 
by APCs predominantly occurs 6-24 hours following allergen-adjuvant injection and the removal of the 
adjuvant depot 2 hours following injection did not affect B-cell and T-cell responses (Hutchison et al., 
2012). Other investigators also showed that mice deficient in fibrin (a key component of the adjuvant 
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depot) had comparable immune responses to wildtype mice following allergen-adjuvant 
administration (Munks et al., 2010). 
Adjuvants have also been shown to act on immune cell populations. It has been shown that adjuvants 
are capable of promoting monocyte differentiation into dendritic cell phenotypes with enhanced 
expression of co-stimulatory molecules such as MHC-II molecules. Enhanced IL-4 expression has also 
been reported as an effect of adjuvants. Overall, this has led to the proposal of the theory that Alum 
may act on T-cells to produce IL-4 which in turn promotes the increased expression of MHC-II 
molecules on dendritic cells derived from monocytes to enhance their antigen presentation 
capabilities (Seubert et al., 2008; Ulanova et al., 2001). 
Another theory surrounding the mechanisms behind adjuvant activity is that they can induce innate 
inflammatory responses which result in the promotion of allergen uptake by APCs. This is based on 
the fact that organic molecules such as LPS have a similar effect on the immunological response to 
that of adjuvants. Their effects are likely to be mediated via PAMPs and DAMPs to result in the release 
of inflammasome mediated cytokines (Eisenbarth et al., 2002). Indeed, AlumTM has been shown to 
induce the release of IL-1β and IL-18 from inflammatory cell populations via activation of the 
inflammasome which has been shown to be NLRP3 dependent (Li et al., 2008; Hornung et al., 2008; 
Kool et al., 2008a). AlumTM has also been shown to produce endogenous agents which activate the 
inflammasome. Uric acid acts as a danger signal and is released from dying cells. Necrotic cells which 
release Uric acid have been found around AlumTM injection sites (Goto & Akama, 1982, 1984; Goto et 
al., 1997; Shi, Evans & Rock, 2003). Uric acid has been shown to be capable of activating the NLRP3 
inflammasome resulting in the release of IL-1β and IL-18 (Martinon et al., 2006). In vivo experiments 
have also shown that AlumTM injection induced Uric acid release in the peritoneum which resulted in 
the activation and migration of APCs and T-cell proliferation. These effects were abolished with 
Uricase treatment (Kool et al., 2008b). Other studies have contradicted this mechanism of action. It 
has been proposed that the inflammasome is important in AlumTM-induced IL-1β production but this 
does not contribute to adjuvant effects (McKee et al., 2009). One study showed that Alum plus OVA 
application was able to induce the production of extracellular ATP (another DAMP) but this was shown 
not to contribute to AlumTM-induced immunity (Idzko et al., 2007; Kool et al., 2011). 
Other proposed mechanisms of action of adjuvants such as AlumTM include that it may stick to 
dendritic cells and interact with cell membrane lipids to promote high affinity binding of dendritic cells 
to CD4+ T-cells via adhesion molecules (Flach et al., 2011). A role for PGE2 acting independently of the 
inflammasome has also been proposed in the mechanisms behind AlumTM driven immunogenicity 
(Kuroda et al., 2011). 
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Overall, theories behind the mechanisms driving the adjuvant activity of AlumTM remain inconclusive 
and further investigation into this aspect of animal model development is warranted. 
1.10.3 Different Species as Asthma Models 
Animal models of allergic asthma have been established in various species such as the C57BL/6 and 
BALB/c mouse strains, the Brown Norway rat and the Dunkin-Hartley guinea-pig. Various different 
aspects of allergic asthma have been successfully modelled in these species such as EAR, LAR, allergic 
airway inflammation, AHR and airway remodelling events. The guinea-pig is less commonly used as an 
allergic asthma model in comparison with mice and rats due to an enhanced basal level of eosinophils 
in the lung and as such this section will focus mainly on rat and mouse models of asthma (Rothenberg 
et al., 1995). Although many features of allergic asthma have been successfully modelled in rats and 
mice, the following sections will highlight models of bronchoconstriction in response to allergen as 
the focus of this thesis is the LAR. 
1.10.3.1 Rat Models 
The Brown Norway rat is considered to be the most suitable rat strain for use as an allergic asthma 
model. This particular strain is a high IgE producer, it produces robust responses to allergens (distinct 
EAR and LAR) and the infiltration of allergic airway inflammation is considered to be similar to that 
seen in asthmatic patients (Murphey et al., 1974; Eidelman, Bellofiore & Martin, 1988; Elwood et al., 
1992; Haczku et al., 1995a). This particular model is considered advantageous due to the robustness 
of response to allergen challenge in comparison to other species used as allergic asthma models. 
1.10.3.2 Mouse Models 
The mouse is considered to be an advantageous model of allergic asthma due to the possibility of the 
application of GM strains and the fact that it comprises a highly characterised immune system. 
Classically, BALB/c mice were the preferred strain for developing allergic asthma models but more 
recently the use of the C57BL/6 strain has increased due to more GM strains being available on this 
genetic background. 
The EAR and LAR have been largely overlooked in murine asthma models in comparison to other 
features of asthma such as AHR and allergic inflammation. This may reflect the difficulty in achieving 
these endpoints in mice. Despite this, some research groups have reported the EAR and LAR in mouse 
models. Cieslewicz et al (1999) reported that in C57BL/6 mice systemic sensitisation and aerosolised 
challenge with OVA resulted in an EAR 5-30 minutes after challenge, followed by an LAR which peaked 
at 6 hours after challenge. The LAR displayed was considered to be clinically relevant due to the time 
point and a strong association with allergic airway inflammation. The EAR, however, was questionable 
in terms of relevance due to the fact that it was not dependent on IgE and mast cells (Cieslewicz et al., 
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1999a). Nabe et al (2005) demonstrated in BALB/c mice that systemic sensitisation plus 4 intratracheal 
doses of OVA resulted in an EAR and LAR. The EAR was associated with IgE and mast cells and the LAR 
with allergic airway inflammation (Nabe et al., 2005). In contrast, de Bie et al (2000) observed an EAR 
but no LAR in their adjuvant free OVA model (de Bie et al., 2000). 
So far, success in modelling the EAR and LAR in mouse models of allergic asthma has been limited. As 
such, little data is available on the characterisation of these models. Further evaluation of these 
models will hopefully highlight their strengths and weaknesses with respect to human disease in the 
future. 
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1.11 Thesis Plan 
The LAR is experienced by approximately 50% of asthma sufferers and is routinely used as a clinical 
endpoint when exploring new therapeutic options (Booij-Noord et al., 1972; O’Byrne, Dolovich & 
Hargreave, 1987; Stevens & van Bever, 1989; Muller et al., 1993). Despite this, the specific 
mechanisms driving the LAR remain unclear. Inhaled glucocorticoids are known to significantly 
attenuate the LAR implying a role for airway inflammation within the response (Bousquet et al., 2000; 
Barnes, 2008). Within the Respiratory Pharmacology group, animal models of the LAR have also 
suggested possible roles for airway sensory nerves, central reflexes and parasympathetic cholinergic 
constrictor responses (Raemdonck et al., 2012). The overall aim of this thesis was to build upon this 
body of work in order to further explore the driving mechanisms behind the LAR. 
1.11.1 Hypothesis 
The hypothesis that formed the basis of this project was; 
“Mast cells and airway sensory nerves are central to the driving mechanisms behind the LAR”. 
1.11.2 Aims 
The aims of this thesis are to: 
 Validate the clinical relevance of mouse and rat models of the LAR using the clinically relevant 
glucocorticosteroid Budesonide (Chapter 3). 
 Explore the roles of key allergic effector cells in the LAR via the application of GM mice to 
preclinical asthma models (Chapter 4). 
 Further explore the role of mast cells in the LAR via the application of Disodium Cromoglycate 
and Compound 48/80 to preclinical asthma models (Chapter 5). 
 Further characterise the role of airway sensory nerves in the LAR via the application of 
Pharmacological tools to animal models of the LAR (Chapter 6). 
 Investigate the possibility that Disodium Cromoglycate attenuates the LAR via a mechanism 
of action on airway sensory nerves using in vivo models and isolated vagus nerve experiments 
(Chapter 7). 
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2 General Methods 
2.1 Introduction 
This chapter outlines a general methodology for experimental protocols used throughout this thesis. 
Specific details of individual experimental protocols and statistical analyses are detailed in the 
methods section of individual chapters. 
2.2 Animals 
All experimental procedures were conducted in accordance with UK Home Office Guidelines for 
animal welfare based on the Animals (Scientific Procedures) Act of 1986. All animals were housed in 
individually ventilated cages (IVC) and a 12 hour light-dark cycle maintained. Prior to and during 
experimental periods, food and water was supplied ad libitum. 
2.2.1 Mice 
C57BL/6 wildtype (Harlan, UK), mast-cell knockout [KitW-sh/HNihrJaeBsmJ] (Jackson Laboratories Ltd, 
USA), B-cell knockout [B6J-IgHtm1 Mom](SchwImMR collaboration group, Switzerland), CD4 knockout 
[B6-CD4tm1 Mak](SchwImMR collaboration group, Switzerland), CD8 knockout[B6-CD8atm1 Mak] 
(SchwImMR collaboration group, Switzerland) and IgE knockout [BALB/c-IgEtm1Led](SchwImMR 
collaboration group, Switzerland)male mice aged 8-12 weeks were grown in house. Official strain 
names are given in square brackets. Original breeding pairs were purchased from suppliers as 
indicated. 
2.2.2 Rats 
Male Brown Norway Rats (200 g -225 g) were purchased from Charles River Laboratories (UK). Animals 
were housed for at least 7 days prior to experimental procedures being carried out. 
2.2.3 Guinea-Pigs 
Male Dunkin-Hartley Guinea-Pigs (300 g -350 g) were purchased from Charles River Laboratories (UK). 
Animals were housed for at least 7 days prior to experimental procedures being carried out. 
2.3 Validation of Genetically Modified Mice 
Commercial assays for genotyping were not available for all knockout mice. Therefore, it was decided 
to validate the GM mice in terms of their lung cell populations via the use of flow cytometry and 
histology. This was advantageous as it was possible to determine that the mice were in fact deficient 
of their specific knockout cell type as well as observing any changes in baseline levels of other 
leukocyte populations occurring as a result of genetic modification. 
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2.3.1 Cell Preparation 
Naïve animals were culled via overdose with Sodium Pentobarbitone (200 mg/kg i.p.). The systemic 
circulation was then perfused. This was done by opening the thoracic cavity and making an incision in 
the left ventricle and the left atria of the heart. The left ventricle was then cannulated and the systemic 
circulation perfused with sterile saline (0.9%) at approximately 100 mmHg pressure. The purpose of 
this was to remove contaminating systemic cell populations. 
The lungs were removed, weighed and finely chopped using a Mcllwain tissue chopper (Campden 
Instruments Ltd, UK) and transferred to 1 ml Roswell Park Memorial Institute media (RPMI)/Penicillin-
Streptomycin. This was then added to 4mls RPMI supplemented with 10% Foetal Bovine Serum (FBS), 
collagenase (1 mg/ml) and DNase (25 g/ml) and incubated in a water bath with gentle agitation for 
1 hour at 37 °C. Following this, samples were filtered using a 70 µm mesh sieve. The samples then 
underwent two rounds of centrifugation at 807 g, discarding the supernatant and resuspending the 
pellet in 10 mls RPMI (supplemented as previous) each time. For each sample, a total leukocyte cell 
count was performed using a Sysmex XP-300 cell counter (Sysmex Ltd., UK). 
2.3.2 Staining Protocol 
Cells were stained for surface markers as detailed in Snelgrove et al (2008). Briefly, cell suspensions 
were resuspended at 1x106 cells/ml and 200 µl transferred to the relevant wells of a 96-well v-
bottomed staining plate (Sigma, UK). The plates were centrifuged (1398 g, 2 minutes, room 
temperature) before the supernatant was discarded. The cells were stained using 50 µl per well 
(diluted 1/1000 in PBS) of a fixable near-IR dead cell stain kit for 633/635 nm excitation (Invitrogen, 
UK) and incubated for 15 minutes at room temperature. The basis of the live/dead cell stain kit is 
detailed in figure 2.1. A further 150 µl PBS per well was added before the plates were centrifuged 
(1398 g, 2 minutes, room temperature) and the supernatant discarded.  
Cell suspensions were then stained for surface markers using the relevant monoclonal antibody 
conjugate stains as detailed in Table 2.1. The stains were prepared in PBA (PBS containing 0.1% 
(wt/vol) sodium azide and 1% (wt/vol) BSA) before 30 µl of the relevant stain was added to each well 
and incubated for 30 minutes on ice. A further 150 µl per well PBA was added, the plate centrifuged 
(1398 g, 2 minutes, room temperature) and the supernatant discarded. The cells were washed a 
further two times by adding 200 µl PBA, centrifuging (1398 g, 2 minutes, room temperature) and 
discarding the supernatant. The cells were then fixed by adding 50 µl per well of 4% formaldehyde 
(diluted in PBS) and incubating at room temperature for 15 minutes. Following this a final wash in 100 
µl PBA was performed by resuspending and centrifuging (1398 g, 2 minutes, room temperature) 
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before a final resuspension in 200 µl PBA was performed. The plates were sealed and stored at 4 °C 
until Flow Cytometry was performed (Snelgrove et al., 2008). 
 
 
 
 
Figure 2.1: Demonstrating the basis of the live/dead cell stain kit. Assays are based upon the ability 
of the fluorescent reactive dye to react with cellular amines. The reactive dye can permeate the 
compromised membranes of necrotic cells and react with amines on the interior of the cell as well 
as on the cell surface. Viable cells are stained only on the cell surface. The difference in staining 
intensity between live and dead populations is typically 50-fold more intense in the dead 
population. (Adapted from Invitrogen Molecular Probes Experimental Protocols). 
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Stain Monoclonal Antibody Conjugates Dilution in PBA 
Stain 1 CD19 (FITC) 
NKp46 (PE) 
CD4 (PercP) 
CD8 (APC) 
100x 
200x 
200x 
200x 
Stain 2 Gr-1 (FITC) 
F4/80 (PE) 
CD11b (PercP) 
CD11c (APC) 
100x 
100x 
400x 
200x 
Stain 3 Gr-1 (FITC) 
SiglecF (PE) 
CD11b (PercP) 
CD11c (APC) 
100x 
200x 
400x 
200x 
 
Table 2.1: Outlining monoclonal antibody conjugate combinations and dilution factors used to 
stain cell populations. 
2.3.3 Flow Cytometry 
Data was acquired on a BD FACS Canto II (BD Biosystems, UK) and 30000 events per sample were 
analyzed using FlowJo analysis programme (Treestar Ashland, USA).  Forward scatter and side scatter 
gates were used to exclude debris, and dead cells were excluded using a fixable near-IR dead cell stain 
kit for 633 or 635-nm excitation (See figure 2.1). Cell types were characterised by their forward and 
side scatter profiles and by their specific phenotypes (See Table 2.2 and figures 2.3, 2.4 and 2.5). 
Unstained controls were used to account for the auto-fluorescence of the samples and the 
Photomultiplier tube (PMT) gains set accordingly. Single stained controls were used to account for 
spectral overlap and the flow cytometer compensations set accordingly (See figure 2.2). Gates to 
assess positive and negative staining were set using standard fluorescence minus one (FMO) controls 
for each monoclonal antibody conjugate. This particular type of control contains every fluorophore 
conjugated antibody in the stain apart from the one you are controlling for. As a result of performing 
this control, you can discard negative staining by gating it out and thus determine a positive 
population. 
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Figure 2.2: Spectral overlap of fluorophores. Spectra from fluorophores FITC and PE with two band-
pass filters superimposed. Some of the light from FITC will pass through the filter used to collect 
light from PE (indicated by arrow). By using single stained controls, compensations can be set on 
the flow cytometer to account for this (Adapted from Ormerod 2008). 
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Cell Type Surface marker Phenotype Monoclonal Antibody 
Conjugate 
B-cells CD19+ Rat anti-mouse CD19 (FITC) 
CD4+ T-cells CD4+ CD4 (PerCP) 
CD8+ T-cells CD8+ CD8 (APC) 
Neutrophils Ly-6Ghigh 
CD11bhigh 
CD11clow  
F4/80low 
Ly6G (FITC) 
CD11b (PerCP) 
CD11c (APC) 
F4/80 (PE) 
Eosinophils CD11bhigh 
CD11clow 
Ly6Glow 
SiglecFhigh 
CD11b (PerCP) 
CD11c (APC) 
Ly6G (FITC) 
SiglecF (PE) 
Alveolar Macrophages CD11blow-intermediate 
CD11chigh 
F4/80high 
Ly-6Glow 
CD11b (PerCP) 
CD11c (APC) 
F4/80 (PE) 
Ly6G (FITC) 
Inflammatory 
monocytes/tissue 
macrophages 
CD11bhigh 
CD11clow 
F4/80high 
CD11b (PerCP) 
CD11c (APC) 
F4/80 (PE) 
 
Table 2.2: Outlining surface marker antigens and relevant conjugated monoclonal antibodies used 
to identify various cell populations 
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Figure 2.3: Characterisation of Lymphocyte Populations. (A) Lymphocytes were defined as small, 
non-granular cells (based upon their forward and side-scatter profiles) and gated upon this 
characteristic. Within the lymphocyte gate, cells were classified according to their expression of 
surface antigens; (B) CD19+ cells defined as B-cells (red box); (C) CD4+ cells defined as CD4+ 
lymphocytes (green box) and CD8+ cells defined as CD8+ lymphocytes (purple box). All gates were 
set using the relevant Fluorescence Minus One (FMO) controls. 
 
 
 
 
 
 
Figure 2.4: Characterisation of eosinophil population. Cells were characterised by their forward 
and side scatter profiles; and then according to their CD11b and CD11c expression. 
CD11clow/CD11bhigh cells were gated for (purple box). These cells were then characterised in terms 
of their SiglecF and Ly-6G expression. SiglecFhigh/Ly-6Glow cells were classified as eosinophils (red 
box). 
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Figure 2.5: Characterisation of neutrophils, alveolar macrophages and inflammatory 
monocytes/tissue macrophages. Cells were characterised by their forward and side scatter profiles; 
and then according to their CD11b and CD11c expression. CD11chigh/CD11blow cells were gated for 
(green box) and then characterised in terms of F4/80 and Ly-6G expression. F4/80 high/Ly6G low 
cells (orange box) were classified as alveolar macrophages. CD11clow/CD11bhigh cells (purple box) 
were also classified in terms of F4/80 and Ly-6G expression. F4/80low/Ly-6Ghigh cells were classified 
as neutrophils (red box). F4/80high cells (blue box) were classified as inflammatory monocytes/tissue 
macrophages [N.B. A forward/side scatter profile of this gate was performed and any characteristic 
eosinophils were gated out. Eosinophil populations were determined using a different stain (see 
figure 2.4) due to the number of fluorophores which could be detected by the FACS machine being 
a limiting factor]. 
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2.3.4 Histology 
Mast cells were identified using a standard Toluidine blue histological stain. Mice were culled via 
overdose with Sodium Pentobarbitone and the systemic circulation perfused as detailed in section 
2.3.1. The trachea was then cannulated and the lungs superfused with formalin before being placed 
in formalin for 24 hours. Following this, they were transferred into 70% ethanol until paraffin wax 
embedding and slicing could take place. 
The paraffinized lung samples were cut into 4 µm sections. The sections were stained using a standard 
toluidine blue and eosin counterstain protocol as in Yagil et al (2012). Briefly, the lung sections were 
dewaxed using Histochoice clearing agent ® (Sigma, UK) and rehydrated in a series of ethanol dilutions 
(100%, 90%, 70%). The slices were then washed in deionised water and stained in 0.1% Toluidine Blue 
(Sigma, UK) for 5mins. Sections were then washed in distilled water before counterstaining with Eosin-
Phloxine solution (Sigma, UK) for 1 min. A final wash in distilled water then took place before the slices 
were dehydrated using a series of ethanol dilutions (70%, 90%, 100%). The slices were left to dry at 
room temperature and mounted onto glass slides(Yagil et al., 2012). 
The stained sections were analysed under light microscopy at x40 magnification, the observer blinded 
to the specimen identities. The numbers of mast cells per slide (3 slides per lung sample) were counted 
(figure 2.6). 
 
Figure 2.6: Demonstrating histological staining for mast cells in mouse lung tissue sections. Mast 
cells in Toluidine Blue and eosin counterstained tissue sections were identified by characteristic dark 
purple staining (see arrows). Mast cells were counted on a per slide basis under light microscopy 
(X40 magnification) by a blinded observer (3 slides per lung sample). 
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2.4 Models of Allergic Asthma 
The OVA driven rat and mouse models of LAR have previously been developed ‘in house’ (Raemdonck 
et al 2011). Studies should ideally contain 4 control groups as follows: Saline-Sensitised/Saline 
Challenged, Saline-Sensitised/OVA-challenged, OVA-Sensitised/Saline-Challenged and OVA-
Sensitised/OVA-Challenged. This is important as it allows the determination of whether responses are 
allergic (in sensitised mice) or innate occurring independently of sensitisation. Following a short time-
course study, it was deemed practical for the studies included in this thesis, to include just 2 groups; 
Saline-Sensitised/OVA-Challenged and OVA-Sensitised/OVA-Challenged. Throughout the studies, 
AlumTM diluted 1:1 with saline was used as an adjuvant during the sensitisation of animals. AlumTM 
refers to 20 mg.ml-1 aluminium hydroxide and 20 mg.ml-1 magnesium. 
2.4.1 The OVA Driven Mouse Model of LAR 
Male mice (20 g-25 g) were sensitised with OVA in AlumTM (50 µg per mouse, 500 µl i.p.) or vehicle 
(AlumTM diluted 1:1 with saline, 500 µl i.p) on days 0 and 14 (see figure 2.7). On day 28, mice were 
given a single intra-tracheal (i.t.) dose of OVA (2% OVA, 25 µl). For the i.t. dosing, mice were placed in 
a Perspex chamber connected to an anaesthetic machine (Bowring Medical Engineering Ltd, Witney, 
UK) and exposed to 4% isoflurane in 0.5% oxygen until sufficiently anaesthetised. Mice were dosed 
into the trachea using a dosing gavage and then monitored until fully recovered. 
 
 
Figure 2.7: Timeline demonstrating the protocol used for OVA driven mouse model of LAR 
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2.4.2 The OVA Driven Rat Model of LAR 
Male Brown Norway rats (200 g-225 g) were sensitised with OVA in AlumTM (100 µg per rat, 1 ml i.p.)or 
vehicle (AlumTM diluted 1:1 with saline, 1 ml i.p) on days 0, 14 and 21 (see figure 2.8). On day 28, rats 
were placed in a Perspex chamber and challenged with1% (w/v) aerosolised OVA for 30 minutes. 
 
Figure 2.8: Timeline demonstrating the protocol used for OVA driven rat model of LAR 
 
2.5 Assessment of Lung Function 
The LAR is characterised by bronchoconstriction occurring approximately 3-8 hours following allergen 
exposure. It is therefore essential to assess lung function in order to successfully model this feature of 
asthma. 
Resistance and Compliance is a specific way of assessing lung function in animal models of asthma. 
However, the technique is highly invasive and requires anaesthesia, tracheal intubation and artificial 
ventilation; meaning that the technique must be performed under non-physiological conditions. This 
method is also terminal which results in the prevention of further endpoints (e.g. inflammation) from 
being assessed in the same animal. Raemdonck et al (2012) showed that anaesthesia abolishes the 
LAR, meaning that for the purpose of this body of work, Resistance and Compliance was not deemed 
a viable technique for the measurement of lung function. 
Whole Body Plethysmography (WBP) is a non-invasive method of assessing enhanced pause (Penh) in 
animal models of asthma. As part of this technique, the animals are conscious, unrestrained and 
therefore have more natural breathing patterns. Penh was used as an indicator of lung function 
throughout this thesis and is discussed below. 
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2.5.1 WBP and Penh 
Flow Whole Body Plethysmography (FWBP) encompasses a pneumotachograph in its wall (measuring 
pressure changes between the main chamber and reference chamber) and was used for all studies 
measuring lung function within this thesis.  
Within WBP, respiration is considered as the exchange of air between the body and the chamber. As 
this process occurs, pressure changes within the WBP are recorded as the respiratory waveform. 
During inspiration air is drawn into the animal from the chamber (chamber pressure decreases), which 
results in thoracic displacement (chamber pressure increases). The increase in pressure due to 
thoracic displacement is greater than the previously decreased pressure. This is due to conditioning 
(heating and humidification) of the air as it moves from chamber conditions to body conditions and 
results in a net increase in pressure during inspiration. It should also be noted that nasal flow always 
lags behind thoracic flow. This means that as the thorax expands there is a delay before air is drawn 
into the lungs due to airway resistance. This difference is greater in a state of constriction. The 
difference between the two waveforms makes up an FWBP waveform and Penh is calculated from this 
waveform. Penh is “a non-dimensional parameter based on a characteristic change in the expiratory 
wave shape of the unrestrained plethysmography box signal” (Lomask, 2006). 
There is some controversy over the relevance of using Penh in investigations of lung function. Penh 
has been widely used in AHR studies in mice (Pennock et al., 1979; Hamelmann et al., 1997; Dohi et 
al., 1999; Cieslewicz et al., 1999a)and it has been shown to correlate with airway resistance 
(Hamelmann et al., 1997). Penh has also been shown to correlate with allergen induced bronchial 
changes (Dohi et al., 1999). However, studies also exist which dispute the use of Penh as an indicator 
of lung function. The main arguments are that the contribution of the nasal component means that 
the respiratory signal obtained cannot strictly be used to represent changes within the airways and 
that the contribution of air conditioning may also interfere with pressure change recordings (Adler, 
Cieslewicz & Irvin, 2004; Bates et al., 2004; Sly et al., 2005; Lundblad et al., 2007). 
Although some controversy still exists surrounding the use of Penh, the technique was deemed 
necessary for this body of work. Raemdonck et al (2012) showed that the neurological output of the 
CNS must be preserved in order to observe the LAR and so a conscious modelling system was required 
(Raemdonck et al., 2012).There are currently no alternative ways of attaining these measurements 
without using restraint, and Home Office restrictions would not allow the use of restraint for the 
prolonged periods of time necessary to achieve the LAR response. Therefore, Penh was used as an 
arbitrary measure of airway constriction in order to assess lung function within this thesis. 
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2.5.2 Mouse WBP 
Immediately following recovery from i.t. dosing, mice were placed in WBP chambers (Buxco 
Electronics, USA) and pressure changes continuously recorded by Buxco Finepointe Software (Buxco 
Electronics, USA). The average Penh was recorded at 10 minute intervals for a total duration of 12 
hours and was used for analysis. 
2.5.3 Rat WBP 
Following OVA aerosol, rats were placed in rat WBP chambers (Buxco Electronics, USA). Pressure 
changes were recorded from 30 minutes following the end of OVA challenge using Buxco Finepointe 
Software (Buxco Electronics, USA). The average Penh was recorded at 10 minute intervals for a total 
duration of 5 hours and was used for analysis. Drugs were dosed around the OVA challenge as detailed 
in the relevant chapters. 
2.5.4 Data Analyses 
The Penh average was plotted against time following challenge for rat and mouse studies. The Area 
Under Curve and Penh average at peak response for the various experimental groups was calculated 
using Graphpad Prism Software (Graphpad Software Inc., USA) and used for statistical analyses as 
detailed in the relevant chapters. 
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2.6 Sample Harvesting and Processing 
2.6.1 Blood Sampling 
Animals were euthanized via overdose with Sodium Pentobarbitone (200 mg/kg i.p.). Blood was 
attained via cardiac puncture with a heparinised syringe. Samples were then centrifuged (1398 g, 10 
minutes, 4 °C) and the plasma supernatant transferred to eppendorfs and stored at -20 °C until 
subsequent analysis. 
2.6.2 Bronchoalveolar Lavage 
The trachea was exposed via blunt dissection and cannulated. A syringe was used to introduce RPMI 
media (Life Technologies) into the lungs for 30 seconds, before being withdrawn. For mice 0.3 mls was 
introduced 3 times. For rats 3 mls was introduced 2 times. The samples were then pooled to give 1 
sample per animal, before being prepared for total and differential cell counts. 
2.6.3 Cell Counts 
The total leukocyte cell counts in BAL fluid were attained using a Sysmex XP-300 automated cell 
counter (Sysmex Ltd., UK). 
Slides for differential cell counts were prepared using 100 µl BAL fluid in a cytospin (807 g, 5 minutes, 
room temperature, low acceleration) (Shandon, Runcorn, UK). Slides were stained using a Hema-tek 
2000 automated slide stainer (Ames Co., Elkhart, USA) using ACCUSTAIN ® modified Wright-Giemsa 
stain (Sigma). Slides were analysed under light microscopy at x40 magnification by an observer blinded 
to the specimen identities. Differential counts were completed on 200 cells per slide using standard 
morphological criteria (See Table 2.3). The percentage of macrophages/monocytes, neutrophils, 
eosinophils and lymphocytes were calculated. Macrophages and monocytes were counted as one 
group. Other cell types such as epithelial cells and red blood cells were ignored. 
2.6.4 Histology 
The trachea was exposed via blunt dissection and cannulated. The lungs were superfused with 
formalin, before being placed in formalin for 24 hours. Following this, lungs were transferred into 70% 
ethanol until paraffin wax embedding and slicing could take place. A standard toluidine blue staining 
protocol and eosin counter stain was then performed upon the formalin fixed lung tissue slices. The 
numbers of mast cells were analysed as previously described (section 2.3.4). 
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Neutrophil 
 
 
Multi-lobed, darkly stained 
nucleus. Granular, but 
lightly stained, cytoplasm 
 
Macrophage/Monocyte 
 
 
 
Large cell with a free shape. 
Darkly stained nucleus and a 
very large cytoplasm 
 
Lymphocyte 
  
Small cell with little to no 
cytoplasm. A single very 
darkly stained nucleus 
 
Eosinophil 
 
 
 
Multi-lobed nucleus which 
often assumes a donut or 
figure 8 appearance. 
Granular cytoplasm which 
stains pink 
 
Table 2.3: Morphology of Cells Counted in BAL Fluid. (Adapted from Blumenreich, 1990) 
 
2.6.5 Measurement of Plasma IgE 
The level of plasma IgE was used as a marker of allergic sensitisation and measured using Enzyme 
Linked Immunosorbant Assay (ELISA). This technique was also used in order to ascertain that the IgE 
knockout mice were deficient of IgE. 
2.6.5.1 Total IgE 
Total IgE levels were measured using BD OptEIATM set for mouse immunoglobulin E (BD Biosciences, 
Oxford, UK) in accordance with the manufacturer’s instructions. Briefly,96 well plates (Thermo 
Scientific, Rockford, USA) were coated with 100 µl of specific capture antibody diluted to working 
concentration in coating buffer (0.1 M Sodium Carbonate, pH 9.5) and incubated at 4 °C overnight. 
Wells were washed three times with wash buffer (0.05% Tween-20 in PBS) in order to remove any 
unbound antibody. Wells were then incubated for 1 hour at room temperature with assay diluent 
(10% FBS in PBS) in order to block non-specific binding. Following this, the wells were washed three 
times with wash buffer; and 100 µl of the standards (serial dilutions in assay diluent) and plasma 
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samples (diluted 1:10 with assay diluent) were added and incubated for 2 hours at room temperature. 
Assay diluent was used as a negative control. The plate was then washed five times with wash buffer 
before 100 µl of substrate solution was added (1:1 mixture of H2O2 and tetramethylbenzidine; R&D 
Systems). The plate was incubated in the dark at room temperature for 15-30 minutes. If the cytokine 
of interest was present then the reaction with the substrate solution produced a blue colour. The 
reaction was stopped with the addition of 50 µl of 2 N H2SO4 when the colour change was seen in the 
standards. The plate was read at wavelengths of 450 nm and 570 nm using a spectrophotometer 
(BiotekPowerWave XS Plate Reader). The absorbance was calculated by taking the absorbance at 570 
nm away from the absorbance at 450 nm. The standard curve was used to measure the amount of IgE 
in each sample minus the negative control values. The upper limit of detection was 100 ng/ml and 
lower limit of detection was 1.6 ng/ml. 
2.6.5.2 Allergen Specific IgE 
OVA specific IgE was also measured using ELISA. This was an adapted protocol from BD Biosciences. 
Briefly, OVA (20 µg/ml in PBS) was added to 96 well plates (Thermo Scientific, Rockford, USA) at 50 
µl/well and incubated overnight at 4 °C. Plates were washed three times with wash buffer (0.05% 
Tween-20 in PBS) and 50 µl of the plasma samples were added neat. Plasma from IgE deficient mice 
was used as a negative control. The samples were incubated overnight at room temperature and then 
washed three times as previous. Biotinylatedanti-IgE (2 µg/ml, 50 µl/well, BD Biosciences) was added 
and incubated for 1 hour shaking at room temperature. The plates were washed three times with 
wash buffer before 100 µl of substrate solution was added (1:1 mixture of H2O2 and 
tetramethylbenzidine; R&D Systems). This was incubated for 15-30 minutes as done for the total IgE 
assay before the reaction was stopped using 2 N H2SO4. The absorbance was read at 450 nm using a 
spectrophotometer (BiotekPowerWave XS Plate Reader). Unlike for the Total IgE assays, there was no 
commercially available quantitative OVA-specific IgE assay available. Due to this, the absorbances 
were simply used for qualitative assessment of the samples. 
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2.7 Isolated Vagus Nerve Preparation 
2.7.1 Nerve Dissection 
Male Brown Norway rats (200 g-250 g; Charles River Laboratories UK) were euthanized via overdose 
with Sodium Pentobarbitone (200 mg/kg i.p.). Skin was removed via midline incision and the trachea 
and thorax exposed. The ribcage, connective tissue and smooth muscle was removed to observe the 
vagal nerves running from the base of the skull, parallel to the trachea, to the heart. The vagal nerves, 
caudal to the nodose ganglia, were removed and placed in Krebs-Henseleit (KH) solution (mM: NaCl 
118; KCl 5.9; MgSO4 1.2; CaCl2 2.5; NaH2PO4 1.2; NaHCO3 25.5 and glucose 5.6; pH 7.4) and bubbled 
with 95% O2/5% CO2. 
Human lung samples were received from various locations in the US via the International Institute for 
the Advancement of Medicine (IIAM: NJ, US). The tissue received was donor tissue unsuitable for 
transplant, and was approved by local Human Tissue Ethics Committee. Whole lungs were received in 
isotonic saline on ice, and within 48 hrs of cross-clamp. On receipt, the whole lungs were placed in KH 
solution and bubbled with 95%O2/5% CO2. Vagal nerves running parallel to the trachea and bronchi 
were dissected free of the lungs and placed in oxygenated KH solution. 
Following procurement of the tissue, the vagal nerve was desheathed and cut into 10-15 mm sections 
before being placed back into oxygenated KH solution where it remained for the duration of the 
experiments. Throughout, care was taken not to stretch or damage the nerve in anyway. 
2.7.2 Measurement of Depolarisation 
The desheathed nerve was mounted in a “grease gap” recording chamber by drawing it longitudinally 
through a narrow channel (measuring 2 mm diameter by 10 mm length) in a custom made Perspex 
block (See figure 2.9). Petroleum jelly was injected through a side arm into the centre of the channel, 
covering the centre of the nerve. This was done to create an area of high chemical and electrical 
resistance such that the passage of ions and solutions was prevented between the two ends of the 
nerve trunk. One end of the nerve trunk was superfused with KH solution at a rate of 2 ml/min in order 
to allow the delivery of test compounds. The other end was perfused with just KH solution. The KH 
solution applied was constantly bubbled with 95%O2/5% CO2 and maintained at 37 °C via the use of a 
water bath and thermal jacket. Hollow glass rods (1.5 mm diameter) were inserted into Ag/AgCl pellet 
half-cell electrodes (Mere 2 Flexible reference electrodes, World Precision Instruments) and the air 
spaces filled with KH solution. The electrodes were positioned at each end of the nerve trunk such 
that the glass rods made contact with the nerve. Potential difference was recorded via a DAM50 
differential amplifier unit (World Precision Instruments) which amplified the DC potential signal (X10 
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gain, high filter 1 KHz, sample rate 5 Hz) which was then recorded on a chart recorder (LectroMed 2, 
Lectromed, UK [now Digitimer, UK]). 
This system indirectly measures compound depolarisation of the membranes of all nerve fibres 
contained within the vagus nerve. It does not measure action potentials or firing of the nerve. This is 
done by recording the difference in ionic potential between the two ends of the nerve. In the end of 
the nerve that is perfused with KH solution containing test compounds, once a sufficient concentration 
of activating ligand to achieve depolarisation is achieved, there is an influx of Na+ ions from the KH 
solution into the axon cytosol (from high Na+ to low Na+). This has the net effect of depolarisation (see 
figure 2.9). The now decreased concentration of positive ions in the KH solution near to the electrode 
leaves the Cl- ions in a ‘freer’ state to react with the electrode pellet. The difference between the 
increased potential on the electrode at the perfused end and the unaltered potential at the reference 
end of the nerve trunk is amplified and recorded via the amplifier unit and chart recorder. 
For this technique it should be noted that the depolarisation measured may not be of sufficient 
magnitude to generate an action potential and so the depolarisation measured is not necessarily equal 
the firing of a nerve fibre. Another point to make is that the vagus nerve supplies innervating fibres, 
not just to the airways, but also to other organs such as the heart and gut. It should also be considered 
that the cell bodies and nerve termini are not present in the isolated vagus trunk. This means that 
there is the possibility of differences in terms of receptors and associated signalling proteins between 
the nerve axon and the nerve terminals. However, it should also be noted that there is a good 
correlation between compounds eliciting an effect using this technique and in in vivo studies (Birrell 
et al., 2009a; Grace et al., 2012b; Freund-Michel et al., 2010). This system is also amenable to 
pharmacology, meaning that many compounds can be tested on tissue from the same animal, thus, 
reducing the overall numbers of animals used. 
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Figure 2.9: Apparatus setup for isolated vagus nerve depolarisation recordings. Vagus nerve was 
drawn into a channel in a Perspex chamber and the two ends of the nerve trunk isolated chemically 
and electrically with petroleum jelly. KH solution was constantly perfused onto the left side of the 
nerve where test compounds could be applied at a rate of 2 ml/min. The right side of the nerve was 
bathed in just KH solution. Ag/AgCl half-cell electrodes were placed in contact with both sides of 
the vagus nerve. The signal from the electrodes was passed through an amplifier and the signal 
output documented on a chart recorder. 
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2.7.3 Agonist/Antagonist Experimental Protocols 
The following protocol was used to measure depolarisation (stimulation) and inhibition of stimulation 
of the vagus nerve. There were several variations in the incubation timings and concentrations of 
drugs, details of which can be found in the relevant results chapters. 
Initially, 2-3 control stimulations were performed in order to attain two depolarisations of consistent 
magnitude. This involved incubating with stimulation drug for 2 minutes, before washing with KH 
solution in order to return to baseline depolarisation, and repeating. Following this, the nerve was 
incubated with drug for 10 minutes, before reapplying the stimulating agent in the presence of drug 
for 2 minutes. The nerve was then washed with KH solution for 10 minutes until baseline 
depolarisation was achieved. A final application of stimulating agent was applied to the nerve for 2 
minutes in order to ascertain that the nerve was still viable. A single concentration of drug was tested 
on any single piece of nerve from 1 individual animal or patient (See figure 2.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B C D 
Figure 2.10: Example trace showing protocol for testing inhibitory effect of drugs in the vagus nerve preparation. 
(A) Two control stimulations were evoked to achieve 2 stimulations of consistent magnitude. (B) The nerve was 
incubated with drug for 10 minutes before (C) applying the stimulating agent in the presence of the drug. (D) 
After washing to re-establish baseline, a final application of stimulating agent was applied in order to confirm 
nerve viability. 
74 
 
2.7.4 Data Recording and Analysis 
The chart recorder was calibrated such that a scale of 1 cm: 0.1 mV was set. The magnitude of 
depolarisation was calculated by taking a measurement from the baseline (prior to application of 
stimulating agent) to the peak of the response evoked by the stimulating agent. In order to calculate 
inhibition of a stimulus by a drug, the average magnitude of 2 consistent control stimulations was 
taken. The magnitude of depolarisation in the presence of the inhibitory drug was then compared to 
the control stimulations in order to give a % inhibition as per the following equation: 
% 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = 100 −  (
𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑖𝑛 𝑝𝑟𝑒𝑠𝑒𝑛𝑐𝑒 𝑜𝑓 𝑣𝑒ℎ𝑖𝑐𝑙𝑒 𝑜𝑟 𝑑𝑟𝑢𝑔
𝑀𝑒𝑎𝑛 𝑜𝑓 𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠
 × 100) 
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2.8 In Vivo Single Afferent Fibre Recording 
2.8.1 Surgery 
Male Dunkin Hartley guinea-pigs (400 g -650 g; Harlan UK) were anaesthetised with Urethane (1.5 g/kg 
i.p.) and supplemented with additional Urethane as required. Body temperature was monitored via 
the use of a rectal probe and maintained (37 °C) using a heated blanket and control unit (Harvard 
Apparatus, UK).  A midline incision was performed to expose the trachea. The trachea was cannulated 
and the animal artificially ventilated (tidal volume 10 ml/kg; 50-60 breaths per minute) using a small 
animal ventilator (Ugo Basile, Italy). The right carotid artery was cannulated so that systemic arterial 
blood pressure and heart rate could be continuously measured. This was done using a pressure 
transducer (either Gould P2X3L or MEMSCAP SP 844), linked to the Spike 2 software data acquisition 
system via a CED Micro1401 interface. Tracheal pressure was also similarly monitored using an air 
pressure transducer (either SenSymb647 or MEMSCAP SP 844) attached to a side arm of the tracheal 
cannula. The right jugular vein was cannulated in order to allow the delivery of Vecuronium Bromide 
which was delivered initially at 0.1 mg/kg and then supplemented every 20 minutes at 0.05 mg/kg. 
This was used in order to paralyse the animal such that spontaneous muscle spasm didn’t interfere 
with the single afferent fibre recordings. Due to this application, the depth of anaesthesia was 
assessed throughout the experiment by monitoring heart rate and blood pressure. The cervical vagus 
nerves were dissected free and cut at the central end. The skin and muscle around the initial incision 
were sutured to a metal ring to form a well which was filled with light mineral oil. The left vagus nerve 
was desheathed and the nerve fibre placed on the recording electrode, the sheath placed on the 
reference electrode. The nerve was teased under a binocular microscope until recordings from a single 
nerve fibre type could be recorded. 
2.8.2 Recording Equipment 
Bipolar Teflon-coated platinum electrodes were used for recording purposes. The electrodes were 
connected to a pre-amplifier NL100K head stage (Digitimer, UK) to record action potentials. The signal 
was amplified using a NL104 amplifier (Digitimer, UK) and then filtered using a NL125 filter module 
(Digitimer, UK). The signal was then passed through a Humbug noise reducer (Automate Scientific, US) 
and then input into the Micro1401 interface and the Spike 2 software package. The software allows 
pulse train counting over selected time periods. Signals were also monitored on a Tektronix DP02012 
digital storage Oscilloscope (BidSync, US) and fed through an audio amplifier to a loud speaker (See 
figure 2.11). 
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Figure 2.11: Apparatus setup for in vivo single afferent recording. Cervical vagus nerves were 
dissected free and cut at the central end. The left vagus nerve was desheathed and teased until 
recordings from a single fibre type could be observed. Action potentials were recorded via platinum 
recording electrodes, a digital oscilloscope and output into the Spike 2 software package. Tracheal 
pressure was also recorded in this manner. 
2.8.3 Nerve Fibre Identification 
Single nerve fibres can be identified as belonging to one of three major groups of airway sensory nerve 
endings: Slowly Adapting Stretch Receptors (SARs), irritant receptors (rapidly adapting stretch 
receptors, RARs, Aδ-fibres) and pulmonary/bronchial C-fibre receptors. C-fibres were identified using 
several criteria outlined in Adcock et al (2003). They were defined as having no obvious pattern of 
spontaneous discharge, non-responding to hyperinflation/hyperdeflation and responding to capsaicin 
aerosol. At the end of the experiment, the fibre type was verified by assessing the conduction velocity 
in order to make sure a slow conducting non-myelinated C-fibre had been attained as opposed to a 
fast conducting myelinated Aδ-fibre. This was done by stimulating the nerve using bipolar silver 
electrodes and stimulator (Grass Products-Natus Neurology Inc., US) set to a suprathreshold voltage 
of 0.5 ms, 1 Hz. The time from stimulus to response and the distance between the stimulating and 
recording electrode was measured. A C-fibre was defined as having action potential conduction 
velocity of under 1m.s-1as opposed to the faster conducting Aδ-fibres, ranging from 2.0 m.s-1to 23 m.s-
1 (Adcock et al., 2003; Fox et al., 1993b; Riccio, Myers & Undem, 1996; Mazzone, 2004). 
 
 
Figure 2.5. Diagram of apparatus for single fibre nerve recordings 
Top: Anaesthetised guinea pigs were carefully dissected to reveal the 
vagus nerves, which were both cut posterior to the vagal ganglia. The left 
vagus nerve was teased, and a single nerve was placed onto a platinum 
recording electrode, connected to a digital oscilloscope, outputted to 
spike2 software on a computer to record nerve action potentials. Animals 
were ventilated and tracheal pressure was monitored via an intra-tracheal 
cannula. Nebulised drugs were delivered via a side-arm of the tracheal 
cannula. Bottom: representative traces showing effect of capsaicin on 
tracheal pressure and action potentials 
nebulised 
delivery 
ventilation 
platinum electrode 
tracheal pressure (PT) 
urethane 
NMBs – vecuronium bromide 
vagus nerve fibre 
Capsaicin 
5 s 
amplifier)
1 min 
Caps (100 µM) 15 s 
T
ra
c
h
e
a
l 
 
P
re
s
s
u
re
 
(c
m
H
2
O
) 
A
c
ti
o
n
 
P
o
te
n
ti
a
ls
 
(m
V
) 
77 
 
2.8.4 Recording Protocol 
Following identification of a suitable C-fibre, a 2 minute baseline recording took place. Following this, 
capsaicin (100 µM) was administered by aerosol for 15 seconds using an Aerogen Nebuliser (Buxco, 
US) which was connected by a side arm in line with the ventilator and tracheal cannula for delivery 
into the airways. Changes in nerve fibre firing, intratracheal pressure and blood pressure were 
recorded until baseline levels were re-established. Two reproducible responses to acrolein aerosol (10 
mM, 1.0 min) were established and after a suitable interval, either Disodium Cromoglycate (DSCG; 10 
mg/kg) or Vehicle was administered i.t. and incubated for 30 minutes. Following this, a response to 
acrolein was attained before a final capsaicin response took place. Guinea pigs were euthanized by an 
overdose of pentobarbitone (i.p.) at the end of the experiment. 
2.8.5 Data Recording and Analysis 
Action potentials and tracheal pressure were recorded using the Spike 2 software package. The data 
from this software was output into Microsoft Excel (Microsoft, US) and GraphPad Prism 5 (Graphpad 
Software Inc., USA). Data was recorded and expressed as number of peak impulses per second 
(peak.impulses.S-1). 
2.9 Statistical Analysis 
All data was analysed using GraphPad Prism 5. Data was expressed as mean ± s.e.m. Multiple 
measurements were analysed by one-way ANOVA, non-parametric Kruskal-Wallis test and post-
hoc comparisons were performed by Dunn’s multiple comparison test, comparing selected 
columns to a control. Additionally, a non-parametric Mann Whitney test, with two-tailed p values, 
was carried out to determine statistical significance between two groups. Differences were 
considered statistically significant if p<0.05. The figures have been graphically presented on a 
range-specific axis. 
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3 Optimisation of animal models of the Late Asthmatic Response 
3.1 Rationale 
The LAR is a key symptom of allergic asthma with susceptible patients typically experiencing this form 
of bronchoconstriction 3-8 hours following allergen exposure. Glucocorticoids are effective clinically 
in significantly inhibiting this feature of asthma, although the driving mechanisms behind the LAR 
remain unclear (Murai et al., 2005; Kidney et al., 1997; Miyagawa et al., 2009; Inman et al., 2001; Leigh 
et al., 2002). 
Pre-clinical models closely mimicking the cardinal features of asthma are useful in understanding the 
mechanisms driving the disease. Within the Respiratory Pharmacology group, the LAR has been 
modelled successfully in Brown Norway rats and C57BL/6 mice (Raemdonck et al 2012). The overall 
aim of this thesis is to explore the mechanisms driving the LAR, therefore, it was necessary to utilise 
animal models of LAR for this purpose. The Brown Norway rat model of LAR has been used traditionally 
to explore this feature of asthma(Stevenson & Belvisi, 2008). It was also considered advantageous to 
also use the mouse model of LAR as this would open up the possibility of applying GM mice to the 
model.  This would enhance the toolbox for exploration of the LAR as various knockout mice could be 
applied to this model in order to ascertain the importance of specific cells and mediators in an 
observable functional response. 
Preceding these investigations it was considered important to assess the clinical relevance of these 
models. Therefore, the aim of this chapter was to characterise the OVA driven rat and mouse models 
using the clinically relevant glucocorticoid steroid Budesonide. The results of this investigation would 
determine which models were taken forward for further understanding the driving mechanisms 
behind the LAR. 
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3.2 Methods 
The following methods were carried out as detailed in chapter 2. Details of individual experiments are 
described below. 
3.2.1 Assessment of Lung Function 
Due to the uncertainty of the role of inflammation within the LAR (see section 3.4), it was decided that 
when investigating the driving mechanisms behind the LAR within this thesis, the functional response 
of the LAR was measured as opposed to an inflammatory response. The LAR was measured via the use 
of whole body plethysmography (WBP; Penh) as described in chapter 2. It was not possible to use 
invasive resistance measurements as anaesthesia has been shown to inhibit the response(Raemdonck 
et al., 2012). Due to this, a conscious modelling system was required. It was considered unethical and 
Home Office restrictions would not allow for the use of restraint for the prolonged periods of time 
required to observe the LAR. There are currently no alternative methods for measuring lung function 
in a conscious, unrestrained model. Therefore, Penh was used as an arbitrary measure of airway 
constriction in order to assess lung function in this chapter and throughout this thesis. 
3.2.2 The OVA Driven Rat Model of LAR 
Male Brown Norway rats (200-225g) were sensitised and challenged as detailed in general methods 
section 2.4.2. On the day of allergen challenge, rats were dosed orally with Budesonide (0.03, 0.3, 3 
and 30 mg/kg at 2 ml/kg) or vehicle (0.5% methylcellulose, 0.2% Tween80 in water) 60 minutes before 
allergen challenge and 30 minutes following the end of allergen challenge (See figure 3.1). Two 
Budesonide doses were administered pre and post antigen stimulant as per standard practice in order 
to ensure adequate coverage for the duration of the LAR measurement period. Penh was recorded 
from 30 minutes after the final drug administration for a period of 5 hrs as detailed in general methods 
section 2.5.3. 
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Figure 3.1: Timeline demonstrating protocol for drug administration in OVA driven rat model of the 
LAR 
 
3.2.3 The OVA Driven Mouse Model of LAR 
Male C57BL/6 mice (20-25g) were sensitised and challenged as detailed in general methods 2.4.1. On 
the day of allergen challenge, mice were dosed orally with Budesonide (3 mg/kg at 1 ml/kg) or vehicle 
(0.5% methylcellulose, 0.2% Tween80 in water) 60 minutes before allergen challenge. Immediately 
following recovery from allergen challenge, mice were placed in WBP chambers and Penh recorded 
for 12 hours as detailed in general methods section 2.5.2. 
 
3.2.4 Statistical Analysis 
Data were analysed using Graphpad Prism 5. Data was expressed as mean ±s.e.m. Non-parametric 
Mann Whitney-U tests with two-tailed p-values were carried out in order to assess statistical 
significance between 2 groups. Differences were considered statistically significant if p<0.05. 
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3.3 Results 
3.3.1 Characterisation of the rat OVA-driven LAR model using Budesonide 
OVA challenge resulted in a marked LAR in OVA sensitised rats. This response peaked at 2-3 hours and 
lasted for up to 6 hours after challenge. The saline sensitised rats did not display a response following 
OVA challenge (figure 3.2). 
Budesonide treatment in the OVA sensitised/OVA challenged rats resulted in a significant attenuation 
of the LAR at doses of 0.3 mg/kg, 3 mg/kg and 30 mg/kg in terms of both Penh AUC and Penh Peak 
responses when compared with vehicle treated rats. Budesonide treatment in the control saline 
sensitised/OVA challenged rats did not have any impact on baseline Penh recordings when compared 
with vehicle treated animals (figure 3.2). 
 
3.3.2 Characterisation of the mouse OVA-driven LAR model using Budesonide 
OVA challenge resulted in a marked LAR in OVA sensitised mice. This response peaked at 3 hours and 
lasted for up to 8 hours after challenge. The saline sensitised mice did not display a response following 
OVA challenge (figure 3.3). 
A dose of 3 mg/kg of Budesonide was chosen for use in the mouse model which was based on an 
effective dose in the rat model. Budesonide treatment resulted in a significantly decreased LAR in the 
OVA sensitised/OVA challenged mice in terms of both Penh AUC and Penh Peak response when 
compared with vehicle treated rats (figure 3.3). As no effects on the Penh baseline recordings were 
found with respect to Budesonide administration in the rat model, it was not considered necessary to 
include the Saline sensitised/OVA-challenged Budesonide treated group in this subsequent mouse 
study. This is compliant with the 3R’s. 
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Figure 3.2: Effect of Budesonide treatment in the rat OVA-driven LAR. 1 hour following allergen 
challenge rats were placed in WBP chambers and Penh recorded for a further 5 hours. Data is 
expressed as A) Penh average over the recording time period; B) Penh Area Under Curve; and C) 
Penh average at peak response. Data expressed as mean ± s.e.m. n=12. Mann-Whitney U-test. 
*p<0.05 Vehicle/Saline compared to Vehicle/Ovalbumin. #p<0.05 Budesonide (0.03 mg.kg-1, 0.3 
mg.kg-1, 3 mg.kg-1 and 30 mg.kg-1)/Ovalbumin compared to Vehicle/Ovalbumin. 
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Figure 3.3: The effect of Budesonide treatment in the mouse OVA-driven LAR. Immediately 
following recovery from allergen challenge, mice were placed in WBP chambers and Penh recorded 
for 12 hours. Data is expressed as A) Penh average over the recording time period; B) Penh Area 
Under Curve; and C) Penh average at peak response. Data expressed as mean ± s.e.m. n=5-8. Mann-
Whitney U-test. *p<0.05 Vehicle/Saline compared to Vehicle/Ovalbumin. #p<0.05 Budesonide (3 
mg.kg-1)/Ovalbumin compared to Vehicle/Ovalbumin. 
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3.4 Discussion 
The aim of this chapter was to characterise the rat and mouse OVA driven models of LAR in terms of 
their time points and clinical relevance with respect to human LAR. The results of this chapter would 
determine which animal models would be taken forward to further investigate the driving 
mechanisms behind the LAR within this thesis. 
In human asthmatic patients, the LAR typically occurs 3-8 hours following allergen exposure 
(Raemdonck et al., 2012). Both the rat and mouse models exhibited in this chapter demonstrated 
response time points similar to these. The rat model exhibited a response peaking at 2-3 hours, lasting 
for up to 6 hours after challenge. The mouse model response peaked at 3 hours and returned to 
baseline at 8 hours post challenge. 
It could, however, be noted that the responses appear to begin earlier than those shown in clinic, with 
both models beginning to respond at 1hour post allergen challenge. It was, therefore, desirable to 
characterise these models to show that they were displaying a true LAR and not an EAR. The EAR takes 
place up to 1 hour following allergen exposure and the mechanisms driving the response have been 
well established by researchers. Allergen challenge induces the cross-linking of IgE-FcR1 complexes 
on mast cells which in turn causes mast cell degranulation to release preformed mediators such as 
histamine, leukotrienes and prostaglandins which act locally to result in bronchoconstriction 
(EAR)(Barnes, 2008; Holgate, 2008a; Buc et al., 2009). The mechanisms driving the EAR are thought to 
be different to that of the LAR as in clinic steroids have been shown to inhibit LAR but not the EAR in 
asthmatics(Booij-Noord, Orie & De Vries, 1971; Cockcroft & Murdock, 1987; Kidney et al., 1997; Leigh 
et al., 2002). Therefore, in order to ascertain if the bronchoconstriction seen in the animal models in 
this chapter was reminiscent of an EAR or an LAR, the clinically relevant glucocorticoid steroid 
Budesonide was employed in the models. Budesonide was successful in significantly attenuating the 
responses in both models, thus demonstrating that both models were displaying bronchoconstriction 
consistent with the LAR, not the EAR, and were clinically relevant. Glucocorticoid steroids are the 
mainstay of treatment in asthma and treat the chronic inflammation associated with the disease 
(Barnes, 1998). Their anti-inflammatory mechanism is thought to occur by modulating the 
transcription of genes within inflammatory cells. Steroids bind to GRs in the cytoplasm in various cell 
types which results in the dimerization and migration of the GR to the nucleus. Here, it binds to a GRE 
– a location on the promoter region of steroid responsive genes- and causes either up regulation of 
anti-inflammatory gene transcription or down regulation of pro-inflammatory gene transcription 
(Barnes, Pedersen & Busse, 1998). Steroids have also been reported to interact directly with 
transcription factors such as NF-κB(Ray & Prefontaine, 1994), and also recruit Histone Deacetylases 
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(Kagoshima et al., 2001; Ito, Barnes & Adcock, 2000; Ito et al., 2006) to ultimately result in the 
attenuation of cellular inflammation in the airways (see Introduction section 1.9). 
The fact that steroids are anti-inflammatory and attenuate the LAR could mean that cellular 
inflammation is the main driving factor behind this response. However, in the rat OVA driven model 
of LAR it has previously been shown within the Respiratory Pharmacology group, that while a single 
OVA challenge results in a robust LAR, a temporal link to cellular inflammation is not apparent within 
this particular model. Studies have also indicated that depleting cellular inflammation does not always 
attenuate the LAR. Indeed, targeting eosinophilia via the application of anti-IL-5 antibodies in animal 
models and in the clinic has been shown to have minimal effect on the  development of the LAR  (Nag 
et al., 2003; Molet et al., 1999; Leckie et al., 2000; Flood-Page et al., 2007; Kips et al., 2003). 
Inflammatory responses also result in oedema which has been reported as important in the LAR. 
However, Magnetic Resonance Imaging (MRI) studies have shown that no temporal link between 
oedema following allergen challenge and the LAR exists. In these investigations in animal models, 
allergen challenge resulted in an LAR at 3 hours post challenge, but oedema changes were not seen 
until 6 hours after challenge and did not subside until 96 hours after challenge (Beckmann et al., 2001; 
Tigani et al., 2007). These data suggest that oedema is not involved in the driving mechanisms behind 
the LAR. 
Overall, it seems that the LAR is not temporally linked to cellular inflammation, although low levels of 
inflammatory cells such as eosinophils are present at the time of the response. Eosinophil depletion 
does not attenuate the LAR. Due to this, it could be hypothesised that only small levels of cellular 
inflammation are required to induce the LAR with other mechanisms driving the response taking over 
later on. It has previously been shown by the Respiratory Pharmacology group that the LAR maybe 
mediated by TRPA1 channels on airway sensory nerves (Raemdonck et al., 2012). Therefore, allergen 
challenge could lead to the production of an endogenous TRPA1 ligand which stimulates receptors on 
airway sensory nerves, leading to an LAR (see Introduction section 1.8). Glucocorticoid steroids such 
as Budesonide are successful in attenuating the LAR. It has also been reported that an IKK-2 inhibitor 
successfully blocked NF-κB translocation and inhibited the development of the LAR in vivo (Birrell et 
al., 2005). This implies that the endogenous mediator(s) responsible for TRPA1 activation in the 
development of the LAR are under transcriptional control. In the present models employed, the LAR 
begins 1-2 hours after challenge, so synthesis of an endogenous TRPA1 ligand in the mechanisms 
behind the LAR would need to occur quickly. In vitro, transcription factor activation can be detected 
as soon as 1hour after stimulation (Birrell et al., 2005, 2008) and in vivo can be detected at 2 hours 
following stimulation (Eltom et al., 2011; Rastrick et al., 2013) meaning that it is possible for mediators 
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to be produced to stimulate airway sensory nerves within the LAR timescale. Factors surrounding this 
hypothesis will be further investigated in the subsequent chapters of this thesis. 
In summary, this chapter has introduced the Brown Norway rat and C57BL/6 mouse models of LAR 
and demonstrated that they are suitably clinically relevant with respect to response time points and 
inhibition by glucocorticoid steroid. As a result of this, it was decided to take both these models 
forward for further investigating the driving mechanisms behind the LAR. The mouse model was 
considered a particularly advantageous tool as GM mice could now be applied to the model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
88 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
Exploring the Role of Key Allergic 
Effector Cells in the LAR 
 
89 
 
4 Exploring the role of key allergic effector cells in the LAR 
4.1 Rationale 
The aetiology of the LAR is widely reported to involve the infiltration of numerous inflammatory cells 
and mediators (Aalbers et al., 1993a, 1993b).  This thesis aims to investigate the driving mechanisms 
behind the LAR. Therefore, it was considered desirable to explore the roles of key allergic effector cells 
within this response. 
The LAR has been linked to the B-cell-IgE-Mast cell products axis (Barnes, 2008; Holgate, 2008a). 
Patients being treated with corticosteroids have been shown to have decreased numbers of mast cells 
in the smooth muscle and epithelium (James et al., 2012). DSCG, a known mast cell stabiliser, has been 
shown to inhibit the LAR in asthmatic patients and in animal models of the LAR (Cockcroft & Murdock, 
1987; Pepys et al., 1968, 1974; Booij-Noord, Orie & De Vries, 1971). The IgE antibody, Omalizumab, 
has also been shown to suppress allergen induced late phase bronchoconstriction (Busse et al., 2001; 
Holgate et al., 2004, 2005). 
Evidence for IgE independent mechanisms driving the LAR also exist. Clinical studies have shown that 
sensitisation to allergens and the accompanying allergen specific IgE is not always predictive of an LAR 
(Hatzivlassiou et al., 2010).Studies involving the inhalation of T-cell peptides derived from the feline 
allergen Fel d 1demonstrated the induction of an isolated LAR without an accompanying EAR, implying 
the LAR to be T-cell dependent and IgE independent (Ali et al., 2004a). Other studies investigating the 
effects of Cyclosporin A (a T-helper cell inhibitor) on asthma specific endpoints has pointed to a role 
for T-cells within the LAR (Khan et al., 2000). 
In Chapter 3, the mouse and rat OVA-driven models of the LAR were demonstrated to be clinically 
relevant with respect to the response time points and inhibition of the response with the 
corticosteroid Budesonide. Investigations utilising monoclonal antibodies targeting key effector cells 
in animal models of the LAR have yielded conflicting results. Issues concerning the specificity of certain 
antibodies have also been raised. For example, the antibody MAR-1, targeting the high affinity 
receptor FcεRI has not only been shown to inhibit mast cell driven processes, but has been shown to 
activate mast cells(Kojima et al., 2007; Ohnmacht et al., 2010; Voehringer, 2013). This uncertainty is 
less than desirable when trying to delineate the mechanisms behind a response. Therefore, it was 
decided to employ GM mice to investigate the key allergic effector cells driving the LAR which has not 
yet been reported on within the associated literature. 
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The first aim of this chapter was to validate and confirm the phenotype of CD4-/-, CD8-/-, B-cell-/- and 
mast-cell-/- mice. The second aim was to apply these mice to the OVA-driven mouse model of the LAR 
to determine the role of these cell types within the response. 
4.2 Methods 
The following methods were carried out as detailed in chapter 2. Details of individual experiments are 
described below. 
4.2.1 Validation of Genetically Modified Mice by Flow Cytometry 
Wildtype (C57BL/6) and GM (B-cell-/- , CD4-/- , CD8-/- and Mast-cell-/-) naive male mice (20-25g) were 
culled, their systemic circulations perfused and their lung tissue isolated which underwent standard 
enzymatic digest in order to obtain a leukocyte population. Leukocytes were counted, stained and 
underwent flow Cytometry as described in general methods section 2.3.3. Lymphocytes were gated 
for based on their forward/side scatter profile and then assessed in terms of their characteristic 
expression of surface markers to identify B-cells, CD4+ cells and CD8+ cells. This was to ascertain that 
the relevant knockouts were deficient of their corresponding cell type and to determine that there 
was no compensation in terms of these cell populations for knocking out a particular cell type. 
The lung tissue leukocyte populations were also assessed for eosinophils, neutrophils, 
monocytes/tissue macrophages and alveolar macrophages. This was also done using their 
characteristic forward/side-scatter profiles and surface expression profiles as detailed in Snelgrove et 
al. 2008 and in general methods section 2.3.3. This was done to validate that each genetic modification 
had no downstream effects such as the up regulation or down regulation of other inflammatory cell 
populations. 
4.2.2 Validation of Genetically Modified Mice by Histology 
Wildtype (C57BL/6) and GM (B-cell-/- , CD4-/- , CD8-/- and Mast-cell-/-) naive male mice (20-25g) were 
assessed for the presence of mast cells within the lung tissue in order to confirm that the mast cell-/- 
mice were deficient of mast cells, and to verify that there were no effects in terms of the mast cell 
population in the other GM strains.  Briefly, mice were culled, their systemic circulations perfused and 
their lung tissue isolated. Lung tissue was fixed and stained using a standard Toluidine Blue stain. The 
tissue slices were mounted on slides and assessed using light microscopy by a blinded observer as 
detailed in general methods section 2.3.4. 
4.2.3 The OVA Driven Mouse Model of LAR 
Following phenotypic validation it was decided that the Wildtype and GM (B-cell-/- , CD4-/- , CD8-/-, 
Mast-cell-/- and IgE-/-) could be applied to the OVA-driven mouse model of LAR. Male mice (20-25g) 
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were sensitised, challenged and Penh recorded for 12 hours as described in general methods sections 
2.4.1 and 2.5.2. 
4.2.4 Plasma IgE Analysis 
Following Penh recordings, mice were culled via overdose with Sodium Pentobarbitone (200 mg/kg 
i.p.) and a heparinised blood sample obtained via cardiac puncture. The samples were processed as 
detailed in general methods section 2.6.1 and the plasma assessed for Total and OVA-specific IgE via 
ELISA (see general methods section 2.6.5). 
4.2.5 Further Exploration of the Enhanced Baseline Response 
After observing such a prominent increase in Penh in the saline sensitised mast cell-/- and IgE-/- strains, 
it was considered necessary to further investigate these GM strains with respect to various aspects of 
the experimental protocol. 
The first aspect considered was the effect of the anaesthetic (isoflurane) on these mice. Naïve male 
wildtype (C57BL/6), mast cell-/- and IgE-/-mice (20-25g) were either placed directly into, or anesthetised 
using isoflurane and allowed to recover as previously described in general methods section 2.4.1 
before being placed into WBP chambers and Penh recorded for 12 hours. 
The second part of the protocol investigated with respect to these mice was the intratracheal 
challenge method to assess if the responses observed were an innate response to the presence of 
OVA or a result of the intratracheal dosing itself. Naïve male wildtype (C57BL/6), mast cell-/-and IgE-/-
mice (20-25g) were anaesthetised, dosed i.t. with either saline or OVA in saline and allowed to recover 
as described previously (general methods section 2.4.1). They were then placed in WBP chambers and 
Penh recorded for 12 hours. 
4.2.6 Statistical Analysis 
Data were analysed using Graphpad Prism 5. Data was expressed as mean ±s.e.m. Multiple 
measurements were analysed by one-way ANOVA, non-parametric Kruskal-Wallis test and post-hoc 
comparisons were performed by Dunn’s multiple comparison test, comparing selected columns to a 
control. Additionally, a non-parametric Mann Whitney test, with two-tailed p values, was carried out 
to determine statistical significance between two groups. Differences were considered statistically 
significant if p<0.05. 
With respect to the observations of Penh within the mouse model of LAR, non-parametric Mann 
Whitney test was used to assess observations between specific groups. The group comparison 
wildtype (Saline) vs. wildtype (OVA) was of interest as this confirmed a positive response to validate 
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that the sensitisation and challenge protocols were effective within the experiments. Comparisons 
were made between the Wildtype (Saline) and KO (Saline) groups in order to confirm that the genetic 
modification conferred no effect on the baseline response (negative control). The group comparison 
wildtype (OVA) vs. KO (OVA) was the comparison of interest in order to assess the question of whether 
the cells of interest were key within the LAR response. The groups KO (Saline) and KO (OVA) were not 
compared as this was of little interest in addressing the main research question. The main area of 
interest was the effect of the KO in the OVA response when compared with wildtype. The other group 
comparisons served as positive and negative controls. If it had been decided to compare the groups 
KO (Saline) vs. KO (OVA) then multiple measurements would have been analysed using one-way 
ANOVA, non-parametric Kruskal-Wallis test and post-hoc comparisons performed using Dunn’s 
multiple comparison test. 
4.3 Results 
4.3.1 Validation of Genetically Modified Mice 
The CD4-/-, CD8-/- and B-cell-/- GM mice were all confirmed to be deficient of their specific knockout 
cell via flow cytometry (See figure 4.1). Negligible levels of CD4+ cells were found in the CD4 knockout 
mice compared with wildtype mice (CD4 KO 0.47 ± 0.38 cells/mg tissue vs. wildtype 427.3 ± 61.62 
cells/mg tissue). Levels of CD8+ T-cells were also found to be negligible in CD8 knockout mice 
compared with wildtype mice (CD8 KO 0.4 ± 0.3 cells/mg tissue vs. wildtype 266.5 ± 39.22 cells/mg 
tissue), as were levels of CD19+ cells in B-cell knockout mice compared with wildtype mice (B-cell KO 
8.11 ± 0.93 cells/mg tissue vs. wildtype 905.2 ± 145.9 cells/mg tissue). Lung tissue populations of CD4+, 
CD8+ and CD19+ cells in the knockout mice were found to be comparable to those seen in wildtype 
mice where the cell type was not the deficient population (see figure 4.1). 
The mast cell knockout mice were confirmed to be deficient of lung mast cells using the standard 
histological stain Toluidine Blue on lung tissue slices. No significant differences with respect to the 
mast cell population in the other GM strains were found compared with the wildtype group (see figure 
4.2). 
Baseline levels of eosinophils, neutrophils, alveolar macrophages and monocytes/tissue macrophages 
were assessed for by flow cytometry in wildtype mice compared with the various transgenic mice. No 
significant differences in these cell types were found across the GM strains compared with the 
wildtype group (see figure 4.3). 
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Following confirmation that the GM mice were deficient of the relevant effector cells and their 
inflammatory baseline leukocyte levels were comparable to those seen in the wildtype group, they 
were applied to the OVA driven mouse model of the LAR. 
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Figure 4.1: Validation of Lymphocyte Populations in Genetically Modified Mice by Flow Cytometry. 
Leukocytes from the lung tissue of Wildtype (C57BL/6), B-cell-/- , CD4-/- , CD8-/- and Mast-cell-/- 
naïve male mice were attained via enzymatic digest. Flow Cytometry was used to assess the 
numbers of: A) CD4+ cells; B) CD8+ cells and C) CD19+ cells. Data is expressed as mean cell number 
per mg of lung tissue ± s.e.m. n=6-8. One-way ANOVA, Kruskal-Wallis test with post-hoc 
comparisons using Dunn’s multiple comparison test. *p<0.05 compared to Wildtype control group. 
 
 
Figure 4.2: Validation of Mast Cell Populations in Genetically Modified Mice by Histology. Lung 
tissue slices were obtained from Wildtype C57BL/6, B-cell-/- , CD4-/- , CD8-/- and Mast-cell-/- naïve male 
mice. They were stained utilising a standard Toluidine Blue histological stain and numbers of mast 
cells per slide were counted (x40 magnification) by a blinded observer. Data is expressed as mean 
cell number per slide ±s.e.m. n=6-8.One-way ANOVA, Kruskall-Wallis test with post-hoc 
comparisons using Dunn’s multiple comparison test. #p<0.05 compared to Wildtype control group. 
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Figure 4.3: Validation of Additional Leukocyte Populations in Genetically Modified Mice by Flow 
Cytometry. Leukocytes from the lung tissue of Wildtype (C57BL/6), B-cell-/- , CD4-/- , CD8-/- and Mast-
cell-/- naïve male mice were attained via enzymatic digest. Flow Cytometry was used to assess the 
numbers of: A) Eosinophils; B) Neutrophils; C) Alveolar Macrophages and Monocytes/Tissue 
Macrophages. Data is expressed as mean cell number per mg of lung tissue ± s.e.m. n=6-8. One-way 
ANOVA, Kruskall-Wallis test with post-hoc comparisons using Dunn’s multiple comparison test. 
*p<0.05 compared to Wildtype control group. 
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4.3.2 The Role of CD4+ Cells in the OVA Driven Mouse Model of LAR 
The results of this model showed that OVA challenge resulted in a marked LAR in wildtype OVA 
sensitised mice which peaked at 3 hours and lasted for up to 8 hours after challenge, compared to 
saline sensitised wildtype mice. The saline sensitised CD4-/- mice displayed a baseline response 
comparable to the saline sensitised wildtype group. A significant attenuation of response was 
observed in the OVA sensitised CD4-/- mice compared to OVA sensitised wildtype group in terms of 
both Penh AUC and Penh Peak response (figure 4.4). 
 
Figure 4.4: The Role of CD4+ Cells in the OVA-driven Mouse Model of LAR. Immediately following 
recovery from allergen challenge, mice were placed in WBP chambers and Penh recorded for 12 
hours. Data is expressed as A) Penh average over the recording time period; B) Penh Area Under 
Curve; and C) Penh average at peak response. Data expressed as mean ± s.e.m. n=13-21. Mann-
Whitney U-test. *p<0.05 Wildtype Saline sensitised compared to Wildtype Ovalbumin sensitised 
groups. #p<0.05 CD4-/- Ovalbumin sensitised compared to Wildtype Ovalbumin sensitised groups. 
No significant difference between groups is denoted ns. 
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4.3.3 The Role of CD8+ Cells in the OVA Driven Mouse Model of LAR 
OVA-sensitised wildtype controls displayed a distinct LAR compared with Saline sensitised wildtype 
mice. Saline sensitised CD8-/- mice exhibited a baseline response comparable to Saline sensitised 
wildtype mice following OVA challenge. CD8-/- OVA sensitised and challenged mice presented an 
enhanced response compared to the wildtype OVA sensitised and challenged group. This difference 
was significant with regards to Penh AUC and Penh Peak response (figure 4.5). 
 
Figure 4.5: The Role of CD8+ Cells in the OVA-driven Mouse Model of LAR. Immediately following 
recovery from allergen challenge, mice were placed in WBP chambers and Penh recorded for 12 
hours. Data is expressed as A) Penh average over the recording time period; B) Penh Area Under 
Curve; and C) Penh average at peak response. Data expressed as mean ± s.e.m. n=14-17. Mann-
Whitney U-test. *p<0.05 Wildtype Saline sensitised compared to Wildtype Ovalbumin sensitised 
groups. #p<0.05 CD8-/- Ovalbumin sensitised compared to Wildtype Ovalbumin sensitised groups. 
No significant difference between groups is denoted ns. 
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4.3.4 The Role of B-Cells in the OVA Driven Mouse Model of LAR 
The wildtype OVA sensitised and challenged group again demonstrated an LAR peaking at 3 hours and 
resolving at around 8 hours after challenge. Interestingly, the B-cell-/- saline sensitised controls 
exhibited a significantly increased Penh AUC and Peak Penh compared with the equivalent saline 
sensitised wildtype group. No significant differences were observed between the OVA-sensitised and 
challenged B-cell-/- and wildtype groups (figure 4.6). 
 
Figure 4.6: The Role of B-Cells in the OVA-driven Mouse Model of LAR. Immediately following 
recovery from allergen challenge, mice were placed in WBP chambers and Penh recorded for 12 
hours. Data is expressed as A) Penh average over the recording time period; B) Penh Area Under 
Curve; and C) Penh average at peak response. Data expressed as mean ± s.e.m. n=12-14. Mann-
Whitney U-test. *p<0.05 Wildtype Saline sensitised compared to Wildtype Ovalbumin sensitised 
groups. #p<0.05 Wildtype Saline sensitised compared to B-cell-/-Saline sensitised groups. No 
significant difference between groups is denoted ns. 
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4.3.5 The Role of Mast Cells in the OVA Driven Mouse Model of LAR 
The wildtype controls responded as previously described, with a distinct LAR in the OVA sensitised 
group compared with the saline sensitised wildtype group as a result of OVA challenge. Similarly to 
the B-cell-/- mice, the saline sensitised mast cell-/- mice had a significant enhancement in Penh AUC and 
Peak Penh in response to OVA challenge compared to the saline sensitised wildtype mice. The OVA-
sensitised mast cell-/- group displayed a response to OVA challenge which was not significantly 
different to that seen in the OVA sensitised wildtype group (figure 4.7). 
 
Figure 4.7: The Role of Mast Cells in the OVA-driven Mouse Model of LAR. Immediately following 
recovery from allergen challenge, mice were placed in WBP chambers and Penh recorded for 12 
hours. Data is expressed as A) Penh average over the recording time period; B) Penh Area Under 
Curve; and C) Penh average at peak response. Data expressed as mean ± s.e.m. n=8-12. Mann-
Whitney U-test. *p<0.05 Wildtype Saline sensitised compared to Wildtype Ovalbumin sensitised 
groups. #p<0.05 Wildtype Saline sensitised compared to Mast cell-/-Saline sensitised groups. No 
significant difference between groups is denoted ns. 
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4.3.6 The Role of IgE in the OVA Driven Mouse Model of LAR 
An LAR was exhibited by the wildtype OVA sensitised group compared to the wildtype saline sensitised 
group. Again, similarly to the B-cell-/- and mast cell-/- mice, the saline sensitised IgE-/- group exhibited a 
significantly enhanced Penh AUC in response to OVA challenge compared to the saline sensitised 
wildtype mice. No significant differences were observed between the OVA-sensitised and challenged 
IgE-/- and wildtype groups (figure 4.8). 
 
Figure 4.8: The Role of IgE in the OVA-driven Mouse Model of LAR. Immediately following recovery 
from allergen challenge, mice were placed in WBP chambers and Penh recorded for 12 hours. Data 
is expressed as A) Penh average over the recording time period; B) Penh Area Under Curve; and C) 
Penh average at peak response. Data expressed as mean ± s.e.m. n=6-9. Mann-Whitney U-test. 
*p<0.05 Wildtype Saline sensitised compared to Wildtype Ovalbumin sensitised groups. #p<0.05 
Wildtype Saline sensitised compared to IgE-/-Saline sensitised groups. No significant difference 
between groups is denoted ns. 
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4.3.7 Plasma IgE Levels in the OVA Driven Mouse Model of LAR 
After attaining Penh recordings, mice were culled and blood samples obtained which were assessed 
for the presence of OVA-specific IgE. This was to confirm allergen specific allergic sensitisation in the 
wildtype mice, to assess the effect of the various genetic modifications on plasma IgE levels in an 
allergic environment and to observe IgE levels in relation to the functional LAR. 
In all experiments assessing the various cell deficient mice in the LAR model, wildtype mice were 
confirmed to have been allergically sensitised by a significant increase in plasma OVA-specific IgE in 
the OVA sensitised groups compared with the saline sensitised groups. All saline sensitised GM strains 
were confirmed to be deficient of plasma OVA-specific IgE. OVA sensitised CD4-/-and B-cell-/-mice had 
significantly decreased plasma OVA-specific IgE compared with wildtype OVA-sensitised mice. No 
significant differences were found between the OVA sensitised wildtype controls and corresponding 
CD8-/- and mast cell-/-groups (figure 4.10). 
In the IgE knockout mice, plasma total IgE levels and OVA-specific IgE levels were assessed in order to 
validate that the mice were deficient of IgE. Negligible levels of total and OVA-specific IgE was 
measured in the saline sensitised and OVA sensitised IgE-/- mice in comparison to the wildtype groups 
(figure 4.9). 
 
Figure 4.9: Plasma IgE Levels in IgE Deficient Mice. Following Penh recordings, blood samples were 
attained via cardiac puncture and plasma samples assessed for A) Total IgE and B) OVA-Specific IgE 
via ELISA. IgE knockout mice in comparison to wildtype groups were assessed. Data is expressed as 
raw absorbance values taken at 450nm ±s.e.m. n=6-9.Mann-Whitney U-test. *p<0.05 Wildtype 
Saline sensitised compared to Wildtype Ovalbumin sensitised groups. #p<0.05 IgE-/- Ovalbumin 
sensitised compared to Wildtype Ovalbumin sensitised groups. 
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Figure 4.10: Plasma OVA-Specific IgE Levels in Cell Deficient Mice. Following Penh recordings, blood 
samples were attained via cardiac puncture and plasma samples assessed for OVA-Specific IgE via 
ELISA. Genetically modified strains in comparison to wildtype groups assessed were: A) CD4-/-; B) 
CD8-/-; C) B-cell-/- and D) Mast cell-/-. Data is expressed as raw absorbance values taken at 450nm 
±s.e.m. n=6-11.Mann-Whitney U-test. *p<0.05 Wildtype Saline sensitised compared to Wildtype 
Ovalbumin sensitised groups. #p<0.05 Knockout Ovalbumin sensitised compared to Wildtype 
Ovalbumin sensitised groups.  No significant difference between groups is denoted ns. 
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4.3.8 Further Exploration of the Enhanced Baseline Response 
No increases in Penh were observed in the naive OVA challenged wildtype mice compared with naive 
saline challenged mice. The naive mast cell-/- and IgE-/- mice did not display an enhanced response 
compared with wildtype controls as a result of OVA challenge (figure 4.11). 
 
 
 
Figure 4.11: Further Exploration of the Enhanced Baseline Response. A) Naive Wildtype (C57BL/6) 
mice were challenged with either Saline or OVA (25 µl; 2% OVA, i.t.) before being placed in WBP 
chambers upon recovery and Penh recorded for 12 hours. B) Naive Wildtype (C57BL/6), Mast cell-/- 
and IgE-/- mice were challenged with OVA (25 µl, 2% OVA, i.t.) before being placed into WBP 
chambers and Penh recorded for 12 hours. Data is expressed as i.) Penh average over the recording 
time period and ii.) Penh Area Under Curve. Data is expressed as mean ± s.e.m. n=4. 
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4.4 Discussion 
The overall aim of this chapter was to investigate the relevance of key allergic effector cells in the LAR 
by applying GM mice to the OVA-driven mouse model of LAR. Before these investigations could take 
place it was considered necessary to characterise the phenotype of the mice with respect to the cell 
populations within the lung tissue by flow cytometry and histology. 
All GM strains were found to be deficient of their relevant knockout cell type. For example Mast cell 
knockout mice were found to be deficient of mast cells. No subsequent effects in terms of the CD4+, 
CD8+, B-cell and Mast cell lung populations were observed in the non-relevant strains. For example 
mast cell deficient mice had no significant up regulation or down regulation of lung tissue CD4+ cells, 
CD8+ cells or B-cells. Baseline levels of eosinophils, neutrophils, alveolar macrophages and 
monocytes/tissue macrophages were found to be comparable to those in wildtype mice across all GM 
strains. It could be concluded that knocking out a particular cell type via genetic modification had no 
resulting effects on other lung tissue cell populations. The results of these studies confirmed that the 
GM mice were suitable for application to the OVA-driven mouse model of the LAR. 
The GM strains were then applied to the OVA-driven mouse model of the LAR. The CD4-/- mice 
displayed a much attenuated response compared with wildtype mice, suggesting a role for CD4+ cells 
in the driving mechanisms behind the LAR.  
Clinical studies have also explored the importance of CD4+ cells within the LAR. Researchers have 
identified increased levels of CD4+ cells in asthmatic bronchial biopsies compared with healthy 
controls (Mueller et al., 1996). Allergen challenge has been associated with less circulating CD4+ T-
lymphocytes in isolated early responders compared with dual responders (those displaying an EAR 
and LAR) (Muratov et al., 2005). Inhibition of the LAR by Cyclosporin A in steroid dependant asthmatics 
was linked with a decrease in the numbers of BAL CD4+ T-lymphocytes (Khan et al., 2000). Animal 
models have also demonstrated the importance of CD4+ cells within the driving mechanisms behind 
the LAR. Increased levels of CD4+ cells have been found in the BAL fluid of dogs with ragweed allergy 
at 4 hours post allergen challenge (Out et al., 2002). Enhanced levels of CD4+ cells in murine models 
of asthma have also been shown to correlate with the LAR (Nabe et al., 2005). Depletion and adoptive 
transfer studies in rats and mice have also deduced a central role for CD4+ cells within this response 
(Meyts et al., 2008; Nabe et al., 2011b; Ohtomo et al., 2009; Watanabe et al., 1995). 
In this chapter, the CD8-/- mice displayed a significantly enhanced response compared to wildtype 
mice, implicating a protective role for CD8+ cells within the LAR. The literature on the subject indicates 
that these cells have also been explored with respect to the LAR in animal models by other 
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researchers. Increased numbers of CD8+ T-cells have been found in the airway submucosa of sensitised 
rats exposed to OVA and depletion of these cells using a monoclonal antibody has been shown to 
enhance the LAR (Haczku et al., 1995a; Watanabe et al., 1995; Olivenstein et al., 1993a; Allakhverdi et 
al., 2000). Adoptive transfer studies have shown that the application of sensitised CD8+ cells into rat 
models of the LAR resulted in suppression of the response upon allergen re-exposure (Suzuki et al., 
1999). This LAR suppression has been shown to correlate with enhanced levels of the cytokine IFN-γ 
in the BAL fluid and the administration of this cytokine to rat models can reduce the LAR  (Isogai et al., 
2000, 2003). CD8+ T-cells are known producers of IFN-γ and so could elicit a protective effect in the 
allergic airway via this cytokine (Kemeny et al., 1994; Li et al., 1995). Indeed, adoptive transfer studies 
have shown that application of CD8+γδ T-cells into rat models of allergic asthma resulted in a 
diminished LAR. Pre-treatment of CD8+γδ T-cells with an antisense oligonucleotide to inhibit IFN-γ 
before transfer into sensitised recipients resulted in complete recovery of the LAR (Isogai et al., 2007). 
Relationships between CD4+ cells and CD8+ cells with respect to the LAR have been explored by 
researchers using animal models. As previously mentioned, CD8+ T-cells are known producers of IFN-
γ. It has been shown in numerous investigations that IFN-γ can suppress the proliferation of Th2 type 
CD4+ T-cells and it has been shown to inhibit the infiltration of CD4+ cells into the airways in a mouse 
allergic asthma model (Gajewski, Goldwasser & Fitch, 1988; Gajewski, Joyce & Fitch, 1989; Young & 
Hardy, 1995; Nakamura et al., 1997; Iwamoto et al., 1993). Isogai and colleagues showed that 
transferring CD4+ cells into recipient rats resulted in an LAR upon allergen exposure; and in the same 
study showed the depletion of CD8+ cells using monoclonal antibodies resulted in an enhanced LAR 
(Isogai et al., 2005). 
Levels of CD4+ and CD8+ cells have been explored clinically in the asthmatic lung. Human subjects 
experiencing an isolated EAR after undergoing allergen challenge have been shown to have relative 
increases in CD8+ cells in the BAL fluid compared to patients experiencing a dual response who have 
increased levels of CD4+ cells in their BAL fluid (Gonzalez et al., 1987). Studies assessing the effects of 
intradermal challenge in humans showed that a higher proportion of CD4+ T-lymphocytes and a lower 
proportion of CD8+ T-lymphocytes were accumulated in skin chamber fluids during the late phase 
response (Werfel et al., 1995). Allergen inhalation challenge in atopic asthmatic subjects is associated 
with decreased IFN-γ positive CD8+ T-lymphocytes in peripheral blood and sputum (Matsumoto et al., 
2002; Yoshida et al., 2005). 
The studies undergone so far exhibit CD4+ T-cells as drivers of the LAR, with CD8+ T-cells providing an 
inhibitory input. These studies have mainly involved the utilisation of monoclonal antibodies targeting 
specific cell types, or adoptive transfer models. So far, the application of GM mice deficient in CD4+ 
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and CD8+ cell types when exploring the specific mechanisms behind the LAR is a missing determinant 
in this field. This application is advantageous as there is the argument that the previous models 
applying monoclonal antibodies to allergic asthma models may target other cell types non-specifically. 
The results obtained in this chapter correspond with the findings of CD4+ T-cells being LAR drivers and 
CD8+ T-cells having a protective role in this response and so further supports the existing literature on 
the subject. 
Plasma IgE levels were also measured in the mice from these experiments in order to observe this 
parameter in relationship to the presence of an LAR. IgE-/- mice were confirmed to be deficient of total 
and OVA-specific IgE as were all saline sensitised mice. OVA-sensitised Wildtype mice were confirmed 
for allergic sensitisation by enhanced levels of plasma OVA-specific IgE which also corresponded with 
the presence of an LAR. The CD4-/-mice had significantly decreased levels of plasma OVA-specific IgE 
which mirrored the diminished LAR seen in this strain. The B-cell deficient mice had negligible levels 
of Plasma allergen specific IgE, which one may expect due to the fact that B-cells are the IgE producing 
cells (Barnes, 2008; Holgate, 2008a). The mast cell deficient plasma IgE levels were found to be 
comparable to the corresponding wildtype groups, as were those seen in the CD8-/- mice. It is difficult 
to interpret in the B-cell, mast cell and IgE deficient strains whether their plasma IgE levels 
corresponded with an LAR due to the interesting responses exhibited by the non-sensitised controls 
in these experiments. In the experiments where this wasn’t an issue, the CD4 deficient mice, which 
exhibited a decreased LAR, were also found to have diminished levels of plasma OVA-specific IgE. 
However, the CD8 deficient mice, which exhibited an enhanced LAR response, did not exhibit raised 
levels of allergen specific IgE. Overall, further investigations into the relationship between IgE and the 
LAR are warranted as from these results it is still unclear as to what this link is, if in fact there is one. 
In this chapter the roles of B-cells, Mast cells and IgE in the driving mechanisms behind the LAR were 
also explored. GM mice deficient in B-cells, Mast cells and IgE were applied to the mouse LAR model. 
Upon application, OVA sensitised and challenged B-cell-/-, Mast cell-/-and IgE-/-mice displayed a 
response which was comparable to that seen in wildtype mice, suggesting that these cell types and 
mediators are not involved in the driving mechanisms behind the LAR. Interestingly, however, these 
particular GM mouse strains also exhibited an enhanced baseline response even though they were 
not sensitised to allergen, making these results difficult to draw conclusions from. When the mast cell 
deficient mice were applied to the mouse model of the LAR, the negative control saline sensitised 
mast cell-/- mice also displayed enhanced bronchoconstriction. Similar results were also obtained 
when the IgE-/- and B-cell-/- mice were applied to the mouse OVA-driven LAR model, making the results 
difficult to interpret. Upon further investigation into the nature of this finding in naive mice, it was 
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established that the chamber environment, the anaesthesia (isofluorane), the intratracheal challenge 
method nor the innate presence of OVA resulted in enhanced Penh. From this we can thus far 
conclude that the responses seen in these particular strains are associated with the sensitisation 
protocol and warrants further investigation. Thus far, we know that when Alum is administered 
intraperitoneally, even in the absence of the allergen, a response was exhibited in response to 
intratracheal instillation of OVA in the mast cell/IgE/B-cell deficient mice but not in wildtype mice. It 
could therefore be considered that these cell types exert possible protective effects against inhalation 
of non-specific stimuli. Indeed, OVA contains LPS and mast cells have been shown to be stimulated by 
LPS via TLR4 to release anti-inflammatory cytokines, reactive oxygen species and antimicrobial 
peptides (REF). The Alum adjuvant requirement for this response to occur is certainly interesting. 
There is little evidence within the literature of Alum interactions with these cell types. It could be 
postulated that Alum boosts the response to innate stimuli and this is usually downplayed by the mast 
cell/IgE/B-cell axis. Further investigation into this area could provide conclusions relating to the 
mystery surrounding the mechanism of action of Alum in boosting immune responses.  Overall, for 
the purposes of this investigation into the role of these cell types in the LAR, we can unfortunately 
draw no conclusions as yet. 
The existing literature on the involvement of the B-cell – Mast cell – IgE products axis in the LAR is 
varied and conflicting. Different authors state contrasting conclusions on whether the LAR occurs 
dependently or independently of B-cells, Mast cells and IgE. 
Some clinical studies have indicated a prominent role for these cell types and mediators in the LAR. 
Increased numbers of mast cells and increased levels of IgE in BAL fluid has been associated with the 
magnitude of the LAR (Peebles et al., 2001; Crimi et al., 1991). Patients being treated with 
corticosteroids (which inhibit the LAR) have been shown to have decreased numbers of mast cells in 
the smooth muscle and epithelium (James et al., 2012). DSCG, a known mast cell stabiliser, has been 
shown to inhibit the LAR in asthmatic patients (Cockcroft & Murdock, 1987; Pepys et al., 1968, 1974; 
Booij-Noord, Orie & De Vries, 1971; Cieslewicz et al., 1999b). Anti-IgE monoclonal antibodies have also 
been shown to suppress allergen induced late phase bronchoconstriction (Busse et al., 2001; Holgate 
et al., 2004, 2005; Fahy et al., 1997). 
In contrast, other clinical studies have alluded to mechanisms independent of B-cells, Mast cells and 
IgE to be important in driving the LAR. In asthmatic patients, Durham et al(1984) failed to see an 
association between total or allergen specific IgE and the LAR. Total IgE has been shown to be a poor 
indicator of the LAR (Tschopp et al., 1998). In the African population, serum levels of IgE have even 
been reported to be higher in non-asthmatics compared to asthmatics (Scrivener & Britton, 2000). 
108 
 
Studies involving the inhalation of T-cell peptides derived from the feline allergen Fel d 1demonstrated 
the induction of an isolated LAR without an accompanying EAR, implying the LAR to be T-cell 
dependent and IgE independent (Ali et al., 2004a). Khan et al (2000) demonstrated that while 
Cyclosporin A decreased the LAR in patients, no effects were seen on the EAR indicating that the LAR 
occurs independently of the B-cell-Mast cell- IgE products axis. 
Animal models of the LAR have also resulted in conflicting conclusions being drawn on the role of B-
cells, Mast cells and IgE in the LAR. Mizutani et al (2012) demonstrated that mice sensitised with OVA-
specific IgE displayed an LAR upon OVA challenge. Inhibitors of mast cell products such as Cysteinyl 
Leukotrienes have been shown to inhibit the LAR at least partially (Nabe et al., 2002; Roquet et al., 
1997). Nabe et al (2005) demonstrated a correlation between the presence of mast cells and the ability 
to display an LAR in a mouse asthma model. However, the authors in this investigation also exhibited 
that the LAR was not associated with IgE as Dexamethasone was shown to suppress the LAR but not 
plasma levels of IgE(Nabe et al., 2005).The same authors also more recently showed that applying an 
antibody targeting mast cells did not attenuate the LAR (Nabe et al., 2013). Investigators adoptively 
transferring CD4+ and CD8+ cells into rat models of the LAR noted that there were no changes in the 
EAR and serum IgE levels where there were effects upon the LAR (Watanabe et al., 1995; Isogai et al., 
2003). Interestingly, McMenamin et al. (1995) showed that CD8+γδ T-cells suppress plasma IgE levels, 
although the authors did not demonstrate a functional link to the LAR. 
Overall, the existing literature on the subject of the involvement of B-cells, Mast cells and IgE in the 
LAR is sparse and conflicting. This could be due to the fact that at present there are limited tools for 
examining the roles of these cells and mediators with respect to asthmatic responses such as the LAR. 
Specificity issues concerning depleting antibodies in asthma investigations have been raised. For 
example, the antibody MAR-1, targeting the high affinity receptor FcεRI has not only been shown to 
inhibit mast cell driven processes, but has been shown to activate mast cells (Kojima et al., 2007; 
Ohnmacht et al., 2010; Voehringer, 2013). Due to this, the utilisation of cell deficient mice was 
desirable for this investigation when attempting to delineate the mechanisms behind the LAR.  
Cell deficient strains have been used by others investigating other features of asthma such as AHR and 
airway inflammation. These investigations have yielded conflicting results and this variation seen in 
experimental results has been attributed to differences in genetic background, differences in 
sensitisation and challenge protocols and also the use of adjuvants (Lei et al., 2013).More prominently, 
questions have also been raised as to the suitability of mouse asthma models and the fact that there 
is a discrepancy between the results obtained in these models and those obtained in clinical trials 
(Krug & Rabe, 2008). When assessing the roles particularly of mast cells in murine models, it should 
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be noted that there are differences between mice and humans with respect to lung mast cell 
populations. In terms of location, in humans mast cells are found around the airways and vessels in 
both the large and small airways and in the parenchyma, whereas in mice, mast cells are mainly 
located in the trachea and larger airways only (Andersson et al., 2009; Xing et al., 2011). Mast cells in 
murine lungs preferentially secrete 5-HT, compared to human mast cells which secrete histamine and 
other preformed mediators, in response to IgE activation (Szelenyi, 2000). In mice, mast cell driven 
responses such as the EAR are driven by 5-HT being released by mast cells which causes the release 
of neuronal ACh which in turn binds to muscarinic M3 receptors to cause 
bronchoconstriction(Fernandez-Rodriguez et al., 2010; Moffatt, Cocks & Page, 2004). This is in 
contrast to humans whereby mast cells release histamine, Cysteinyl Leukotrienes and prostaglandins 
which directly bind to receptors in ASM to cause bronchoconstriction (Roquet et al., 1997; Curzen, 
Rafferty & Holgate, 1987).It could be that when investigating mast cell responses (and possibly other 
linked cells and mediators such as B-cells and IgE) the mouse model is not the best model to employ. 
More favourable models in terms of investigating mast cells are considered to be Guinea-Pig or Rat 
models. These models have a wider distribution of mast cells throughout the lung which is more 
similar to humans (Bachelet, Bernaudin & Fleury-Feith, 1988). Rat models in particular display more 
similar features of pulmonary reactivity to humans such as a more obvious observable biphasic 
asthmatic response(Stevenson & Birrell, 2011; Lei et al., 2013). Overall, for the purposes of this 
investigation, when further pursuing the role of mast cells within the LAR, it could be concluded that 
it would be worthwhile using an alternative model. The Brown Norway Rat model of the LAR has 
already been established and characterised within the Respiratory Pharmacology group and so would 
be an ideal model to apply to the purpose of further investigating the role of the B-cell – Mast cell – 
IgE products axis in the LAR. 
In summary, this chapter explored the possible roles of CD4+ cells, CD8+ cells, Mast cells, B-cells and 
IgE in the LAR. This was done by applying GM mice to an OVA-driven mouse model of the LAR which 
is currently a missing determinant in this field. The data obtained highlighted a driving role for CD4+ 
cells and an inhibitory role for CD8+ cells in the LAR which is consistent with the existing literature on 
the subject. Unfortunately, no conclusions with respect to the roles of Mast cells, B-cells and IgE could 
be drawn with respect to the LAR. However, it was concluded that this particular mouse model is 
unsuitable to investigate the roles of these particular effector cells and mediators in this response. 
The existing literature on the subject is difficult to draw conclusions from due to its conflicting nature. 
Therefore, further work is required to delineate the role of the B-cell -Mast cell – IgE axis in the LAR. 
The next chapter explores this further. 
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5 Utilising Compound 48/80 and Disodium Cromoglycate as tools 
to further explore the LAR 
5.1 Rationale 
In the previous chapter it was concluded that further work was necessary to delineate the role of the 
B-cell – Mast cell – IgE products axis within the LAR. Therefore, the aim of this chapter was to further 
investigate this via the application of pharmacological tools to the animal models of the LAR. In the 
previous chapter, the mouse model was utilised due to the availability of knockout mice. However, as 
it is possible to apply pharmacological compounds to both the rat and mouse models of the LAR, both 
models were considered within this chapter. 
Compound 48/80 is described as a Mast cell degranulating agent and when administered acutely, mast 
cells degranulate to release their preformed mediators such as histamine, 5-HT, Leukotrienes and 
prostaglandins (Hannon et al., 2001). A number of investigations have also used this compound to 
deplete mast cells of their mediator stores via repeated administration in sub-chronic treatment 
schedules (Das, Flower & Perretti, 1997; Vergnolle, Hollenberg & Wallace, 1999; Hannon et al., 2001; 
Haddad et al., 2002). The first aim of this chapter was to deplete mast cells in naive rats and mice via 
sub-chronic treatment with compound 48/80 as done in Vergnolle et al. 1999 and Haddad et al. 2002. 
The success of the mast cell depletion was evaluated via histologically staining mast cell contents in 
lung tissue samples. The second aim was to apply the sub-chronic compound 48/80 treatment 
schedule to the OVA-driven models of LAR in order to ascertain the importance of mast cells within 
this response. The species this was carried out in was determined by the success of the mast cell 
depletion protocol. 
DSCG is described as a mast cell stabilising compound (Sheard & Blair, 1970; Storms & Kaliner, 2005). 
A number of studies have applied this compound to animal models when investigating the role of mast 
cells in features of disease (Das, Flower & Perretti, 1997; Hannon et al., 2001; Haddad et al., 2002; 
Schemann et al., 2012). The third aim of this chapter was to apply DSCG to the OVA driven animal 
models of the LAR in order to further explore the role of Mast cells in this response. The species this 
was carried out in was determined from the results of the first two aims in this chapter in order to 
ensure experimental continuity within the investigation. 
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5.2 Methods 
The following methods were carried out as detailed in chapter 2. Details of individual experiments are 
described below. 
5.2.1 Validation of the Compound 48/80 Dosing Protocol 
Naive male Brown Norway rats (200-225g) and C57BL/6 mice (20-25g) were dosed with either vehicle 
(saline, 5 ml/kg i.p.) or Compound 48/80 (0.6 mg/kg; 5 ml/kg i.p.) twice daily for 3 days. On day 4, the 
animals received a final higher dose of either Compound 48/80 (1.2 mg/kg; 5 ml/kg i.p.) or vehicle 
(saline, 5 ml/kg i.p.) in the morning. In the evening, the animals were culled via overdose with Sodium 
Pentobarbitone. The Compound 48/80 dosing regimen was based on the methodology used in 
Vergnolle et al. 1999 and Haddad et al. 2002. A BAL fluid sample was obtained and leukocyte 
population analysed by differential cell count as detailed in general methods section 2.6.3. Lung tissue 
was isolated, fixed and stained for mast cells using a standard Toluidine Blue stain. The tissue slices 
were mounted on slides and assessed for the presence of mast cells using light microscopy by a 
blinded observer as detailed in general methods section 2.3.4. 
 
 
 
 
Figure 5.1: Timeline demonstrating protocol for drug administration of Compound 48/80 
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5.2.2 The OVA Driven Rat Model of LAR 
5.2.2.1 Compound 48/80 Protocol 
Male Brown Norway rats (200-225g) were sensitised as detailed in general methods section 2.4.2. On 
days25-28, rats were dosed as previously described with Compound 48/80. On day 28, the rats 
underwent allergen challenge such that the final dose of Compound 48/80 was administered 60 
minutes before challenge (see figure 5.2). Penh was recorded from 60 minutes after the end of 
allergen challenge for a period of 5 hours as detailed in general methods section 2.5.3. 
 
 
Figure 5.2: Timeline demonstrating protocol for final administration of Compound 48/80 in OVA 
driven rat model of LAR 
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5.2.2.2 DSCG Protocol 
For the DSCG experiments, male Brown Norway rats were sensitised and challenged as detailed in 
general methods section 2.4.2. On the day of allergen challenge, rats were dosed with DSCG (10 
mg/kg; 1 ml/kg; i.t.) or vehicle (0.5% ethanol in saline, 1 ml/kg; i.t.) 60 minutes before allergen 
challenge and 30 minutes following the end of allergen challenge (see figure 5.3). Dosing regimens 
were based on those used in Das et al. 1997 and Hannon et al. 2001. Penh was recorded from 30 
minutes after the final drug administration for a period of 5 hours as detailed in general methods 
section 2.5.3. 
 
Figure 5.3: Timeline demonstrating protocol for DSCG administration in OVA driven rat model of 
LAR 
 
 
5.2.3 Statistical Analysis 
Data were analysed using Graphpad Prism 5. Data was expressed as mean ±s.e.m. Non-parametric 
Mann Whitney-U tests with two-tailed p-values were carried out in order to assess statistical 
significance between 2 groups. Differences were considered statistically significant if p<0.05. 
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5.3 Results 
5.3.1 Validation of the Compound 48/80 Dosing Protocol 
In order to validate that the dosing protocol had successfully depleted the contents of lung tissue mast 
cells, a pilot study was performed. In these experiments animals were culled following completion of 
the dosing protocol at the time when, if the dosing was successful, the LAR would be measured in the 
follow up investigation. The lung tissue mast cell population was assessed as well as BAL leukocyte 
populations in order to observe the effects of Compound 48/80. 
In both the rat and mouse, Compound 48/80 conferred no significant increases or decreases, 
compared to vehicle, in the BAL lymphocyte, macrophage, neutrophil or eosinophil populations (See 
figures 5.4 and 5.5). 
 
Figure 5.4: Assessment of BAL fluid following treatment with compound 48/80 in naive (C57BL/6) 
mice. BAL fluid was obtained from naive (C57BL/6) mice following completion of the Compound 
48/80 treatment protocol and was assessed via differential cell count for numbers of: A) 
Lymphocytes; B) Macrophages; C) Neutrophils and D) Eosinophils. Data is expressed as mean cell 
number per ml of BAL fluid ± s.e.m. n=4. Mann-Whitney U-test. *p<0.05 compared to vehicle (saline) 
treated control group. No significant difference between groups is denoted ns. 
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Figure 5.5: Assessment of BAL fluid following treatment with compound 48/80 in naive Brown 
Norway Rats. BAL fluid was obtained from naive rats following completion of the Compound 48/80 
treatment protocol and was assessed via differential cell count for numbers of: A) Lymphocytes; B) 
Macrophages; C) Neutrophils and D) Eosinophils. Data is expressed as mean cell number per ml of 
BAL fluid ± s.e.m. n=4. Mann-Whitney U-test. *p<0.05 compared to vehicle (saline) treated control 
group. No significant difference between groups is denoted ns. 
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In the mouse model, the numbers of undepleted lung tissue mast cells in the compound 48/80 dosed 
animals were found to be comparable to the vehicle group (Compound 48/80 75.17 ±11.62 mast 
cells/tissue slice vs. Vehicle 101.2±7.32 mast cells/tissue slice). In the rat model, the stained lung tissue 
mast cells were significantly decreased in the Compound 48/80 group compared with the vehicle 
group (Compound 48/80 281.8 ± 36.38 mast cells/tissue slice vs. 722.9 ± 21.17 mast cells/tissue slice). 
Therefore, the dosing protocol successfully depleted lung tissue mast cell contents in the rat but not 
the mouse model. Due to this, the OVA-driven Brown Norway rat model was used in order to assess 
the effects of depleting mast cells using Compound 48/80 on the LAR (See figure 5.6). 
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Figure 5.6: Validation of Mast Cell depletion by Compound 48/80. Lung tissue slices were obtained 
from A) Wildtype C57BL/6 mice and B) Brown Norway Rats following treatment protocol with (i) 
Vehicle (saline) or (ii) Compound 48/80. They were stained utilising a standard Toluidine Blue 
histological stain and numbers of mast cells per slide were counted (x40 magnification) by a blinded 
observer. Data is expressed as mean cell number per slide ±s.e.m. n=4. Mann-Whitney U-test. 
*p<0.05 compared to vehicle (saline) treated control group. No significant difference between 
groups is denoted ns. 
A.(i) 
A.(ii) 
B.(i) 
B.(ii) 
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5.3.2 The Effect of Compound 48/80 on the LAR 
OVA challenge resulted in a marked LAR in OVA sensitised rats. This response peaked at 2-3 hours and 
lasted for up to 6 hours after challenge. The saline sensitised rats did not display a response following 
OVA challenge. 
Compound 48/80 treatment in the OVA sensitised/OVA challenged rats resulted in a significant 
enhancement of the LAR in terms of Penh Peak response but not Area Under Curve response when 
compared with vehicle treated rats. Compound 48/80 treatment in the control saline sensitised/OVA 
challenged rats did not have any impact on baseline Penh recordings when compared with vehicle 
treated animals (See figure 5.7). 
 
Figure 5.7: Effect of Compound 48/80 treatment in the rat OVA-driven LAR. 1 hour following allergen 
challenge rats were placed in WBP chambers and Penh recorded for a further 5 hours. Data is 
expressed as A) Penh average over the recording time period; B) Penh Area Under Curve; and C) 
Penh average at peak response. Data expressed as mean ± s.e.m. n=8. Mann-Whitney U-test. 
*p<0.05 Vehicle/Saline compared to Vehicle/Ovalbumin. #p<0.05 Compound 48/80 
treated/Ovalbumin compared to Vehicle/Ovalbumin. No significant difference between groups is 
denoted ns. 
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5.3.3 The Effect of DSCG on the LAR 
Again, OVA challenge resulted in a distinct LAR in the OVA sensitised rats, peaking at 2-3 hours and 
lasting for up to 6 hours after challenge. The saline sensitised rats did not display a response following 
OVA challenge. 
DSCG treatment resulted in a significantly decreased LAR in the OVA sensitised/OVA challenged rats 
in terms of Penh Peak response when compared with vehicle treated rats (figure 5.8). 
 
Figure 5.8: Effect of DSCG treatment in the rat OVA-driven LAR. 1 hour following allergen challenge 
rats were placed in WBP chambers and Penh recorded for a further 5 hours. Data is expressed as A) 
Penh average over the recording time period; B) Penh Area Under Curve; and C) Penh average at 
peak response. Data expressed as mean ± s.e.m. n=8. Mann-Whitney U-test. *p<0.05 Vehicle/Saline 
compared to Vehicle/Ovalbumin. #p<0.05 DSCG treated/Ovalbumin compared to 
Vehicle/Ovalbumin. No significant difference between groups is denoted ns. 
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5.4 Discussion 
The overall aim of this chapter was to further investigate the role of the B-cell – Mast cell – IgE products 
axis in the LAR via the application of pharmacological tools to the OVA-driven rat and mouse models 
of the LAR. This was to be done by applying the Mast cell degranulating agent, Compound 48/80, and 
the Mast cell stabilising compound, DSCG, to the rat and mouse LAR models. 
Before these investigations could take place, it was considered necessary to validate the Compound 
48/80 treatment schedule in order to determine its success at depleting the contents of the lung tissue 
mast cell population. This was done as a pilot study in naive rats and mice where lung tissue samples 
were assessed for mast cells using the standard Toluidine blue histological stain. BAL leukocytes were 
also evaluated in order to ascertain that the dosing regimen conferred no additional effects in terms 
of the inflammatory cell population. In both species, no significant differences were observed in 
vehicle treated animals compared with Compound 48/80 treated animals in terms of the BAL 
macrophage, lymphocyte, neutrophil and eosinophil populations. The treatment protocol resulted in 
a significant decrease in the number of intact lung tissue mast cells in rats but not mice. From this it 
could be concluded that the Compound 48/80 treatment schedule was successful in the rat, but not 
the mouse model and the treatment conferred no additional effects in terms of other inflammatory 
cell populations. Literature on the subject of lung mast cells in mouse models suggests that in wildtype 
(C57BL/6) mice there is a distinct lack of a prominent mast cell response compared with other 
species(Lei et al., 2013).  The distribution of mast cells is different in the mouse lung compared with 
humans, with the majority of cells located in the larger airways compared with the smaller airways 
and parenchyma respectively (Andersson et al., 2009; Xing et al., 2011). Recent investigations have 
shown more distinctive mast cell responses in mast cell deficient mice having undergone mast cell 
engraftment, and authors have postulated that this is due to the mast cells being present in greater 
numbers and located in the more peripheral areas of the lung (Gersch et al., 2002; Fuchs et al., 2012; 
Wolters et al., 2005). Taking this into consideration, the observation of a lack of Mast cell content 
depletion in the mouse lung by Compound 48/80 in this chapter could be explained by the fact that 
there is a lack of mast cell presence in the lungs of wildtype (C57BL/6) mice to begin with. This is 
interesting, however, as even though mast cell numbers within the mouse lung are low, the mast cell 
deficient mice within Chapter 4 of this thesis did exhibit an alternative LAR. Overall, it was not 
considered suitable to proceed with the mouse model of the LAR to investigate the role of mast cells 
within the response. Due to this the rat OVA-driven LAR model, and not the mouse model, was used 
to assess the effect of depleting mast cells in the LAR. 
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Compound 48/80 is defined as a secretagogue compound, activating mast cells to degranulate and 
release their preformed mediators (Hannon et al., 2001). Its mechanism of action is receptor 
independent and is thought to occur via a hydrophobic moiety of the compound penetrating the 
membrane of cells and directly activating the Gi/o class of G-proteins to result in degranulation (Aridor, 
Traub & Sagi-Eisenberg, 1990; Mousli et al., 1990; Chahdi et al., 1998; Chahdi, Fraundorfer & Beaven, 
2000; Palomäki & Laitinen, 2006). In this chapter, we applied the compound to chronically deplete 
mast cell contents in order to investigate their importance within the LAR. Overall, no abrogation of 
LAR was observed with mast cell content depletion. It is noteworthy that though compound 48/80 
was seen to significantly deplete the lung tissue mast cell population of their content, it was not 
completely abolished. Therefore, if mast cells were central to an LAR, it is possible that only small 
numbers are required to elicit factors contributing to the response. Another possibility is that even 
though the stores of preformed mediators were depleted, the Mast cells’ ability to synthesise and 
excrete mediators de novo was not. This means that it is still feasible that a mediator produced by 
mast cells is involved in the driving mechanisms behind the LAR. While no difference in the response 
was found in terms of the Area Under Curve analysis between the vehicle treated and Compound 
48/80 treated OVA-sensitised rats upon OVA challenge, a significant increase in Peak Penh was 
observed in the OVA sensitised Compound 48/80 treated animals. The saline sensitised compound 
48/80 treated control animals did not exhibit a response, ruling out an effect of the dosing protocol in 
itself. Thus, on an allergic background compound 48/80 conferred additional effects, enhancing the 
LAR response in this experimental setting. Due to experimental caveats such as this, it was considered 
desirable to investigate the role of mast cells in the OVA-driven rat model further using additional 
pharmacological tools. 
Further investigation into the role of mast cells in the LAR was carried out via the application of DSCG, 
a mast cell stabiliser, to the rat model. In this model, the LAR was attenuated with DSCG treatment 
compared to vehicle treated animals. This decrease in response was significant in terms of Peak Penh. 
DSCG has been shown to be effective in the treatment of features of asthma, but due to the fact that 
it has to be taken 4 times daily, its use is limited, alluding to a poor pharmacokinetic profile(Patel et 
al., 1986; Yahav et al., 1988; Kato et al., 1999). This could be why at the beginning of the LAR in the 
rat model (i.e. the Peak Penh response) the LAR was diminished significantly in the DSCG treated 
group, but later in the recording period, the Penh average was again enhanced, resulting in the overall 
AUC appearing to be diminished in the DSCG group, though not significantly. 
It is not surprising that DSCG was effective in the treatment of the LAR in this model. Indeed, this 
compound has previously been shown to be an effective treatment in this particular feature of 
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asthma(Booij-Noord, Orie & De Vries, 1971; Cockcroft & Murdock, 1987). It is, however, of interest 
that although this compound is described as a mast cell stabiliser and is effective in modulating the 
LAR; the previous experiments depleting mast cell contents conferred no diminishing effects in terms 
of the response. This alludes to a mechanism of action of DSCG in the attenuation of the LAR which is 
unrelated to the stabilisation of mast cells. Literature on the subject also implies DSCG to confer 
activity outside of the mast cell degranulation paradigm. It has been shown to be effective in inhibiting 
bronchoconstriction against stimuli such as exercise, SO2, cold air and distilled water; all of which are 
considered unrelated to mast cell degranulation. In addition to this, newly developed mast cell 
stabilisers have been shown to have little effect in clinic (Poppius et al., 1970; Breslin, McFadden & 
Ingram, 1980; Robuschi et al., 1989; Allistone et al., 1985; Dixon & Barnes, 1989). 
Whilst, as a result of the experiments in this chapter and in chapter 3 we cannot substantiate a 
definitive role for mast cells within the driving mechanisms behind the LAR, we can conclude that 
there is the possibility of DSCG modulating the LAR via a mechanism independent of mast cells. Further 
exploration into this mechanism of action could lead to the development of novel therapeutics 
without the poor pharmacokinetic profile of DSCG. Other investigators have suggested that DSCG acts 
independently of mast cells, with studies pointing towards the modulation of sensory nerve 
responses(Dixon & Barnes, 1989; Barnes, 1993; Jackson, Pollard & Roberts, 1992; Norris & Alton, 1996; 
Dixon, Jackson & Richards, 1980) . Within the Respiratory Pharmacology group, a role for airway 
sensory nerves and the ion channel TRPA1 has been suggested to be involved in the driving 
mechanisms behind the LAR (Raemdonck et al., 2012). It could be hypothesised that DSCG could be 
inhibiting the LAR via its actions on airway sensory nerves.  
In summary, this chapter further explored the possible roles for the B-cell – Mast cell – IgE axis in the 
driving mechanisms behind the LAR. This was achieved by pharmacologically targeting Mast cells for 
depletion and stabilisation in the OVA-driven rat model of the LAR, as the mouse model was deemed 
unsuitable for this purpose. Interestingly the mast cell stabiliser DSCG conferred suppressive effects 
on the LAR, whilst depleting mast cell contents using compound 48/80 did not inhibit the response. 
Although from this a role for mast cells within the driving mechanisms behind the LAR could neither 
be confirmed not refuted, the possibility of an alternative mechanism of action for DSCG, independent 
of mast cells, could be proposed. Literature on the subject has implied DSCG to interact with sensory 
nerves (Dixon, Jackson & Richards, 1980; Dixon & Barnes, 1989; Barnes, 1993; Jackson, Pollard & 
Roberts, 1992; Norris & Alton, 1996). Within the Respiratory Pharmacology group a role for airway 
sensory nerves and the ion channel TRPA1 has previously been proposed to be central to the driving 
mechanisms behind the LAR(Raemdonck et al., 2012). It could therefore be hypothesised that DSCG 
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attenuates the LAR via modulation of airway sensory nerve responses. This possibility will be further 
investigated in chapters 6 and 7 of this thesis. 
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Chapter 6 
Further Exploration into the Role of 
Airway Sensory Nerves in the LAR 
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6 Further exploration into the role of airway sensory nerves in the 
LAR 
 
6.1 Rationale 
It has been proposed that airway sensory nerves are central to the driving mechanisms behind the 
LAR. Within the Respiratory Pharmacology group, animal models of the LAR initially demonstrated 
that the LAR, but not the EAR was lost under general anaesthesia indicating the involvement of the 
CNS. Application of the non-selective ion channel inhibitor, Ruthenium Red, abolished the LAR, 
highlighting the possibility of sensory nerve involvement in this response. Further investigation 
utilising selective ion channel blockers highlighted a role for the TRPA1 channel within the LAR. The 
LAMA, Tiotropium Bromide, was found to inhibit the LAR, demonstrating the possibility of cholinergic 
constriction within this response. This lead to the overall hypothesis that airway sensory nerves, a 
central reflex arc and a parasympathetic cholinergic effector arm are involved in the aetiology behind 
the LAR (see figure 6.1) (Raemdonck et al., 2012).  
The involvement of a cholinergic constrictor response in the LAR was initially concluded based upon 
the application of the LAMA Tiotropium, to the rat LAR model. However, it has since been shown that 
Tiotropium has off target effects involving the modulation of TRPV1 responses on airway sensory 
nerves (Birrell et al., 2014). In light of this new data, it was deemed desirable to further characterise 
the role of the parasympathetic cholinergic effector response and the roles of TRPA1 and TRPV1 in the 
LAR. The first aim of this chapter was to investigate if cholinergic constrictor responses are central to 
the LAR via the application of a second LAMA, Glycopyrrolate, to the OVA-driven rat model of the LAR. 
The second aim of this chapter was to test new TRPA1 and TRPV1 inhibitors, Janssen130 and 
XEND0501 respectively, in the rat model of the LAR. The rat model was used in order to ensure 
experimental continuity from the previous chapters within this thesis. 
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Figure 6.1: The Proposed Mechanisms involved in the LAR. Allergen challenge is thought to lead to 
a sequence of events resulting in 1.) The activation of airway sensory nerves via TRPA1 channels 
(blocked by Ruthenium Red and selective ion channel blockers); 2.) Central reflex events (blocked 
via anaesthesia); 3.) Parasympathetic Cholinergic response (blocked by Tiotropium). 
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6.2 Methods 
The following methods were carried out as detailed in chapter 2. Details of individual experiments are 
described below. 
6.2.1 The OVA Driven Rat Model of LAR 
6.2.1.1 Tiotropium and Glycopyrrolate Protocol 
Male Brown Norway rats were sensitised and challenged as detailed in general methods section 2.4.2. 
On day 28, rats were dosed with; Vehicle (0.5% ethanol in saline, 1 ml/kg; i.t.), Tiotropium (1 mg/kg, 1 
ml/kg; i.t.) or Glycopyrrolate (1 mg/kg, 1 ml/kg; i.t.) 60 minutes before and 30 minutes following the 
end of allergen challenge (see figure 6.2). Penh was recorded from 30 minutes after the final drug 
administration for a period of 5 hours as detailed in general methods section 2.5.3. 
 
 
 
Figure 6.2: Timeline demonstrating protocol for Tiotropium and Glycopyrrolate administration in 
the OVA driven rat model of LAR 
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6.2.1.2 Janssen130 and XEND0501 Protocol 
For Janssen130 (TRPA1 inhibitor) and XEND0501 (TRPV1 inhibitor) experiments, male Brown Norway 
rats were sensitised and challenged as previously described in general methods section 2.4.2. On the 
day of allergen challenge, rats were dosed with either Vehicle (0.5% Methylcellulose + 0.2% Tween80 
in saline, 10 ml/kg; i.p. across 2 sites) or Janssen 130 (100 mg/kg or 300 mg/kg, 10 ml/kg; i.p. across 2 
sites) or XEND0501 (10 mg/kg; i.p. across 2 sites) 60 minutes before allergen challenge and 30 minutes 
following the end of challenge (see figure 6.3). Dosing regimens were decided based upon 
pharmacokinetic profiling of these compounds. Penh was recorded from 30 minutes after the final 
drug administration for a period of 5 hours. 
 
 
 
Figure 6.3: Timeline demonstrating protocol for Janssen130 administration in OVA driven rat model 
of LAR 
 
6.2.2 Statistical Analysis 
Data were analysed using Graphpad Prism 5. Data was expressed as mean ±s.e.m. Non-parametric 
Mann Whitney-U tests with two-tailed p-values were carried out in order to assess statistical 
significance between 2 groups. Differences were considered statistically significant if p<0.05. 
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6.3 Results 
6.3.1 The Effect of Tiotropium and Glycopyrrolate on the LAR 
OVA sensitised rats displayed a marked LAR upon OVA challenge. This response peaked at 2-3 hours 
and lasted for up to 6 hours following allergen challenge. Saline sensitised rats did not display a 
response following OVA challenge. Treatment with Tiotropium and Glycopyrrolate resulted in a 
significant attenuation of the LAR in terms of both Penh AUC and Peak Penh responses in the OVA 
sensitised and challenged rats (figure 6.4).  
 
 
Figure 6.4: Effect of Tiotropium and Glycopyrrolate treatment in the rat OVA-driven LAR. 1 hour 
following allergen challenge rats were placed in WBP chambers and Penh recorded for a further 5 
hours. Data is expressed as A) Penh average over the recording time period; B) Penh Area Under 
Curve; and C) Penh average at peak response. Data expressed as mean ± s.e.m. n=8. Mann-Whitney 
U-test. *p<0.05 Vehicle/Saline compared to Vehicle/Ovalbumin. #p<0.05 Drug treated/Ovalbumin 
compared to Vehicle/Ovalbumin. 
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6.3.2 The Effect of Janssen130 on the LAR 
OVA challenge resulted in a marked LAR in OVA sensitised rats, peaking at 2-3 hours and lasting for up 
to 6 hours after challenge. The saline sensitised rats did not display a response following OVA 
challenge. Application of Janssen130 resulted in a diminished LAR in the OVA sensitised/OVA 
challenged rats at both doses tested. This decrease in response was significant at the 300 mg/kg 
concentration in terms of both Penh AUC and Peak Penh response (figure 6.5). 
 
Figure 6.5: Effect of Janssen130 treatment in the rat OVA-driven LAR. 1 hour following allergen 
challenge rats were placed in WBP chambers and Penh recorded for a further 5 hours. Data is 
expressed as A) Penh average over the recording time period; B) Penh Area Under Curve; and C) 
Penh average at peak response. Data expressed as mean ± s.e.m. n=4-8. Mann-Whitney U-test. 
*p<0.05 Vehicle/Saline compared to Vehicle/Ovalbumin. #p<0.05 Janssen130 (various 
concentrations) treated/Ovalbumin compared to Vehicle/Ovalbumin. 
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6.3.3 The Effect of XEND0501 on the LAR 
The OVA sensitised rats, again, displayed a marked LAR upon OVA challenge. The response peaked at 
2-3 hours and lasted for up to 6 hours after challenge. The XEND0501 treated rats displayed a 
diminished response compared to the OVA sensitised/Vehicle treated group. This difference, 
however, was not significant in terms of either Penh AUC or Peak Penh response (figure 6.6). However, 
it could be deemed as approaching significance (p=0.0792) and as such a non-significant result could 
simply be due to low n numbers within the experiments. 
 
Figure 6.6: Effect of XEND0501 treatment in the rat OVA-driven LAR. 1 hour following allergen 
challenge rats were placed in WBP chambers and Penh recorded for a further 5 hours. Data is 
expressed as A) Penh average over the recording time period; B) Penh Area Under Curve; and C) 
Penh average at peak response. Data expressed as mean ± s.e.m. n=3-8. Mann-Whitney U-test. 
*p<0.05 Vehicle/Saline compared to Vehicle/Ovalbumin. #p<0.05 XEND0501 treated/Ovalbumin 
compared to Vehicle/Ovalbumin. 
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6.4 Discussion 
It has previously been proposed that airway sensory nerves, a central reflex arc and parasympathetic 
cholinergic constrictor responses are involved in the aetiology behind the LAR. In these investigations, 
a parasympathetic cholinergic constrictor response within the driving mechanisms behind the LAR was 
deduced based upon the observation that the LAR was diminished in animals treated with Tiotropium, 
a LAMA (Raemdonck et al., 2012). Since then, Tiotropium has been shown to have off target effects 
involving the modulation of TRPV1 responses on airway sensory nerves (Birrell et al., 2014). This is 
interesting as the study by Raemdonck et al (2012) also deduced that TRPA1 and not TRPV1 were 
central to the driving mechanisms behind the LAR using pharmacological intervention. The original 
conclusions were made based upon results from single tool compounds in animal models of the LAR. 
Therefore, when further pharmacological tools became available it was deemed desirable to further 
investigate the possible roles of cholinergic constrictor responses, and the ion channels TRPA1 and 
TRPV1 in the LAR. The aim of this chapter was to further validate the roles of these factors in the LAR 
via the application of newly available pharmacological tools to the OVA-driven rat model. 
Application of the LAMA, Glycopyrrolate, to the OVA-driven rat model resulted in a diminished LAR 
similar to that previously seen with Tiotropium. Whereas Tiotropium has more recently been shown 
to have off target effects involving the modulation of TRPV1 on airway sensory nerves, the same 
investigation also showed that these effects were not applicable to Glycopyrrolate (Birrell et al., 2014). 
Therefore, it could be validated that a parasympathetic cholinergic effector arm is central to the 
aetiology behind the LAR. 
In order to further validate a role for TRPA1 in the mechanisms behind the LAR, the TRPA1 inhibitor 
Janssen130 was applied to the OVA-driven rat model. In these experiments an attenuated LAR was 
observed in a dose-dependent manner with Janssen130 treatment, highlighting a role for TRPA1 in 
the driving mechanisms behind the LAR. TRPA1 is thought to be mainly expressed in neurons such as 
airway sensory nerves (Bautista et al., 2006a; Story et al., 2003; Bandell et al., 2004; Jang et al., 2012; 
Nassenstein et al., 2008). As the functional relevance of TRPA1 on airway sensory nerves has been 
well characterised, it could be deduced that TRPA1 present on airway sensory nerves triggers a 
neuronal response resulting in the bronchoconstriction that is the LAR (Grace & Belvisi, 2011; 
Raemdonck et al., 2012). However, a non-neuronal role for TRPA1 in the LAR cannot be ruled out as 
expression of TRPA1 has also been reported in non-neuronal cell types such as CD4+ T-cells, CD8+ T-
cells, B-cells and Mast cells (Banner, Igney & Poll, 2011b; Prasad et al., 2008). The role of TRPA1 in 
other features of asthma such as inflammation and AHR has been explored by researchers. It was 
reported that TRPA1 deficient mice have reduced inflammation and AHR when applied to mouse 
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models of allergic asthma (Caceres et al., 2009). Conversely, it has also been shown that application 
of acrolein (a known TRPA1 agonist) resulted in a decreased inflammatory response in a murine 
allergic asthma model (Spiess et al., 2013). Other studies have indicated a role for TRPA1 in the direct 
control of airway tone. It has been reported that activation of TRPA1 channels on isolated guinea-pig 
bronchus results in constriction which is secondary to the release of neuropeptides via local axons 
(Andre et al., 2008). Further investigation into possible functions of non-neuronal TRPA1 is warranted. 
Overall, with respect to the LAR, it can be concluded that TRPA1, possibly on airway sensory nerves, 
is central to the driving mechanisms behind the LAR. However, it also cannot be ruled out that TRPA1 
on a non-neuronal cell type is central to the aetiology behind the LAR. 
Application of the TRPV1 selective inhibitor, XEND0501, to the rat model of LAR did not result in 
significant attenuation of the response. However, it must be noted that although not significant a 
slightly diminished response in terms of Penh AUC and Peak Penh was observed with XEND0501 
treatment in OVA sensitised and challenged rats. Similarly to TRPA1, TRPV1 has been reported to be 
mainly expressed in airway sensory nerves but expression is also present in lung tissue (Kunert-Keil et 
al., 2006; Banner, Igney & Poll, 2011b; Jang et al., 2012). Studies investigating the role of TRPV1 in the 
control of airway tone in diseases such as asthma have yielded conflicting results. Agonists of TRPV1 
have been shown to contract isolated guinea-pig ASM via mediating the release of sensory 
neuropeptides from finite stores in nerve endings which consequently act upon neurokinin receptors 
on ASM (Belvisi et al., 1992). Investigations utilising animal models have reported TRPV1 to have a 
proinflammatory role in allergic asthma (Rehman et al., 2013b), whilst others have shown TRPV1 to 
be protective against allergic inflammation (Mori et al., 2011). Other researchers have reported that 
TRPV1 is not involved at all in features of allergic asthma (Raemdonck et al., 2012; Caceres et al., 
2009). Overall, studies investigating the role of TRPV1 in allergic asthma have produced conflicting 
results. With respect to the role of TRPV1 in the aetiology behind the LAR, Raemdonck et al (2012) 
previously reported that no attenuation of the LAR was observed with the application of the TRPV1 
selective inhibitor, JNJ-17203212. The results in this chapter also denote that although a slight 
attenuation of response was observed with the application of the TRPV1 inhibitor XEND0501, this 
reduction was not significant. It should be noted that as this particular TRPV1 inhibitor is a recent 
development and extensive pharmacological profiling is ongoing. As such off-target effects cannot be 
ruled out. Thus far, it can be concluded that TRPV1 is not involved in the aetiology behind the LAR. 
However, due to the conflicting nature of current literature on the subject, it would be desirable to 
further investigate the role of this ion channel in the LAR (and other aspects of asthma) should new 
investigative tools become available in the future. 
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In summary, this chapter has further explored the role of cholinergic constrictor responses, TRPA1 and 
TRPV1 within the LAR via the application of pharmacological tools to the OVA-driven rat model of the 
LAR. The LAMA Glycopyrrolate attenuated the LAR, confirming a role for cholinergic constrictor 
responses within the response. Selective inhibitors of TRPA1 (Janssen130) and TRPV1 (XEND0501) 
confirmed a role for TRPA1 but not TRPV1 within the LAR. In Chapter 5, DSCG was found to inhibit the 
LAR and the possibility of an alternative mechanism of action for DSCG involving airway sensory nerve 
modulation was raised. Chapter 6 has provided further evidence for the hypothesis that TRP channels, 
airway sensory nerves, a central reflex arc and parasympathetic cholinergic responses are central to 
the driving mechanisms behind the LAR. Therefore, it could be hypothesised that DSCG attenuates the 
LAR via modulation of airway sensory nerve responses involving TRP channels such as TRPA1. This will 
be investigated in Chapter 7. 
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Chapter 7 
The Role of Disodium Cromoglycate on 
Airway Sensory Nerves in the LAR 
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7 The Role of Disodium Cromoglycate on airway sensory nerves in 
the LAR 
7.1 Rationale 
It was observed in Chapter 5 that the mast cell stabiliser DSCG modulated the LAR; however, depleting 
mast cell contents had no effect on the response. This led to the consideration that DSCG could be 
attenuating the LAR via a mechanism that is independent of mast cells. Literature on the subject 
suggested that DSCG interacts with airway sensory nerves and a role for airway sensory nerves within 
the LAR has previously been shown (Dixon, Jackson & Richards, 1980; Dixon & Barnes, 1989; Barnes, 
1993; Jackson, Pollard & Roberts, 1992; Norris & Alton, 1996; Raemdonck et al., 2012). This has led us 
to postulate that DSCG could attenuate the LAR via its action on airway sensory nerves. The overall 
purpose of this chapter is to further investigate this possibility and explore possible mechanisms of 
action associated with this. 
The first aim of this chapter was to investigate the possible direct inhibitory actions of DSCG on TRP 
channel mediated airway sensory nerve depolarisation utilising an ex vivo isolated vagus nerve setup.  
It was then considered desirable to further explore the mechanism of action of DSCG on inhibiting 
TRPA1 mediated sensory nerve depolarisation. The literature on the subject suggested that DSCG is 
an agonist at the G-protein coupled receptor 35 (GPR35) and agonists of this receptor modulate 
calcium signalling in neurons (Guo et al., 2008; Yang et al., 2010). Therefore, the second aim was to 
investigate the possible role of the GPR35 receptor in DSCG mediated inhibition of TRPA1 driven 
depolarisation in the isolated vagus nerve utilising pharmacological tools.  The third aim of this chapter 
was to investigate if the findings in the isolated vagus nerve were applicable to the LAR. This was done 
via the application of DSCG and a GPR35 receptor antagonist to the in vivo rat model of the LAR.  
Finally, it was deemed necessary to corroborate these findings by observing the effects of DSCG and 
its possible mechanism of action on airway sensory nerve firing in vivo. Therefore, the fourth aim of 
this chapter was to investigate the effect of DSCG and a GPR35 receptor antagonist on TRPA1 induced 
firing of C-fibre afferents in whole animal single afferent recording studies. 
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7.2 Methods 
The following methods were carried out as detailed in chapter 2. Details of individual experiments are 
described below. 
7.2.1 Isolated Vagus Nerve Experiments 
7.2.1.1 Effect of DSCG on TRPA1 and TRPV1 mediated depolarisation of the isolated 
vagus nerve 
The animal and human tissue was attained, harvested and mounted in a ‘grease gap’ recording 
chamber as detailed in general methods section 2.7.   
The nerve was allowed to equilibrate for 10 minutes in the ‘grease gap’ recording chamber. Following 
this, 2-3 stimulations of consistent magnitude with either acrolein (300 µM) or capsaicin (1 µM) were 
achieved, washing between stimulations with KH in order to return to baseline depolarisation. The 
nerve was then incubated with either vehicle (0.1% H2O v/v) or DSCG (1, 10 or 100 M) for 10 minutes 
and the stimulant then reapplied in the presence of the drug. The nerve was then washed as previously 
described and a final application of stimulating agent applied in order to ascertain the viability of the 
nerve. A change in the level of depolarisation as a result of drug application was reported as 
percentage of the average of the two initial basal responses (general methods section 2.7). 
It is of note that slightly higher concentrations of DSCG were used than might be deemed 
physiologically relevant. This is because historically the vagus preparation requires higher 
concentrations of ligands possibly due to the fact that the nerve trunk is used rather than the actual 
nerve ending. Nevertheless, as part of this preparation, concentration responses are performed as 
standard, always ensuring that the “effect” is modulated by a specific antagonist across numerous 
species including human tissue. 
7.2.1.2 The role of GPR35 Receptor in DSCG mediated inhibition of TRPA1 driven 
depolarisation in the isolated vagus nerve 
Male Brown Norway rats or Dunkin Hartley guinea-pigs were euthanized, the vagal tissue harvested 
and mounted in a ‘grease gap’ recording chamber as detailed in general methods section 2.7. 
Following a 10 minute equilibration period, 2-3 stimulations of consistent magnitude were attained 
via the application of acrolein (300 µM) as previously described. The nerve was then incubated with 
either vehicle (0.1% v/v DMSO) or the GPR35 inhibitor ML145 (1 µM) for 5 minutes. Following this the 
nerve was then incubated with either DSCG (10 µM) or a known GPR35 agonist – Pamoic Acid (10 µM), 
Kynurenic Acid (10 µM) or Zaprinast (10 µM) for 10 minutes. The stimulant (acrolein, 300 µM) was 
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then applied in the presence of the drug(s), the percentage inhibition reported as previously 
described. The nerve was then finally assessed for viability (see general methods section 2.7). 
Concentrations of TRPA1 and TRPV1 agonists were chosen based on previous experiments within the 
Respiratory Pharmacology group (Birrell et al., 2009b). Concentrations of antagonists were selected 
that were approximately 100-fold the PA2 value (defined as the negative logarithm of the molar 
concentration of an antagonist that would produce a 2-fold shift in the concentration response curve 
for an agonist) as is common practice. 
7.2.2 The OVA Driven Rat Model of LAR 
7.2.2.1 The effect of ML145 on DSCG mediated inhibition of the LAR 
Male Brown Norway rats were sensitised and challenged as detailed in general methods section 2.4.2. 
On day 28, rats were dosed with ML145 (30 mg/kg, i.p) or Vehicle (0.5% MC + 0.2% tween80 in saline; 
10 ml/kg, i.p.) 90 minutes before and 5 minutes after allergen challenge. Rats were also dosed with 
DSCG (10 mg/kg, i.t.) or Vehicle (0.5% ethanol in saline; 1 ml/kg, i.t) 30 minutes prior to and 20 minutes 
following the end of allergen challenge. Penh was recorded from 30 minutes after end of allergen 
challenge for a period of 5 hours as detailed in general methods section 2.5.3. 
 
 
 
 
Figure 7.1: Timeline demonstrating protocol for ML145 and DSCG administration in the OVA driven 
rat model of LAR 
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7.2.3 Whole Animal Single Afferent Recordings 
7.2.3.1 The effect of DSCG on TRPA1 induced firing of C-fibre afferents 
Surgery, setup and identification of a C-fibre were performed as detailed in general methods section 
2.8. Animals were allowed to stabilise for at least 30 minutes before a 2 minute baseline recording 
took place. Capsaicin (100 µM) was then administered by aerosol for 15 seconds and changes in nerve 
fibre firing, intratracheal pressure and blood pressure recorded until baseline levels were re-
established. Two reproducible responses to acrolein aerosol (10 mM, 1.0 min) were attained before 
administration of DSCG (10 mg/kg; i.t.) or Vehicle (0.5% ethanol in saline; 1 ml/kg, i.t). Following a 30 
minute incubation period, a response to acrolein was attained as previously described. A final 
capsaicin response took place at the end of the experiment in order to confirm nerve viability (see 
figure 7.2). Data was recorded and expressed as peak impulses.S-1 as detailed in general methods 
section 2.8. 
 
 
Figure 7.2: Recording protocol for in vivo single afferent recording. Briefly, following a 2 minute 
baseline recording, capsaicin (100 M aerosol, 15 s) was administered. After baseline was re-
established, two reproducible responses to acrolein (10 mM aerosol, 1.0 min) were attained. After 
a suitable interval, DSCG (10 mg/kg, i.t.) or vehicle (i.t.) was administered and an incubation time of 
30 mins took place. A response to acrolein (10 mM aerosol, 1.0 min) was then obtained before a 
final capsaicin (100 µM aerosol, 15 s) response was recorded. 
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7.2.3.2 The effect of ML145 on DSCG mediated inhibition of C-fibre afferent firing 
Surgery and setup were performed as detailed in general methods section 2.8. The dosing and 
recording protocol was performed as previously described (section 7.2.3.1) with the application of the 
following step for the antagonist experiments. Vehicle (0.5% MC + 0.2% tween80 in saline; 10 ml/kg, 
i.p.) or GPR35 receptor antagonist, ML145 (30 mg/kg, i.p) were administered 30 minutes before the 
Vehicle or DSCG (1hour before the final acrolein challenge). 
 
7.2.4 Statistical Analyses 
Data were analysed using Graphpad Prism 5. Data was expressed as mean ±s.e.m. Non-parametric 
Mann Whitney-U tests with two-tailed p-values or Paired t-tests were carried out in order to assess 
statistical significance between 2 groups (details for individual experiments found in figure legends). 
Differences were considered statistically significant if p<0.05. 
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7.3 Results 
7.3.1 Effect of DSCG on TRPA1 and TRPV1 mediated depolarisation of the 
isolated vagus nerve 
In the Brown Norway isolated vagus nerve experiments, DSCG elicited a concentration dependent 
inhibition of TRPA1-mediated depolarisation induced by acrolein (See figure 7.3). Similar inhibition 
was not observed with respect to TRPV1-mediated depolarisation induced by capsaicin.  
 
 
Figure 7.3: Effect of DSCG on TRPA1 and TRPV1 mediated depolarisation of Brown Norway rat vagus 
nerve.  Vagal tissue was harvested and mounted in a ‘grease-gap’ recording chamber. Two basal 
responses to stimulant were obtained after which the tissue was incubated with vehicle (H20, 0.1% 
v/v) or DSCG (1, 10 or 100uM) for 10 minutes. Stimulant was reapplied and changes in the level of 
depolarisation reported as percentage of the average of the two basal responses. Data is expressed 
as A) Percentage inhibition of TRPA1 (acrolein; 300 µM) mediated responses and B) Percentage 
inhibition of TRPV1 (capsaicin; 1 µM) mediated responses. Data expressed as mean ± s.e.m. n=4. 
*p<0.05 comparing depolarisation levels before and after treatment using a paired t-test. 
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In order to translate this finding into human vagal tissue, a sub-maximal concentration of DSCG (10 
µM) was chosen to test against TRPA1 (acrolein) and TRPV1 (capsaicin) mediated depolarisation. DSCG 
inhibited TRPA1 mediated depolarisation by approximately 81% which was not observed with respect 
to TRPV1 mediated depolarisation (approximately 6% inhibition) (See figure 7.4). 
 
 
 
Figure 7.4: Effect of DSCG on TRPA1 and TRPV1 mediated depolarisation of human vagus nerve. 
Vagal tissue was harvested and mounted in a ‘grease-gap’ recording chamber. Two basal responses 
to stimulant were obtained after which the tissue was incubated with vehicle (H2O, 0.1% v/v) or 
DSCG (10uM) for 10 minutes. Stimulant was reapplied and changes in the level of depolarisation 
reported as percentage of the average of the two basal responses. Data is expressed as Percentage 
inhibition of TRPA1 (acrolein; 300 µM) mediated responses and TRPV1 (capsaicin; 1 µM) mediated 
responses.  N=4 (4 donor patients; 3 males, 36-57 years old and 1 female, 45 years old). 
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7.3.2 The role of GPR35 Receptor in DSCG mediated inhibition of TRPA1 driven 
depolarisation in the isolated vagus nerve 
In order to test the hypothesis that DSCG modulated TRPA1-driven sensory nerve effects via the 
activation of GPR35, a range of GPR35 agonists were applied to the isolated vagus nerve in parallel to 
DSCG. The GPR35 agonists elicited inhibition against acrolein induced depolarisation (mean 
inhibitions: Pamoic Acid 51%; Kynurenic Acid 65% and Zaprinast 74%) as did DSCG (mean inhibition: 
68%). In order to confirm that the inhibition observed was via the GPR35 receptor, the GPR35 
antagonist ML145 was utilised. The application of ML145 abolished the ability of DSCG and the other 
GPR35 agonists to inhibit TRPA1-induced depolarisation (mean inhibitions: DSCG 7%, Pamoic Acid 8%, 
Kynurenic Acid 19% and Zaprinast 7%) (See figure 7.5). 
 
 
Figure 7.5: The role of the GPR35 Receptor in DSCG mediated inhibition of TRPA1 driven 
depolarisation in the Brown Norway rat isolated vagus nerve. The effect of various GPR35 agonists 
(PA - pamoic acid, KY - Kynurenic acid, ZA Zaprinast and DSCG, 10uM) on acrolein induced 
depolarisation of rat vagal nerves in the presence of vehicle (0.1% v/v, DMSO) or GPR35 antagonist 
ML145 (1 µM). Data expressed as mean ± s.e.m. n=4. ).* = p<0.05 using a paired t-test to compare 
the response to acrolein in absence and presence of GPR35 agonist. 
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7.3.3 Effect of ML145 on DSCG mediated inhibition of the LAR 
OVA sensitised rats displayed a marked LAR upon OVA challenge. This response peaked at 2-3 hours 
and lasted for up to 6 hours following allergen challenge. Saline sensitised rats did not display a 
response following OVA challenge. Treatment with DSCG resulted in an attenuation of the LAR which 
was significant in terms of Peak Penh response. This attenuation of the LAR was blocked with the 
application of the GPR35 inhibitor, ML145. No effect on the LAR was observed with the application of 
ML145 alone (See figure 7.6). 
 
 
Figure 7.6: Effect of ML145 on DSCG mediated inhibition of the LAR. 1 hour following allergen 
challenge rats were placed in WBP chambers and Penh recorded for a further 5 hours. Data is 
expressed as A) Penh average over the recording time period; B) Penh Area Under Curve; and C) 
Penh average at peak response. Data expressed as mean ± s.e.m. n=7-8. Mann-Whitney U-test. 
*p<0.05 Vehicle/Saline compared to Vehicle/Ovalbumin. #p<0.05 Drug treated/Ovalbumin 
compared to Vehicle/Ovalbumin. 
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7.3.4 The role of TRPA1 and the GPR35 Receptor in DSCG mediated inhibition 
of depolarisation in the Guinea-Pig isolated vagus nerve 
It was previously shown in this chapter that DSCG modulated TRPA1-driven sensory nerve effects via 
the activation of GPR35 in Brown Norway Rat Vagal tissue. This was useful as the in vivo LAR model is 
in this species. The final aims of this chapter involve assessing the modulation of airway sensory nerve 
activation by DSCG in vivo. These investigations utilise a whole animal single afferent recording model 
which is in the Dunkin-Hartley guinea-pig species. Therefore, prior to these investigations taking place, 
it was deemed necessary to validate that DSCG modulates TRPA1-driven sensory nerve responses in 
the guinea-pig and if so assess that the same mechanisms are applicable in this species as was found 
in the Brown Norway rat. 
In the Dunkin-Hartley isolated vagus nerve experiments, DSCG elicited an inhibition of TRPA1-
mediated depolarisation induced by acrolein. This inhibition was not observed with respect to TRPV1-
mediated depolarisation induced by capsaicin (see figure 7.7 (A)). 
In order to investigate that DSCG modulates TRPA1-driven sensory nerve effects via GPR35 (as seen 
in the rat), GPR35 agonists were applied to the isolated vagus nerve in parallel to DSCG. The GPR35 
agonists elicited an inhibition of the acrolein induced depolarisation similar to that observed with 
DSCG (mean inhibitions: Kynurenic Acid 66%; Zaprinast 70% and DSCG 67%). In order to confirm that 
the inhibition observed was via the GPR35 receptor, ML145 was applied. This resulted in a reduction 
in the ability of DSCG and the other GPR35 agonists to inhibit TRPA1-induced depolarisation (mean 
inhibitions: DSCG 23%, Kynurenic Acid 42% and Zaprinast 30%) (see figure 7.7 (B)). 
Overall, it was shown in the Dunkin-Hartley guinea-pig vagal tissue that DSCG inhibits TRPA1 mediated 
responses and the mechanism of action involves GPR35. This is consistent with observations in the 
Brown-Norway rat. Therefore, it was considered acceptable to use the guinea-pig whole animal single 
afferent recording model to further these investigations. 
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Figure 7.7: The role of TRPA1 and the GPR35 Receptor in DSCG mediated inhibition of depolarisation 
in the Guinea-Pig isolated vagus nerve.  A) The effect of DSCG on either TRPA1 (acrolein; 300 µM) or 
TRPV1 (capsaicin; 1 µM) mediated responses. B) The effect of various GPR35 agonists (KY - Kynurenic 
acid, ZA Zaprinast and DSCG, 10 µM) on acrolein induced depolarisation of guinea-pig vagal nerves 
in the presence of vehicle (0.1% v/v, DMSO) or GPR35 antagonist ML145 (1 µM). Data expressed as 
percentage inhibition of stimulant induced response; mean ± s.e.m. n=4. ).* = p<0.05 using a paired 
t-test to compare the response to acrolein in absence and presence of GPR35 agonist. 
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7.3.5 Effect of DSCG on TRPA1 induced firing of C-fibre afferents 
In order to assess that DSCG was modulating airway sensory nerve activation in vivo, the effect of 
DSCG on acrolein-evoked firing of airway-terminating, single vagal afferent chemosensitive C-fibres 
was examined. DSCG significantly reduced the peak firing rate (16.7±2.2 to 4.3±0.9 imp.s-1) evoked by 
acrolein. Little baseline firing was observed (see figure 7.8). 
 
 
 
Figure 7.8: Effect of DSCG on TRPA1 induced firing of C-fibre afferents. All animals were firstly 
exposed to aerosolised capsaicin (15 s; 100 µM), twice to acrolein (1 min; 10 mM) before incubating 
with Vehicle (0.5% EtoH in Saline, i.t.) or DSCG (10 mg/kg, i.t.).  Following this a final response to 
acrolein was obtained prior to subsequent capsaicin stimulation. Panels A and B show the peak imp 
s-1 before and after vehicle or DSCG application: Baseline firing (BF), capsaicin response (C) and 
acrolein response (A). Data is expressed as mean ±s.e.m. n=3. Paired t-test. *p<0.05 acrolein 
responses before and after treatment. 
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7.3.6 Effect of ML145 on DSCG mediated inhibition of C-fibre afferent firing 
In order to ascertain that the inhibition of acrolein-evoked firing of airway-terminating, single vagal 
afferent chemosensitive C-fibres was via the GPR35 receptor, ML145 was applied to this experimental 
protocol. After administration of Vehicle, DSCG significantly inhibited the peak firing rate (12.0±2.3 to 
3.0±0.6 imp.S-1) evoked by acrolein. Following administration of ML145, DSCG did not impact on the 
firing rate (9.7±1.8 to 14±4.2 imp.S-1) evoked by acrolein (see figure 7.9). 
 
 
 
Figure 7.9: Effect of ML145 on DSCG mediated inhibition of C-fibre afferent firing.  All animals were 
firstly exposed to aerosolised capsaicin (15 s; 100 µM), twice to acrolein (1 min; 10 mM) before 
incubating with Vehicle DSCG (10 mg/kg, i.t.) in the presence of either ML145 (30 mg/kg, i.p.) or 
Vehicle (0.5% Methylcellulose + 0.2% Tween 80 in saline, i.p.).  Following this a final response to 
acrolein was obtained prior to subsequent capsaicin stimulation. Data is expressed as peak imp s-1. 
Panels A and B show the effect of either Vehicle or ML145 on DSCG mediated inhibition of acrolein 
driven C-fibre firing. Data is expressed as mean ±s.e.m. n=3. Paired t-test. *p<0.05 acrolein 
responses before and after treatment. 
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7.4 Discussion 
The overall aim of this chapter was to investigate if DSCG attenuates the LAR via an action on airway 
sensory nerves, and to further explore possible mechanisms of action associated with this.  
In Chapter 5 of this thesis, DSCG was shown to inhibit the LAR via a mechanism of action independent 
of mast cells. Other studies have suggested that DSCG interacts with airway sensory nerves  (Dixon, 
Jackson & Richards, 1980; Dixon & Barnes, 1989; Barnes, 1993; Jackson, Pollard & Roberts, 1992; 
Norris & Alton, 1996). Previously within the Respiratory Pharmacology group, a role for airway sensory 
nerves  within the aetiology behind the LAR was deduced (Raemdonck et al., 2012). In chapter 6 of 
this thesis, TRPA1 but not TRPV1 was confirmed to be central to the driving mechanisms behind the 
LAR. The first aim of this chapter was to investigate the action of DSCG on TRP channel mediated 
airway sensory nerve depolarisation utilising isolated vagus nerve experiments. As the LAR 
observations were in the Brown Norway Rat model, this species was initially chosen for the isolated 
vagus nerve experiments. Acrolein (TRPA1 agonist) or capsaicin (TRPV1) was used to evoke 
depolarisation of the isolated nerve and DSCG was applied in order to observe any attenuation of 
depolarisation. DSCG was found to inhibit TRPA1, but not TRPV1, mediated depolarisation in a 
concentration dependant manner. It should be noted that at the highest concentration of DSCG 
tested, around a 40% inhibition was exhibited to TRPV1 stimuli. However, as the sub-maximal dose 
was taken forward for use in further experiments and this dose was not effective in inhibiting TRPV1 
mediated effects it was concluded in this instance that DSCG inhibited TRPA1 mediated depolarisation 
only. These findings were translated into human vagal tissue, where a sub-maximal dose of DSCG was 
also shown to inhibit TRPA1, but not TRPV1, mediated depolarisation. Other studies have also 
reported that DSCG attenuates sensory nerve activity in pre-clinical cough models (Lai & Lin, 2005; 
Jackson, 1988; Dixon, Jackson & Richards, 1980) and also in translational human investigations 
(Moroni et al., 1996; Zielen et al., 2006). The results from this chapter concur with the literature and 
further the understanding in this field via the suggestion of the modulation of specifically TRPA1 driven 
responses on airway sensory nerves. 
After concluding that DSCG inhibits TRPA1 mediated depolarisation of airway sensory nerves, it was 
considered desirable to explore the possible mechanisms of action associated with this. Other 
investigations have shown DSCG to be an agonist of a G-protein coupled receptor known as GPR35 
(Yang et al., 2010). Agonists of this receptor have also been shown to modulate calcium signalling in 
neurons (Guo et al., 2008). Therefore, it was postulated that DSCG could modulate TRPA1 driven 
sensory nerve activity via activation of GPR35. In order to investigate this possibility, experiments were 
performed where agonists of GPR35 were applied to the isolated vagus nerve preparation in parallel 
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to DSCG and their effect on TRPA1 driven nerve depolarisation examined. The GPR35 agonists were 
found to elicit a similar degree of inhibition of TRPA1 mediated nerve depolarisation to that observed 
with DSCG. In order to confirm that the inhibition observed was indeed via GPR35, an antagonist of 
this receptor, ML145, was also applied in this line of investigation. The GPR35 antagonist was observed 
to block the inhibition of sensory nerve responses by DSCG (and the GPR35 agonists), thus leading to 
the conclusion that GPR35 is central to the effect of DSCG on airway sensory nerve responses. 
The next aim of this chapter was to examine if the findings in the isolated vagus nerve were applicable 
to the LAR. In order to achieve this, DSCG was applied to the OVA-driven rat model of the LAR with 
either vehicle or the GPR35 antagonist, ML145. DSCG was shown to inhibit the LAR and ML145 
successfully blocked this inhibition. It has previously been postulated that sensory nerves are central 
to the driving mechanisms behind the LAR (Raemdonck et al., 2012) and DSCG is able to interact with 
airway sensory nerves (Dixon & Barnes, 1989; Barnes, 1993; Jackson, Pollard & Roberts, 1992; Norris 
& Alton, 1996; Dixon, Jackson & Richards, 1980). In this chapter, the mechanisms previously elucidated 
in the isolated vagus nerve have been shown to apply to the LAR in vivo. Therefore, there is strong 
evidence to suggest that DSCG attenuates the LAR via acting on GPR35.  However, it must be noted 
that while applying pharmacological tools to the in vivo LAR model supports the role of GPR35 in the 
DSCG mediated inhibition of response it does not demonstrate that the action is on airway sensory 
nerves. Due to this, the final aim of this chapter was to establish the role of GPR35 in DSCG mediated 
inhibition of airway sensory nerve firing in vivo.  
This final aim of this chapter was achieved via the use of an in vivo single afferent recording model. In 
this set of experiments, DSCG was found to significantly attenuate TRPA1 induced firing of C-fibre 
afferents and the application of ML145 resulted in the modulation of this effect. This demonstrates 
that DSCG attenuates TRPA1 driven airway sensory nerve responses via GPR35. It is of note that this 
model is in the Dunkin Hartley guinea-pig, not the Brown Norway rat. This is because at present in the 
Respiratory Pharmacology group, the whole animal single afferent recording model has been 
characterised only in the guinea-pig. Due to the time-constraints of this thesis it wasn’t deemed 
feasible to set-up, characterise and validate the model in the Brown Norway rat, although this is a 
desirable aim for the future. This would allow us to further investigate the role of airway sensory nerve 
responses on backgrounds of allergic disease more specifically. However, for the purposes of this 
thesis, the use of the guinea-pig model was validated as isolated vagus nerve depolarisation studies 
were paralleled in this species and the results were found to be concordant with those found in the 
rat. 
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DSCG has long been shown to be effective in the treatment of features of asthma, but due to the fact 
that it has to be taken 4 times daily, its use is limited, alluding to a poor pharmacokinetic profile (Patel 
et al., 1986; Yahav et al., 1988; Kato et al., 1999). In the literature, DSCG has been widely shown to be 
effective in inhibiting the LAR (Booij-Noord, Orie & De Vries, 1971; Cockcroft & Murdock, 1987; Nabe 
et al., 2004; Koyama et al., 2005). It was originally postulated that this efficacy is due to its action as a 
mast cell stabiliser, however, newly developed mast cell stabilisers have shown little efficacy in clinic 
(Sheard & Blair, 1970). In this chapter, it was shown that DSCG inhibits the LAR via activation of the G-
protein coupled receptor GPR35, likely via its actions on airway sensory nerves. This data is intriguing 
as not only does it explain why in clinic previously developed mast cell stabilisers have been found 
ineffective in the treatment of asthma, it also presents a novel target for asthma therapy. If a ligand 
with an appropriate pharmacokinetic profile was developed that targeted GPR35, in theory the 
beneficial effects of DSCG would be maintained without the need for repeated dosing regimens. This 
is an extremely exciting prospect for the future which could lead to the development of novel asthma 
therapies. 
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8 Summary and Future Studies 
8.1 Summary 
The hypothesis for this body of work was “mast cells and airway sensory nerves are central to the 
driving mechanisms behind the LAR”. The various experiments undertaken addressing this hypothesis 
are detailed below. 
The LAR is a key feature of allergic asthma and refers to a prolonged bronchoconstriction event taking 
place approximately 3-8 hours following contact with allergen. It is experienced by approximately 50% 
of asthma sufferers and is often used as an endpoint in clinical studies exploring new therapeutic 
options (Booij-Noord, Orie & De Vries, 1971; Booij-Noord et al., 1972). Despite this, the specific 
mechanisms driving the LAR have yet to be elucidated. Studies exploring this particular feature of 
asthma have concluded that it is likely that the LAR is at least in part driven by inflammation. This is 
largely based on the fact that the response is accompanied by cellular inflammatory influx into the 
lung and that steroid treatment impacts on the response (Bousquet et al., 2000; Barnes, 2008). Others 
have suggested other driving mechanisms behind the LAR such as possible roles for airway sensory 
nerves (Raemdonck et al., 2012). The overall aim of this thesis was to further explore the driving 
mechanisms behind the LAR using in vivo models. 
Prior to commencing mechanistic investigations of the LAR it was considered necessary to validate the 
clinical relevance of the in vivo models available. In asthmatic patients the LAR occurs approximately 
3-8 hours following allergen exposure (Raemdonck et al., 2012) and can be attenuated using 
glucocorticoid steroids. Therefore, OVA driven Brown Norway Rat and C57BL/6 mouse models of the 
LAR were characterised in terms of response times and also via application of the clinically relevant 
glucocorticoid steroid Budesonide. Both models demonstrated responses at time points comparable 
to those seen in human disease. The application of Budesonide was successful in significantly 
attenuating the responses in both model species. Overall, these studies demonstrated that both 
models were displaying responses consistent with the LAR as seen in clinic. As a result, it was decided 
to take both these models forward for further investigating the driving mechanisms behind the LAR. 
Previous studies exploring the LAR have concluded that the response is at least in part driven by 
inflammation due to the fact that the response is accompanied by cellular inflammatory influx into 
the lung and that steroid treatment impacts on the response (Bousquet et al., 2000; Barnes, 2008). 
The aim of this thesis was to further explore the driving mechanisms behind the LAR; therefore, it was 
considered desirable to further explore the roles of key allergic effector cell types within this response. 
Previous investigations exploring the roles of inflammatory cell populations in animal models of the 
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LAR have yielded conflicting results. This is thought to be due to the fact that monoclonal antibodies 
targeting key effector cells were employed in these studies and issues concerning the target specificity 
of these antibodies exist. In order to circumvent these issues in the studies as part of this thesis, it was 
decided to instead apply GM mice deficient in key allergic effector cell populations to the OVA driven 
mouse model of the LAR to determine the role of these cell types within the response.  
Before these investigations could commence, the phenotype of the knockout mice (CD4-/-, CD8-/-, B-
cell-/- and mast-cell-/-) was assessed with respect to lung tissue cell populations by flow cytometry and 
histology. All GM strains were found to be deficient of their relevant knockout cell type and no 
subsequent effects in terms of the CD4+, CD8+, B-cell and Mast cell lung populations were observed in 
the non-relevant strains. For example mast cell deficient mice were found to be deficient of lung tissue 
mast cells and had no significant up regulation or down regulation of lung tissue CD4+ cells, CD8+ cells 
or B-cells. Baseline levels of other inflammatory cell populations (eosinophils, neutrophils, alveolar 
macrophages and monocytes/tissue macrophages) were found to be comparable to those in wildtype 
mice across all GM strains. Overall, it was concluded that knocking out a particular cell type via genetic 
modification had no resulting effects on other lung tissue cell populations. The results of these studies 
confirmed that the GM mice were suitable for application to the OVA-driven mouse model of the LAR. 
Following application to the OVA-driven mouse model of the LAR the CD4-/- mice displayed a much 
attenuated response and the CD8-/- animals a significantly enhanced response compared to wildtype 
mice. This implicated CD4+ cells in the driving mechanisms behind the LAR and suggested CD8+ cells to 
have a protective role with respect to this response. These findings were consistent with current 
literature on the subject. The role of B-cells, Mast cells and IgE in the LAR were also investigated in 
this manner. These knockout mice displayed responses comparable to those seen in wildtype mice, 
suggesting that these cells and mediators are not involved in the driving mechanisms behind the LAR. 
However, enhanced baseline responses were displayed in all three GM strains (B-cell-/-, Mast cell-/- and 
IgE-/-) even though they were not sensitised to allergen which made the results from these 
experiments difficult to draw conclusions from. Further investigation into the experimental protocol 
suggested the phenomenon was likely attributed to the sensitisation protocol. However, for the 
purpose of the investigation into the role of B-cells, Mast cells and IgE in the LAR, we could 
unfortunately draw no conclusions from this particular set of experiments. It was concluded that 
further work was required to delineate the role of the B-cell-Mast cell-IgE products axis in the LAR. 
Further investigation into the role of the B-cell - Mast cell - IgE products axis was conducted via 
application of the pharmacological tools; Compound 48/80 (a mast cell degranulating agent) and DSCG 
(a mast cell stabilising compound) to the in vivo models of the LAR. Prior to this it was considered 
156 
 
necessary to validate the Compound 48/80 mast cell degranulation protocol in the Brown Norway Rat 
and C57BL/6 mouse. This was assessed via histologically staining mast cell contents in lung tissue 
samples. The results of this showed that the treatment protocol was successful in significantly 
depleting mast cell contents in the Brown Norway rat but not the C57BL/6 mouse. Due to this, it was 
considered unsuitable to utilise the mouse model of the LAR to ascertain the importance of mast cells 
within the response and the rat model was taken forward into the next phase of the investigation.  
The mast cell depletion protocol was then applied the OVA-driven rat model of the LAR and no 
attenuation of response was observed. DSCG was also applied to the rat LAR model. This resulted in 
an abrogation of response. This was not surprising as DSCG has been shown to be an effective 
treatment in this particular feature of asthma (Booij-Noord, Orie & De Vries, 1971; Cockcroft & 
Murdock, 1987). However, the fact that depleting mast cell contents conferred no effect on the LAR 
lead us to question the mechanism of action of DSCG which is traditionally referred to as a mast cell 
stabilising compound. Overall, as a result of these investigations we were unable to substantiate a 
definitive role for mast cells in the driving mechanisms behind the LAR; however, the possibility of 
DSCG modulating the LAR via a mechanism independent of mast cells was raised. Literature on the 
subject has implied DSCG to interact with sensory nerves and within the Respiratory Pharmacology 
group a role for airway sensory nerves has been proposed to be central to the driving mechanisms 
behind the LAR  (Dixon, Jackson & Richards, 1980; Dixon & Barnes, 1989; Barnes, 1993; Jackson, 
Pollard & Roberts, 1992; Norris & Alton, 1996; Raemdonck et al., 2012). It could therefore be 
hypothesised that DSCG attenuates the LAR via modulation of airway sensory nerve responses. This 
possibility was investigated further in the subsequent chapters of this thesis. 
Previous work conducted within the Respiratory Pharmacology group suggested a role for airway 
sensory nerves, the CNS and a parasympathetic cholinergic constrictor response within the driving 
mechanisms behind the LAR (Raemdonck et al., 2012). A role for TRPA1 and not TRPV1 within the 
response was also postulated. Within this body of work, the involvement of a cholinergic constrictor 
response was concluded based upon the application of the LAMA Tiotropium to the rat model of the 
LAR. However, Tiotropium has since been shown to have off target effects involving the modulation 
of TRPV1 responses on airway sensory nerves (Birrell et al., 2014). Due to this it was considered 
necessary to further investigate the role of the parasympathetic cholinergic constrictor response and 
the roles of TRPA1 and TRPV1 in the LAR within this thesis. This was done via the application of a 
second LAMA, Glycopyrrolate, and newly available inhibitors of TRPA1 and TRPV1 to the OVA-driven 
rat model of the LAR. 
157 
 
The application of Glycopyrrolate to the OVA-driven rat model resulted in a diminished LAR. This effect 
was comparable to that previously seen with Tiotropium, and whereas Tiotropium was previously 
shown to have off target effects upon TRPV1, this was not the case with Glycopyrrolate (Birrell et al., 
2014). Therefore, a role for parasympathetic cholinergic constrictor responses within the LAR could 
be corroborated as a result of this investigation. The application of the TRPA1 and TRPV1 inhibitors to 
the OVA-driven rat model of the LAR concluded a role for TRPA1 and not TRPV1 in the driving 
mechanisms behind the response. Overall, these studies further validated the hypothesis that TRP 
channels, airway sensory nerves, a central reflex arc and parasympathetic cholinergic responses are 
central to the driving mechanisms behind the LAR. 
The investigations as part of this thesis so far showed that DSCG (a mast cell stabiliser) modulated the 
LAR but Compound 48/80 (a mast cell degranulating tool) failed to impact upon the response. This led 
to the consideration that DSCG was attenuating the LAR via mechanisms which were independent of 
mast cells. In the literature DSCG has been shown to interact with airway sensory nerves. A role for 
airway sensory nerves in the driving mechanisms behind the LAR has previously been shown by the 
Respiratory Pharmacology group and this work was further validated within this thesis. Overall this 
led us to hypothesise that DSCG attenuates the LAR via actions upon airway sensory nerves. The final 
part of this thesis was to investigate this hypothesis. 
The direct action of DSCG on airway sensory nerves was investigated utilising isolated vagus nerve 
experiments. As TRP channels were previously implicated in the LAR, the effects of DSCG on TRP 
channel mediated airway sensory nerve depolarisation were assessed. DSCG was found to inhibit 
TRPA1, but not TRPV1, mediated depolarisation and these findings were translated into human vagal 
tissue. This allowed us to conclude that DSCG inhibits TRPA1 mediated depolarisation of airway 
sensory nerves. The next part of the investigation was to explore possible mechanisms of action 
associated with this. 
The literature on the subject of DSCG receptor interactions suggested DSCG to be an agonist of the G-
protein coupled receptor GPR35 (Yang et al., 2010; Guo et al., 2008). Therefore, it was hypothesised 
that DSCG could modulate TRPA1 driven sensory nerve activity via the activation of GPR35. This was 
investigated by applying GPR35 agonists to the isolated vagus nerve in parallel with DSCG and their 
effect on TRPA1 driven depolarisation examined. The results from these experiments showed GPR35 
agonists to confer comparable effects to DSCG. The application of a GPR35 antagonist successfully 
blocked the inhibition of depolarisation by DSCG, confirming that GPR35 is central to the effect of 
DSCG on airway sensory nerve responses.  
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The next study was to examine if the findings in the isolated vagus nerve were applicable to the LAR. 
DSCG was applied to the OVA-driven rat model of the LAR in parallel with a GPR35 antagonist or 
vehicle. The results of this study showed that the DSCG mediated attenuation of the LAR was blocked 
by the GPR35 inhibitor, thus providing evidence that DSCG inhibits the LAR via its action on GPR35. 
The previous results showed that DSCG conferred effects on the LAR via an action on GPR35; however, 
they did not directly demonstrate that these effects were occurring via an action on airway sensory 
nerves. Due to this, the final investigation as part of this thesis was to establish the role of GPR35 in 
DSCG mediated inhibition of airway sensory nerve firing in vivo using a single fibre afferent recording 
model. The results from these studies showed that DSCG attenuated TRPA1 induced firing of C-fibre 
afferents and this could be blocked by a GPR35 antagonist, thus demonstrating that DSCG attenuates 
TRPA1 driven airway sensory nerve responses via the G-protein coupled receptor, GPR35. 
DSCG is traditionally referred to as a mast cell stabiliser and has been shown to be effective in the 
treatment of features of asthma such as the LAR. However, due to the fact that it has to be 
administered 4 times daily, its use is limited and alludes to a poor pharmacokinetic profile (Patel et 
al., 1986; Yahav et al., 1988; Kato et al., 1999). Other mast cell stabilisers have also shown little efficacy 
in clinic (Sheard & Blair, 1970). The results obtained as part of this thesis shown DSCG to confer actions 
on airway sensory nerves via the GPR35 receptor to impact upon the LAR. This data is exciting as not 
only does it suggest why previously developed mast cell stabilisers have been found to be ineffective 
in clinic, it also presents a novel target for future asthma therapy.  
Overall, this body of work provides new insights into the driving mechanisms behind the LAR and may 
have uncovered the mystery of the mechanism of action of DSCG. From this, new therapeutic options 
for asthmatics may become available in the future. In addition, the hypothesis of “mast cells and 
airway sensory nerves are central to the driving mechanisms behind the LAR” was addressed. Central 
roles for both mast cells and airway sensory nerves within the LAR were concluded and so the 
hypothesis could be accepted. Further work surrounding this hypothesis is detailed below (see section 
8.3). 
 
8.2 Thesis Limitations 
Within this thesis there are a number of limitations associated with the experimental techniques 
employed, some of which have been outlined previously. 
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The use of OVA driven models of allergic asthma has received criticism in the past for several reasons. 
Firstly, OVA as a clinically relevant allergen prevalent in human disease is questionable. Secondly, 
tolerance to OVA as an inducer of allergic asthmatic responses has been widely reported as a practical 
disadvantage to the model (Van Hove et al., 2007; Swirski et al., 2002). Due to this, difficulties arise 
when using OVA to model chronic models of allergic asthma.  Thirdly, the model requires systemic 
sensitisation along with AlumTM adjuvant. Atopy in asthma is associated with the lungs and so systemic 
sensitisation is considered to be less clinically relevant than other topical routes. The use of an 
adjuvant is also not considered to be appropriate with respect to clinical asthma (See Introduction 
section 1.10.2). Models utilising more disease relevant allergens such as HDM are currently under 
development. These models have the added advantage that adjuvants are not required to induce 
features of allergic asthma and topical application protocols are employed. So far success has been 
achieved in modelling features of asthma such as AHR, airway inflammation and remodelling events, 
however, none of these models display the LAR (Verheijden et al., 2015; Sivapalan et al., 2014; 
Mariñas-Pardo et al., 2014). Due to this, the use of a HDM driven model in this thesis was not a 
possibility. 
The use of the isolated vagus nerve recording technique allowed for a cost effective, relatively high 
throughout pharmacological evaluation of sensory nerve activity. Another added advantage to this 
technique is that findings can be replicated in human donor tissue allowing for translational data. 
However, there are limitations associated with this technique. The trunk of the vagus nerve carries all 
types of afferent nerve fibres in addition to parasympathetic nerves and fibres innervating other organ 
systems such as the heart and the GI tract. This means that assessment of individual fibre types and 
the activity of specifically airway terminating nerves is not a possibility. The effect on the isolated 
nerve trunk does not necessarily represent what is happening at the nerve terminals. 
The in vivo single fibre afferent recording model was advantageous in that it did allow for 
discrimination between airway and non-airway terminating nerve responses. However, this technique 
is relatively labour intensive and costly as only one nerve fibre can be examined in a single animal. 
Another major disadvantage to the use of this technique in this thesis is that at present the model is 
established in the Guinea-Pig and not the Brown Norway rat where the initial findings in this thesis 
were made. Unfortunately, the time constraints of the thesis did not allow for us to set up, 
characterise and validate the model in the Brown Norway Rat. As part of this thesis, key isolated vagus 
nerve recording experiments were paralleled in the Guinea-Pig in order to allow for the transition of 
species, however, it would have been more desirable to progress straight into a Brown Norway Rat in 
vivo single afferent recording model. 
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8.3 Future Studies 
8.3.1 Further investigation into the Mechanism of Action of DSCG 
8.3.1.1 Further Work to Assess the Translational Nature of the Mechanism of Action 
of DSCG 
Within this thesis DSCG was shown to confer actions on airway sensory nerves via the GPR35 receptor 
to impact upon the LAR. This was deduced using in vivo models of allergic asthma. The initial in vitro 
sensory nerve depolarisation experiments were, however, conducted on the vagus nerve tissue from 
naive animals and non-asthmatic donors. In order to further show that the results translate into 
human disease it would be desirable to repeat key experiments in vagus nerve tissue from allergic 
asthmatic patients. If the tissue was not available, as is often the case, it would at least be considered 
appropriate to repeat key experiments on tissue from models of allergic asthma. 
8.3.1.2 Explore the downstream signalling pathways associated with GPR35 
Having established that DSCG inhibits TRPA1-driven sensory nerve activation through GPR35, it would 
be desirable to investigate the downstream signalling pathways associated with this. It has been 
reported that activation of GPR35 triggers a Gi dependent inhibition of N-type calcium channels in rat 
neurons (Guo et al., 2008). Other studies have reported that Gi can be inactivated by dosing rats with 
Pertussis toxin (Paur et al., 2012). Therefore, it would be proposed that Brown Norway rats would be 
dosed with Pertussis toxin by adapting the protocol used in Paur et al (2012). The animals would then 
be culled, their vagus nerves harvested and the ability of DSCG to inhibit TRPA1 induced nerve 
depolarisation assessed using isolated vagus nerve experiments. 
8.3.1.3 Profile the effects of DSCG and GPR35 on mast cells 
In this thesis we highlighted the possibility that DSCG could exert its actions on airway sensory nerves 
via GPR35. DSCG is traditionally considered to be a mast cell stabiliser and we did not rule out this 
possibility within this body of work. Therefore, it would be desirable to consider if DSCG stabilises 
mast cells via GPR35. Mast cells would be extracted from the lungs of human donors, cultured and 
gene and protein expression levels of TRPA1 and GPR35 assessed. If present on mast cells then the 
functional impact of DSCG and GPR35 agonists and antagonists would be tested using mast cell 
degranulation assays. 
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8.3.2 Further investigate and validate in vivo models 
8.3.2.1 Develop the Brown Norway rat in vivo single afferent recording model 
Within this thesis a disadvantage was that the in vivo single afferent recording model was in the 
Guinea-Pig despite the LAR results being attained using the Brown Norway rat. The time constraints 
of the thesis did not allow for us to set up, characterise and validate the model in the Brown Norway 
Rat. It would therefore be desirable to do this in the future. It would then be possible to assess the 
mechanism of action of DSCG and GPR35 in single fibre afferents using a model species consistent 
with that of the LAR. 
8.3.2.2 Use an alternative double chamber WBP to further validate the LAR data 
Throughout the studies within this thesis single chamber WBP and Penh was used as a measure of 
lung function. As previously described (general methods section 2.5.1) there are currently no 
alternative methods to measure lung function in a conscious modelling system without using restraint. 
The main disadvantage to the single chamber WBP is that the nasal inspiration and thoracic 
displacement due to inspiration are measured within the same chamber. Double chamber WBP allows 
for the measurement of thoracic and nasal flow simultaneously. This technique can be used to 
measure specific airway resistance (sRaw) which is thought to be a good indicator and a more accurate 
measure of lung function. A disadvantage is that the animal must be restrained using this method and 
so snapshots through time would be attainable as opposed to continuous recording. Nevertheless, 
confirmation of Penh measurements by sRaw would further strengthen the LAR data.  
8.3.2.3 Investigate the role of other TRP channels in the LAR models 
Within this thesis the roles of TRPA1 and TRPV1 in the LAR were investigated. Within the literature 
further subtypes of TRP channel are being discovered and roles within allergic disease postulated. 
TRPV4 has been shown to have roles in thermosensitisation, mechanosensitisation and osmotic stress 
(Watanabe et al. 2003; Strotmann et al. 2000; Suzuki et al. 2003; Liedtke & Friedman 2003). The 
bronchial fluid of asthmatics has been reported to be hypotonic due to airway remodelling and this 
implies a role for TRPV4 in asthma (Liedtke & Friedman, 2003b). TRPM8 is a thermosensor of 
temperatures approximately 15-28 °C (McKemy, Neuhausser & Julius, 2002; Zhou et al., 2011). 
Inhalation of cold air has been shown to trigger symptoms of asthma such as bronchoconstriction, 
cough, plasma extravasation and mucosal secretion (Carlsen & Carlsen, 2002). TRPM8, being 
a thermosensor, has been linked to this (Li et al., 2011a; Fisher, 2011). It has also been reported to be 
involved in cold triggered mast cell activation and so further study could implicate it in inflammatory 
processes in diseases such as asthma (Cho et al., 2010a). It would be interesting to investigate the 
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roles of these TRP channels in the LAR by applying antagonists of these channels to in vivo models of 
the LAR should they become available in the future. 
8.3.3 Further Exploration of TRPA1 
8.3.3.1 The Role of TRPA1 in Airway Smooth Muscle Contraction 
Published data suggests that TRPA1 agonists can cause direct constriction of guinea pig ASM (Andre 
et al., 2008). It would therefore be appropriate to assess the effect of TRPA1 ligands on isolated airway 
tissue by performing organ bath experiments as done by Buckley et al 2011 (Buckley et al., 2011). 
Translational data could also be attained using human tracheal and bronchial strips. 
8.3.3.2 Assess if TRPA1 channels are involved in the release of 
acetylcholine from parasympathetic ganglia  
TRPA1 ligands have been shown to modulate sensory nerve activity. However, it is currently unknown 
whether they also interact with other populations of nerve fibres, specifically, the parasympathetic 
cholinergic constrictor nerves that innervate the airways. There is a possibility that TRPA1 has a role 
in the activation of parasympathetic nerves, the release of ACh or a role in the actions of ACh on M3 
receptors on smooth muscle. It would be desirable to assess the role of TRPA1 on ACh release using 
TRPA1 ligands and isolated airway tissue in an organ bath setting. The contractile responses of the 
isolated airway tissue in response to endogenously released ACh initiated by electrical field 
stimulation (EFS) to would be measured and compared to contractile responses to exogenous ACh. 
EFS induced ACh release would also be measured using a tritiated radiolabelling technique as 
described in Patel et al (1995) (Patel et al., 1995b). 
 
 
 
 
 
 
163 
 
8.3.4 Investigate whether the same mechanisms are involved in the LAR on a 
background of cigarette smoke exposure under conditions where 
steroids have limited efficacy 
Preliminary data within the Respiratory Pharmacology group has suggested that allergen induced LAR 
in Cigarette Smoke exposed mice is slightly increased in size and resistant to steroid treatment 
compared with air exposed mice (See figure 8.1). This could be a good model with which to study 
cigarette smoke induced steroid resistance in allergic asthma. The results obtained in this thesis 
provided further evidence for airway sensory nerves in the driving mechanisms behind the LAR. Key 
experiments could be carried out in order to asses if the same mechanisms are involved in driving the 
LAR on a background of cigarette smoke. If the steroid resistant LAR observed in the Cigarette Smoke 
exposed animals is mediated by the same mechanisms then targeting airway sensory nerves in these 
patients could confer therapeutic effects where steroids have limited efficacy. 
 
 
Figure 8.1: Steroid resistance in a murine model of asthma. Mice were sensitised to OVA plus alum 
i.p, days 0 and 14. On days 26-28, mice were exposed to air or cigarette. 1 hour after final CS 
challenge, mice received vehicle or budesonide (3 mg/kg, p.o.), followed by (1 hour later) a single 
intratracheal challenge with saline or ovalbumin and Penh recorded (overnight). (Work carried out 
by MA Birrell, KRG Raemdonck and N Dale) 
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8.4 Concluding Remarks 
 
In summary, the data presented in this thesis provides insight into the driving mechanisms behind the 
LAR. CD4+ cells were found to be central to the driving mechanisms behind the response, with CD8+ 
cells conferring protective effects. Further investigation into the role of the mast cell – B-cell – IgE axis 
using pharmacological tools alluded to the fact that DSCG may work via mechanisms independent of 
mast cells. When exploring this further, a central role for airway sensory nerves within the LAR was 
concluded, with DSCG exerting effects on sensory nerve channels. Further pharmacological 
investigation showed that DSCG confers effects on airway sensory nerves via the G-protein coupled 
receptor, GPR35. Overall, it could be concluded that DSCG inhibits the LAR via GPR35 present on 
airway sensory nerves. This is an exciting finding as not only does it suggest why previously developed 
mast cell stabilisers have been found to be ineffective in clinic, it also presents a novel target for future 
asthma therapy. Future investigations highlighted in section 8.3 will hopefully provide further insight 
into the mechanisms behind the LAR and further targets for future asthma therapy. 
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9 Appendix 
9.1 Chemicals and Reagents 
Drug/Reagent Source 
2 N H2SO4  VWR (UK) 
Acrolein Sigma-Aldrich (UK) 
Albumin from Chicken Egg White (OVA) Sigma-Aldrich (UK) 
AlumTM ThermoFisher Scientific (US) 
BD OptEIATM set for mouse immunoglobulin E  BD Biosciences (US) 
Budesonide Sigma-Aldrich (UK) 
Capsaicin Sigma-Aldrich (UK) 
Collagenase Roche Diagnostics (Germany) 
Compound 48/80 Sigma-Aldrich (UK) 
Disodium Cromoglycate Sigma-Aldrich (UK) 
DMSO Sigma-Aldrich (UK) 
Dnase Roche Diagnostics (Germany) 
Eosin-Phloxine solution  Sigma-Aldrich (UK) 
Ethanol  VWR (UK) 
FBS Invitrogen (UK) 
Fixable near-IR dead cell stain kit for 633/635nm 
excitation  Invitrogen (UK) 
Formaldehyde  Sigma-Aldrich (UK) 
Glycopyrrolate Sigma-Aldrich (UK) 
Isoflurane Abbott laboratories (UK) 
Janssen130 Almirall (Spain) 
Krebs-Henseleit (KH) solution (mM: NaCl 118; KCl 5.9; 
MgSO4 1.2; CaCl2 2.5; NaH2PO4 1.2; NaHCO3 25.5 
and glucose 5.6; pH 7.4) Sigma-Aldrich (UK) 
Kynurenic Acid  Sigma-Aldrich (UK) 
Medical Oxygen BOC Industrial Gases (UK) 
methycellulose Sigma-Aldrich (UK) 
ML145 (GPR35 inhibitor) Sun Pharma Ltd (India) 
Pamoic Acid  Sigma-Aldrich (UK) 
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PBA (PBS containing 0.1% (wt/vol) sodium azide and 
1% (wt/vol) BSA) Sigma-Aldrich (UK) 
PBS Sigma-Aldrich (UK) 
Rat anti-mouse CD11b (PerCP) conjugated mAb eBioscience (UK) 
Rat anti-mouse CD11c (APC) conjugated mAb BD Pharmingen (UK) 
Rat anti-mouse CD19 (FITC) conjugated mAb BD Pharmingen (UK) 
Rat anti-mouse CD4 (PerCP) conjugated mAb BD Pharmingen (UK) 
Rat anti-mouse CD8 (APC) conjugated mAb BD Pharmingen (UK) 
Rat anti-mouse F4/80 (PE) conjugated mAb eBioscience (UK) 
Rat anti-mouse Ly6G (FITC) conjugated mAb BD Pharmingen (UK) 
Rat anti-mouse SiglecF (PE) conjugated mAb BD Pharmingen (UK) 
RPMI Invitrogen (UK) 
Saline Fresenius Kabi (UK) 
Sodium pentobarbitone Merial Animal Health (UK) 
Substrate solution (1:1 mixture of H2O2 and 
tetramethylbenzidine) R&D Systems (US) 
Tiotropium Bromide Sigma-Aldrich (UK) 
Toluidine blue histological stain Sigma-Aldrich (UK) 
Tween80 Sigma-Aldrich (UK) 
Urethane Sigma-Aldrich (UK) 
Vecuronium Bromide  Sigma-Aldrich (UK) 
Wright-Giemsa stain  Sigma-Aldrich (UK) 
XEND0501 Ario Pharma Ltd (UK) 
Zaprinast Sigma-Aldrich (UK) 
 
